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Abstract  
Recent developments of more effective Multiple Sclerosis (MS) medications with 
severe side-effect profiles mean that patients with MS must recall and comprehend 
highly complex risk-benefit treatment information. Yet studies have shown reduced 
risk awareness in people with MS, which may be associated with MS-related 
cognitive impairments (e.g. reduced information-processing speed and learning). 
Spaced presentation, whereby information is presented over time and interspersed 
with breaks, can improve recall in patients with MS on simple paragraph and name-
learning tasks. However the benefits of spaced presentation in patients with MS have 
not been explored for more complex, clinically-relevant information. The present 
study explored whether spaced presentation of treatment-related risk information 
leads to improved recall and understanding in patients with MS (n=30) and healthy 
controls (n=30). Participants heard information about fictitious drugs presented in 
three formats: with gaps (spaced condition), continuously (massed condition), and 
continuously followed by a 10-minute delay (massed-with-delay condition). 
Immediate recall and understanding was assessed. They also completed 
neuropsychological tests. Mixed design ANOVAs showed a main effect of group, 
with MS participants performing significantly worse than controls for both immediate 
recall and understanding of treatment-related risk information. There was also a main 
effect of presentation format for immediate recall. Participants recalled significantly 
more information in the spaced relative to both massed and massed-with-delay 
conditions and in the massed relative to the massed-with-delay condition. Cognitive 
deficits correlated with recall and comprehension in the MS group. This study 
provides initial support for the benefit of spacing for recall of risk information in MS. 
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However, spaced presentation did not aid comprehension of treatment-related risk 
information in either group. The breaks in information presentation may ameliorate 
effects of reduced processing speed on recall. However, the complexity of 
comprehending medication risk information may be too great a challenge for a 
spacing intervention to overcome in the context of MS-related cognitive impairment. 
Clinical implications are discussed.  
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1. Introduction 
1.1. Multiple Sclerosis 
Multiple Sclerosis (MS) is a chronic progressive neurological disorder of uncertain 
aetiology which affects the brain and spinal cord. It is typically diagnosed in early-
middle adulthood (20-40 years) and affects approximately 2.5 million people 
worldwide (Kingwell et al., 2013; Markowitz, 2013).  
1.1.1. Pathophysiology of MS  
The underlying cause of MS is complex, multifactorial and not yet fully understood 
but is thought to result from a combination of genetic predisposition and 
environmental triggers (Compston & Coles, 2008; Hauser & Oksenberg, 2006). The 
pathological processes involved in the development and progression of MS are better 
understood (Compston & Coles, 2008). It is generally accepted that MS development 
involves two primary distinct processes: (i) inflammation and (ii) neuro-degeneration.  
During inflammation, the myelin sheath – a protective, insulating area 
surrounding the axons of nerve cells which aids fast communication between nerve 
cells – becomes damaged, causing demyelination (Compston & Coles, 2008). In 
earlier stages of MS, remyelination can occur, thus restoring communicative function. 
However, repeated inflammation causes plaques, called lesions, to build up in the 
brain and spinal cord (Compston & Coles, 2008; Hauser & Oskenberg, 2006).  
Over time, demyelination leads to neuron and axonal degeneration or cell 
death (Compton & Coles, 2008; Hauser & Oksenberg, 2006). As the disease 
progresses and new lesions develop, axon and neuronal degeneration becomes more 
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widespread, resulting in permanent neurological disability (Tallantyre et al., 2010). 
MS involves both white matter (composed of axons which aid communication 
between grey matter and other areas of the body) and grey matter (composed of nerve 
cells which receive information from and generate information to the rest of the body) 
pathology, with grey matter areas impacted more severely as the disease progresses 
(Calabrese, Filippi, & Gallo, 2010).  
1.1.2. Symptoms, Diagnosis and Clinical Course 
Inflammation, demyelination and neuronal degeneration in the central nervous system 
(CNS) lead to a wide range of potential symptoms which vary substantially between 
people with MS. The heterogeneity of MS symptom profiles and clinical course 
depends in part on the specific lesion sites within the brain (Compton & Coles, 2008). 
Typical symptoms include motor, visual or other sensory difficulties. Cognitive 
functions are also frequently impacted (Hauser & Oksenberg, 2006). Fatigue is one of 
the most commonly reported and disabling symptoms affecting up to 90% of the MS 
population (Bol, Duits, & Hupperts, Vlaeyen, & Verhey, 2009). Depression is also 
common, affecting about 50% of people with MS (Arnett & Strober, 2011). As the 
disease progresses, these physical, cognitive and psychological symptoms can become 
more frequent and severe leading to an increased level of disability and reduced 
quality of life, impacting on an individual’s capacity to engage in work, leisure 
activities and social relationships (Fernandez-Jimenez & Arnett, 2014; Hoogs, Kaur, 
Smerbeck, Weinstock-Guttman, & Benedict, 2011; Janardhan & Bakshi, 2002).  
A clinical diagnosis of MS is typically established in accordance with the 
McDonald criteria (McDonald et al., 2001) based on the presence of lesions within 
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the CNS and two or more discrete episodes of neurological dysfunction (Polman et 
al., 2005).   
1.1.3. MS Subtypes 
MS is classified into 4 clinical sub-types: (i) relapsing-remitting, (ii) primary 
progressive, (iii) secondary progressive and (iv) progressive relapsing MS, each 
characterised by different presentations.  
(i) Approximately 85% of people with MS initially present with relapsing-
remitting MS (RRMS). These patients experience alternating episodes of 
neurological disability followed by subsequent periods of recovery and 
remission, with this interchange lasting between 3-25 years (Confavreux & 
Vukusic, 2004; Hurwitz, 2009).  
(ii) Approximately 90% of patients with RRMS ultimately develop secondary 
progressive MS (SPMS). This sub-type is characterised by continuous, 
permanent neurological decline (Hurwitz, 2009).  
(iii) 10-15% of people with MS receive an initial diagnosis of primary 
progressive MS (PPMS). This involves continuous, progressive 
neurological decline with no remission phases and typically has a later age 
of onset relative to RRMS (Confavreux & Vukusic, 2004; Hurwitz, 2009).  
(iv) Progressive-relapsing MS (PRMS) is a disease course experienced by 
about 5% of people with MS and is characterised by progressive 
neurological decline as well as acute episodes of relapse with or without 
remission (Hurwitz, 2009).  
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1.1.4. Section Summary  
MS is a chronic progressive neurological disease affecting the brain and spinal cord 
(CNS). Inflammation and demyelination cause lesions to develop in sites within the 
CNS, eventually leading to neurodegeneration. This results in a range of visual, 
motor, sensory, cognitive and psychological symptoms which lead to increased 
disability and reduced quality of life as the disease progresses. In the majority of cases 
(85%), patients initially experience alternating episodes of relapse and remission 
which ultimately develops into progressive neurological decline. There is no known 
cure for MS. Instead, treatments centre on disease-modifying medications which help 
to slow progression of the disease and associated disability. 
1.2. Drug Treatment for MS 
There are a number of medications which slow progression of the disease and delay 
development of further lesions thus slowing the progression of neurological disability. 
Consequently, they are known as disease-modifying treatments (DMTs). These 
medications are typically divided into two categories: first-line and second-line 
treatments. There is no gold standard DMT for people with MS, thus treatment 
decisions are a complex, multi-faceted matter which must be made at an individual 
level (Lugaresi et al., 2013).  
1.2.1. Current Status: First Line versus Second Line Disease Modifying 
Treatments (DMTs) 
First-line medications refer to those drugs for which the balance between the known 
risks and benefits ratio is largely positive. These drugs are deemed efficacious, safe 
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and well-tolerated (Ontaneda & Di Capua, 2012). Generally, potential side-effects are 
considered to be minor or ‘acceptable’ but are not life-threatening (Marrie & Rudick, 
2006; Miller, Spada, Beerkircher, & Kreitman, 2008).  Their safety profile has been 
consistent for a number of years, up to 20 years in the case of Beta Interferon and 
Glatiramer acetate (Miller et al., 2008; Ontaneda & Di Capua, 2012). Unfortunately, 
these first-line DMTs are not effective for a relatively large proportion of patients 
(Ontaneda & Di Capua, 2012).  
In contrast, the more recently developed second-line MS medications are 
typically more effective than first-line medications. Yet second-line medications also 
possess severe, potentially life-threatening side effects. Limited medication trials 
mean that their long-term side effects and safety record remains unclear (Lugaresi, 
2013). Given the disparate efficacy and risk profiles of first- and second-line 
medications, patients with MS face a complex decision-making process in which the 
pros and cons of each treatment option must be carefully considered.  
1.2.2. Mechanism of Action of DMTs and Potential Effects on Cognition  
All DMTs are classified as immunotherapies. It is thought that they work by 
regulating the immune system, suppressing the inflammation-inducing T-cells (i.e. 
cells which cause inflammation in the CNS) which the body’s immune system has 
failed to regulate (Compton & Coles, 2008). However, the specific mechanism of 
action of DMTs in MS is not very well understood. This is particularly true for first-
line medications. Beta Interferon, a first-line medication, is a protein which is thought 
to inhibit the uptake of a chemical which can activate T-cells. Therefore, Beta 
Interferon may work by reducing the level of inflammation, leading to reduced 
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neuronal and axonal degeneration and thus slower progression of disability (Kieseier, 
2011).   
The mechanism of action of newer, second-line DMTs is more well-defined. 
These also act by reducing inflammation which then decreases the rate of lesion 
development in the CNS. However, the method of doing so is different. Second-line 
DMTs reduce inflammation by binding to T-cells, inhibiting them, and so the T-cells 
are then unable to trigger the process of inflammation of cells in the CNS (Hoepner et 
al., 2014). These second-line medications may also interrupt inflammation that has 
already begun in the CNS (Hutchinson, 2007).  
A very limited number of studies have explored the effect of DMTs on 
cognitive function in MS (Benedict & Zivadinov, 2011) and thus the effect of most 
DMTs on cognitive function remains uncertain. One recent study explored the 
benefits of Natalizumab for cognitive function and fatigue in MS. Following a 1-year 
treatment period, a significant decrease was observed in the number of MS 
participants who were classified as cognitively impaired, although further 
improvement in the second year was not statistically significant (Iaffaldano et al., 
2012). A significant decrease in fatigue was also reported which may or may not have 
secondary effects in terms of improving cognitive function (e.g. Bailey, Channon, & 
Beaumont, 2007; Krupp & Elkins, 2000). Another more recent study reported 
significant improvements in information-processing speed and attention in MS 
following Natalizumab treatment over a 2-year period (Kunkel et al., 2015). It has 
been hypothesised that DMTs may improve cognitive function or slow cognitive 
decline by slowing the development of new lesions in areas responsible for various 
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cognitive functions (Kunkel et al., 2015), particularly where cortical, gray matter, 
lesions are prevented (Papadopoulou et al., 2013).  
1.2.3. Dangers Associated with DMTs 
In order to further comprehend the complexity of the decisions to be made regarding 
MS treatments, two common second-line DMTs are discussed: Mitoxantrone and 
Natalizumab.  
1.2.3.1. Mitoxantrone 
Mitoxantrone, is a second-line MS medication which is approved for the treatment of 
PRMS, SPMS and aggressive RRMS (i.e. a rare, rapidly evolving form of RRMS 
involving more than two relapses in a year and associated with rapid progression of 
disability), typically where patients have not responded or have partially responded to 
first-line medications (Lugaresi et al., 2013). It has been shown to be highly effective 
in reducing relapse rate and disability progression (Martinelli, Radaelli, Straffi, 
Rodegher, & Comi, 2009), particularly in the case of RRMS (Esposito et al., 2010), 
with long-term benefits following discontinuation (Marriott, Miyasaki, Gronseth, & 
O’Connor, 2010). However, like Natalizumab, Mitoxantrone’s high efficacy needs to 
be evaluated along with its serious potential side-effects including cardiotoxicity such 
as systolic dysfunction (12%) or congestive heart failure (0.2-0.5%) (Marriott et al., 
2010; Martinelli et al., 2009) as well as therapy-related acute myeloid leukaemia 
(TRAL; between 0.25-0.93%) (Chan & Lo-coco, 2013; Marriott et al., 2010).  
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1.2.3.2. Natalizumab 
Natalizumab was initially approved as a second-line treatment for RRMS in the 
European Union in 2006 but with specific safety restrictions due to a number of prior 
fatalities (Hoepner, Faissner, Salmen, Gold, & Chan, 2014). The European Medicines 
Agency (EMA) specifies that Natalizumab may only be prescribed to patients with 
RRMS who have high disease activity and who have not responded to first-line 
medications, typically Beta Interferon or Glatiramer acetate, as well as to newly-
diagnosed individuals with severe, rapidly advancing relapses. It may only be 
prescribed as a monotherapy and not in conjunction with other MS therapies (Hopener 
et al., 2014; Lugaresi et al., 2013).  
Natalizumab is a highly effective treatment for MS. Patients taking 
Natalizumab benefitted from a greater reduction in relapse rate and disability 
progression as well as reduced lesion activity and brain atrophy on MRI scans 
(Lanzillo et al., 2011; Spelman et al., 2015) when compared to patients who were 
prescribed first-line medications such as Beta Interferon therapy. Positive effects on 
quality of life, cognition, fatigue and mood have also been reported (Hoepner et al., 
2014).  
Importantly however, Natalizumab also comes with the risk of Progressive 
Multifocal Leukoencephalopathy (PML), a life-threatening virus of the CNS which 
typically results in moderate to severe disability in survivors (Sorensen et al., 2012). 
The risk of PML in patients with MS who are on Natalizumab is estimated to be 
between 0.09 cases per 1000 patients and 10.6 per 1000 patients (Lugaresi et al., 
2013) depending on a number of known risk factors. The risk of PML on Natalizumab 
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provides a particularly good example of the complexity of information which patients 
with MS must comprehend before making a decision regarding their treatment. 
Specifically, there are three primary risk factors known to substantially 
increase one’s chance of developing PML while on Natalizumab: testing positive for 
the presence of anti-JC virus antibodies in the blood, previous or current 
immunosuppressant use, and treatment duration (Sorenson et al., 2012). An 
individual’s risk of developing PML depends on the number of these risk factors 
present, and this can change over time. For example, patients can change from a 
negative to a positive anti-JC virus antibody status (Lugaresi et al., 2013). 
Natalizumab treatment lasting over two years, as well as higher dosages, further 
increases the risk of PML (Sorenson et al., 2012). A risk-factor algorithm is used to 
interpret an individual’s relative risk of developing PML based on these three primary 
risk factors (Sorenson et al., 2012). Evidently then, the volume of medical and 
statistical information one must consider when evaluating risk of PML is vast and 
complex.  
1.2.4. Complexity of Treatment-related Patient Information  
The risk of PML on Natalizumab described above provides a particularly good 
example of the complexity of medical and statistical information which patients must 
master before being able to make a well-informed decision regarding their treatment. 
The above descriptions of both Mitoxantrone and Natalizumab also elucidates the 
complicated nature of MS-related treatment decisions - evaluation of risk-benefit 
profiles for each treatment option is essential and must be considered in the context of 
an individual’s disease severity and progression, medical history, response to previous 
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DMTs, preferences and quality of life (Lugaresi et al., 2013). In the case of 
Natalizumab and Mitoxatrone as well as other second-line MS treatments, patients 
must balance the higher efficacy rates with complicated risk information. With the 
continued advancement of newer, stronger MS medications (Lugaresi et al, 2013), this 
ability to consider many competing risk-benefit ratios will become more crucial.  
It should also be clear from the above accounts that the types of statistical risk 
information regarding treatments which patients with MS encounter is varied and 
complex, further complicating the processes of comprehending treatment-related risk 
information. Patients may receive statistical risk information which is portrayed in 
percentages (e.g. 80% effective), frequencies (e.g. 1 in 70 patients), odds (e.g. 30 to 
1), number needed to treat (e.g. 50 people need to be treated with this medication for 
1 person to experience a reduction in relapse rate) or classic probabilities (e.g. 0-1) 
(Lipkus, 2007). Furthermore, this information may only be presented in one numerical 
format, which impacts cross-examination. This is known to impede accurate 
understanding of risk information (Lipkus, 2007). The issue of numerical information 
and its role in risk awareness in people with MS is discussed further in subsequent 
sections (see section 1.3.).  
1.2.5. Section Summary 
MS treatments are divided into two categories based on their known efficacy, safety 
and risk profiles, namely first-line and second-line medications. Both have been 
shown to slow disease and disability progression. Currently, second-line medications 
are only licensed for patients on first-line medication with objective evidence of 
breakthrough disease. Unfortunately however, these more efficacious drugs also carry 
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the risk of severe, life-threatening side effects. Consequentially, patients must encode, 
comprehend and recall complex risk information for each treatment option which is 
often presented in high-level numerical and statistical formats. As the development of 
second-line medications progresses, patients will continue to encounter situations in 
which they must choose between more or less efficacious medications with mild to 
potentially life-threatening side effects. Ultimately, a shared decision-making process 
occurs between the physician and patient. They jointly critically evaluate the risk-
benefit profiles of each treatment option in the context of that individual’s MS profile, 
medical history, personal values, preferences and quality of life.  
1.3. Shared Decision-Making and Evidence-Based Patient Information: 
1.3.1. Shared Decision-Making Summary 
Shared decision-making (SDM) refers to a model of patient-clinician communication 
which promotes an active role for patients and an equal balance of power and 
responsibility in relation to decisions about medical care. The central premise 
underlying a SDM model is that patients’ preferences and values should be explored 
and factored into the final treatment decision (Elwyn et al., 2012).  This is in contrast 
to more traditional clinical practice where the ‘clinician as expert’ ideology prevailed 
and clinicians felt able to make decisions for the patient. Balanced information-
sharing by clinicians, for all possible treatment options, is key, particularly in the case 
of chronic or life-threatening illness for which there are a number of potential 
treatments with some degree of uncertainty (Charles, Gafni & Whelan, 1997). The 
overall aim is to provide patients with greater autonomy and confidence to make more 
informed, balanced choices regarding their care. 
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Several different models of how best to implement SDM in practice have been 
put forward. Elwyn and colleagues (2012) developed one such model containing three 
steps: Firstly, clinicians should introduce choice, making sure the patient is aware that 
multiple possible treatment options exist; secondly clinicians should describe each 
treatment option in sufficient detail and in a way that is accessible to the patient; 
finally, clinicians should facilitate an exploration of patients’ preferences before 
engaging in joint deliberation which includes processes such as jointly weighing up 
pros and cons and considering consequences of each option. Ultimately these three 
steps lead to a compromise where an informed joint decision regarding treatment is 
reached (Elwyn et al., 2012). 
Given the chronic nature of MS and its diverse range of treatment options, 
some of which have limited efficacy, severe potential side-effects, or uncertain 
outcomes, SDM has been strongly advocated in MS health settings (Veloso, 2013; 
NICE, 2003). However, a commonly cited challenge for SDM is the measurement of 
patient decision-readiness, particularly their level of risk awareness, with few 
standardised measures available (Department of Health, 2012). This is especially 
pertinent given the frequency of MS-related cognitive impairments and their 
association with understanding of treatment information, reasoning and expression of 
treatment choice (e.g. Basso et al., 2010; McKnight, 2007). Before describing the 
evidence for specific MS-related cognitive impairments and their impact on risk 
awareness, it is worth reviewing the current evidence for reduced risk awareness in 
both the general population and MS population. For the purpose of this study, risk 
awareness is operationalised as the understanding and recall of risk information.   
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1.3.2. Evidence-Based Patient Information (EBPI) 
Evidence-based patient information (EBPI) has been deemed a necessary ‘pre-
requisite’ for SDM (Heesen et al., 2010). EBPI comprises the medical information on 
all available treatment options. It should be accessible, reliable and comprehensive 
and presented in a way that facilitates patient understanding. However, provision of 
accessible EPBI in practice can be challenging. Firstly, individuals have been shown 
to vary greatly in their abilities to comprehend health-related risk information, 
particularly health numeracy (Peters, 2012; Reyna, Nelson, Han, & Dieckmann, 2009) 
and, secondly, consensus on the most appropriate presentation format is lacking 
(Peters, Hibbard, Slovic, & Dieckmann, 2007; Reyna et al., 2009). 
The NICE guidelines for the management of MS in primary and secondary 
care settings stipulate that clinicians should provide patients with oral and written 
EBPI at the time of diagnosis, including information on DMTs, and a face-to-face 
follow-up appointment should be offered within 6 weeks of this diagnosis (NICE, 
2003). The Association of British Neurologists’ guidelines for prescribing medication 
to people with MS state that “patients should be fully informed of relevant facts and 
uncertainties before making a decision in discussion with their treating neurologist” 
(ABN, 2009). It is evident then, that patients should be informed about all the benefits 
and risks of different treatment options. Furthermore, Pietrolongo and colleagues 
(2013) found that increased clinician time, increased facilitation of patient 
involvement by clinicians, and greater attendance by clinicians to patient preferences 
for delivery of information all correlated with better observer ratings of patient 
involvement and satisfactory shared decision-making in initial MS clinical 
consultations.  
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However, there is no entirely standardised way of presenting information in 
MS clinical consultations in terms of the extent of information provided on each 
DMT, the provision of additional material such as information sheets, the number of 
sessions in which DMT information is discussed, or the communication style of 
clinicians which may range from directive to interactive and may vary greatly across 
clinicians (e.g. Pietrolongo et al., 2013; Robinson, 2002). For example, provision of 
verbal and written information (i.e. a NICE-recommended information pack 
specifically for newly diagnosed patients with MS) on DMTs is typically offered in 
MS clinics in a one-off rather than a staged process. However, in the case of 
Natalizumab, a more staged process of decision-making is typical given the risk of 
PML. In this case, oral and written EBPI on the risks and benefits of this medication 
is initially provided. Later patients are screened for the presence of the JC virus 
antibody and, following this, a risk algorithm is drawn up which provides them with 
more personalised risk estimate for PML. Patients then have some time to decide on 
their willingness to take this risk (Lugaresi et al., 2013).   
1.3.3. Limitations on the Understanding of Health-Related Risk Information in 
the General Public 
The primary challenge encountered by clinicians in implementing SDM, even where 
comprehensive EBPI has been provided to individuals, is low numeracy (Elwyn et al., 
2012). Numeracy is typically defined as the ability to accurately comprehend 
mathematical concepts and probabilistic information (Peters, 2012).  
Studies consistently demonstrate that the general public are poor at 
understanding information about health risks including risk-benefit ratios, 
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probabilistic information related to medical treatments, and perceptions of the 
likelihood of a risk occurring (Reyna et al., 2009). This is true even for some highly-
educated individuals (Lipkus, Samsa, & Rimer, 2001). The most recent nationwide 
survey of numeracy skills revealed that just 51% of England’s working-age adult 
population had ‘good numeracy’, defined as GCSE-level (grades D-G) or above, 
while 49%  (17 million adults) had ‘poor’ numeracy, functioning at the level expected 
for schoolchildren aged 5-11 years (DfBIS, 2012).  
A number of tendencies which contribute to the poor perception of numerical 
risk information have been observed. Individuals tend to assume that risks decrease as 
benefits increase and vice versa. However, rather than an inverse relationship, risk-
benefit relationships are often positive (Alhakami & Slovic, 1994). Indeed this is 
typically the case with newer, second-line MS medications where both the potential 
benefits and risks are increased.  
Furthermore, the general public frequently exhibit difficulties in understanding 
interactions between two risk factors, with people typically underestimating the 
magnitude of the combined risk of two or more risk factors (Reyna et al., 2009).  
In a somewhat similar vein, individuals are generally poor at understanding 
cumulative risk, typically making underestimations (e.g. Knauper, Kornik, Atkinson, 
Guberman, & Avdin, 2005), although overestimations have also been documented 
(e.g. Fuller, Dudley & Blacktop, 2004). Again, with many second-line MS 
medications, risk has been shown to increase over time. For example, risk of 
developing PML while taking Natalizumab increases significantly after two years of 
treatment (Sorenson et al., 2012).  
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Finally, it has frequently been demonstrated that the general public have 
difficulties in correctly interpreting small risk probabilities, particularly those below 
1%, with the risk either over-estimated, under-estimated or simply disregarded 
completely (Lipkus, 2007).  
Peters (2012) and others have argued that the issue goes further than numeracy 
comprehension. Affect and psychological factors such as framing effects may also 
limit many people’s interpretation of numerical risk information. The effect to which 
an individual is influenced by these non-numerical factors is associated with their 
level of numeracy (high or low). For example, those with lower numeracy skills are 
more likely to perceive risk as higher when it is framed in negative terms (e.g. 27% 
will develop heart problems) and lower when framed in positive terms (73% will not 
develop heart problems), whereas people with high numeracy judge the risk as similar 
regardless of how the information is framed.  
For those with lower numeracy, positive or negative mood state at the time 
risk information is presented is more likely to result in low-risk likelihood or high 
risk-likelihood perceptions respectively (Petrova, van der Pligt, & Garcia-Retamero, 
2014). Furthermore, individuals can be influenced by feelings even when provided 
with an overt indication that two risks are equally likely. One study asked participants 
to imagine they had been successfully treated for a particular cancer (e.g. Thyroid 
cancer) and then informed participants that they had an equal risk of later developing 
either recurring Thyroid cancer or a new cancer type (Skin cancer). However, 
participants reported experiencing higher levels of worry about developing the 
recurring cancer relative to the new cancer type and a substantial number of 
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participants (44%) consequently reported feeling as if the recurrent cancer was more 
likely to develop (Zikmund-Fisher, Fagerlin, & Ubel, 2010).  
Despite the limitations with numerical communication of risk, it is largely felt 
to be more appropriate than verbal communication of risk. Verbal descriptions of risk 
(e.g. ‘likely’, ‘unlikely’, ‘rare’, ‘possible’) can lead to greater misinterpretation due to 
the wider range of different meanings which individuals may conclude (Lipkus, 
2007). For instance, one person may deem a risk of 55% as likely whereas another 
may deem 75% as likely. Consequently, achieving uniformity of understanding across 
individuals and contexts using verbal risk information appears more challenging than 
doing so with numerical information.  
1.3.4. Limitations on the Understanding of Health-Related Risk Information in 
Non-MS Patients 
Existence of a current health condition and subsequently greater exposure to treatment 
information does not appear to improve risk awareness (i.e. understanding and recall 
of risk information). Individuals with Type II Diabetes have an increased risk of 
developing serious Diabetes-related diseases such as cardiovascular disease. Yet, such 
individuals typically underestimate their risk of developing these conditions which in 
turn influences their decisions about lifestyle choices and medication adherence (e.g. 
Saver, Mazor, Hargraves, & Hayes, 2014).  
In another study, a majority of prostate cancer patients held misconceptions 
about the risks and benefits of treatments, with their treatment decisions being 
influenced more by affect (e.g. fear, anxiety) rather than accurate risk information 
(Denberg, Melhado, & Steiner, 2006). Survivors of breast cancer have been shown to 
30 
 
 
largely misperceive the risk of cancer recurrence. This may be an overestimate or 
underestimate with both level of anxiety (Kelly et al., 2013) and lower health 
numeracy (Kelly, Shedlosky-Shoemaker, Porter, DeSimone, & Andrykowski, 2011) 
fuelling these misperceptions.  
1.3.5. Reduced Health-Related Risk Awareness in MS 
Findings of reduced risk awareness in people with MS are also common. Using a self-
report measure, one study revealed that in the MS population overall level of MS-
related risk knowledge was low (Heesen, Kasper, Segal, Kopke, & Muhlhauser, 
2004), while another found that patients with MS overestimated the 2-year and 10-
year risks of becoming wheel-chair dependent but underestimated the lifetime risk 
(Janssens et al., 2003).  
Other studies have focused on risk awareness specifically in relation to treatment 
decisions. Using a self-report questionnaire, one study measured knowledge and risk 
perceptions about the side effects of Mitoxantrone in people with MS. They revealed 
that 58% underestimated the risk of Leukaemia while 82% underestimated the risk of 
cardiotoxicity (Hoffman et al., 2012). Another study revealed that people with MS 
were more likely than practitioners to overestimate the benefits of the second-line 
treatment Natalizumab (Heesen et al., 2010a).  
A recent examination of health literacy in people with MS concluded that the 
majority of participants (65.5%) performed well on two health literacy measurements 
(Medical Term Recognition Test (METER) & Newest Vital Sign (NVS)) and were 
deemed to have ‘functional health literacy’ (Marrie, Salter, Tyry, Fox, & Cutter, 
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2014). Yet a substantial number, 34.5%, did not reach this functional level on both 
measures. 
Evidently then, there is a need for greater provision of EBPI in MS clinical 
settings. An increased amount of quality information may facilitate greater risk 
awareness in the MS population. Indeed, patients with MS appear to agree. Numerous 
studies demonstrate a desire among patients with MS for greater information 
provision regarding treatment options (e.g. Heesen et al., 2004; Kasper, Kopke, 
Muhlhauser, & Heesen, 2006). Some studies have begun to explore the benefits of 
EBPI within MS.  
1.3.6. Evidence-Based Patient Information as a Means of Improving Risk 
Awareness in MS 
Numerous studies over the past decade have consistently shown that provision of 
EBPI at MS diagnosis significantly improves risk awareness regarding treatment in 
this population (e.g. Heesen, Solari, Giordano, Kasper, & Kopke, 2010b; Kasper et 
al., 2006). One study developed an information aid for newly diagnosed patients with 
MS which consisted of a personal interview with a physician, an information booklet 
and navigable compact disc. The information aid significantly improved MS 
knowledge relative to current clinical practice (diagnosis disclosure alone), evidenced 
by higher scores on the MS Knowledge Questionnaire (MSKQ) (Solari et al., 2010).  
Another study found that treatment-related risk awareness in patients taking 
the second-line medication Mitoxantrone was increased after reading an EPBI 
information brochure. Specifically, they demonstrated a greater understanding of the 
risk of developing Leukaemia while on Mitoxantrone, with the number of patients 
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correctly estimating the risk rising significantly from 40% pre-EBPI intervention to 
82% post-EBPI intervention. They also demonstrated a significant increase in 
estimating the risk of developing cardiotoxicity, with accurate risk awareness rising 
from just 16% to almost 50% following the provision of EBPI. However, a tendency 
to underestimate the risk of potential side effects associated with Mitoxantrone 
persisted in 18% and 50% of the sample when estimating the risk of leukaemia and 
cardiotoxicity respectively (Hofmann et al., 2012).  
This replicated the findings of an earlier study which also measured the 
efficacy of an EBPI intervention in the form of an information brochure. In this study, 
reading of the brochure led to a significant increase in ‘adequate’ risk awareness from 
21% to 41%, yet again, a vast number of patients with MS continued to demonstrate 
‘inadequate’ understanding of risk (Kasper et al., 2006). EBPI-based education groups 
have been another method of significantly improving risk knowledge in people with 
MS (Heesen et al., 2010b). 
EBPI is evidently one way to address poor risk awareness in MS. However, 
provision of the right information is often not sufficient, as was the case in all three of 
the studies presented above (Hoffman et al., 2012; Kasper et al., 2006; Solari et al., 
2010). In all cases, a substantial proportion of the MS sample did not exhibit adequate 
risk awareness following an EBPI intervention. A greater quantity of information is 
unlikely to improve risk awareness in those MS patients with low numeracy, MS-
related cognitive impairment, or both.   
Indeed, specific MS-related cognitive deficits have been documented which 
further complicate the case of risk awareness in MS and are likely to hamper 
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attainment of adequate risk awareness in MS over and above any impact of low 
numeracy. Therefore, further research would benefit from investigating new methods 
of improving risk awareness in clinical settings, perhaps with a focus on altering 
presentation format to offset these specific cognitive deficits. Evidence for particular 
MS-related cognitive deficits and their implications for risk awareness will now be 
reviewed which should further elucidate the need for more than a simple increase in 
quantity or quality of EBPI.  
1.3.7. Section Summary  
A shared decision-making (SDM) model of patient-practitioner communication is 
strongly advocated in MS health settings. Successful implementation of this model 
relies on the provision of comprehensive evidence-based patient information (EBPI) 
that is accessible to patients. EBPI typically comprises numerical and statistical 
information detailing risks and benefits of health and treatment-related issues. 
However, a multitude of studies document low numeracy in the general population, 
non-MS patients and patients with MS, even for some highly-educated individuals. 
Low numeracy leads to widespread under-estimation and over-estimation of risk 
probabilities in these populations. This is particularly consequential for the MS 
population given the continued emergence of newer, stronger MS medications which 
hold greater benefits but may pose more severe consequences.  
While, it has been shown that EBPI can improve risk awareness in some 
individuals with MS, a substantial percentage continue to misperceive risk. Thus, it is 
clear that an increase in quality and quantity of information (i.e. EBPI) alone will not 
lead to an acceptable level of risk awareness in many patients with MS. Moreover, 
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specific MS-related cognitive deficits likely impact further on risk awareness in a 
substantial number of patients. Consequently, this author argues for the need to 
explore new methods of presentation of risk information to facilitate greater risk 
awareness, ideally by offsetting these specific cognitive deficits. To understand the 
types of interventions which may facilitate greater risk awareness in people with MS, 
it is important to understand the nature of MS-related cognitive deficits.  
1.4. Neuropsychological Profile of MS: 
1.4.1. The Prevalence of Cognitive Impairment in MS 
An estimated 40-70% of patients with MS suffer cognitive impairment (Chiaravalloti 
& DeLuca, 2008; Guimares & Sa, 2012; Langdon, 2011; Sahraian & Etesam, 2014). 
Cognitive impairment can occur in all MS subtypes and has been documented even at 
the earliest stages of the disease (Potagas et al., 2008; Shultz, Kopp, Kunkel, & Faiss, 
2006) with impairment increasing as the disease progresses (Benedict et al., 2006; 
Chiaravalloti & DeLuca, 2008). Rather than general cognitive decline, a number of 
domain-specific deficits consistently emerge including impairments in information-
processing speed, memory and new learning, complex attention and executive 
function (Chiaravalloti & DeLuca, 2008; Drew, Tippett, Starkey, & Isler, 2008; 
Hoffman, Tittgemeyer & Yves von Cramon, 2007). Functions such as language 
comprehension, verbal fluency, spatial perception, and simple attention are much less 
affected (Amato et al., 2012; Clemmons, Fraser, Rosenbaum, Getter, & Johnson, 
2004).   
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1.4.2. Memory and Learning 
The ability to learn and later recall new information is often reduced in people 
with MS. Initial studies attributed this to a difficulty in retrieving information from 
long-term memory (‘retrieval-failure hypothesis’) (Rao, Leo, & St. Aubin-Faubert, 
1989). However, recent studies point towards poor acquisition of information as the 
most likely cause (‘learning-deficit hypothesis’) which then has a secondary effect on 
retrieval (Lafosse, Mitchell, Corboy, & Filley, 2013). Numerous studies have found 
that participants with MS required significantly more rehearsals on word-list learning 
tasks than healthy controls in order to reach criterion but, once at criterion, performed 
similarly on verbal recall and recognition (e.g. DeLuca, Gaudino, Diamond, 
Christodolou, & Engel, 1998; Demaree, Gaudino, DeLuca, & Ricker, 2000; Gaudino, 
Chiaravalloti, DeLuca, & Diamond, 2001; Lafosse et al., 2013). This suggests that 
verbal memory in MS is impacted by initial learning rather than long-term memory 
impairment, indicating that memory difficulties in MS are most likely due to poor 
acquisition rather than poor retrieval.  
A recent study was able to quantify memory performance in MS groups. Despite 
performing significantly worse than controls on acquisition and delayed recall list-
learning tasks, memory performance in the MS group was, in clinical terms, in the 
‘average’ range rather than ‘impaired’ range but was consistently half a standard 
deviation below the normative mean (Lafosse et al., 2013). This was taken to indicate 
mild memory impairment in MS, although even mild impairment may impact 
substantially on patients’ lives and treatment-related risk awareness.  
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1.4.3. Information-Processing Speed 
Reduced information-processing speed - the speed and efficiency with which 
individuals process new information (Chiaravolloti, Stojanovic-Radic, & DeLuca, 
2013) - is the most common cognitive deficit in MS. Studies consistently demonstrate 
that participants with MS produce significantly slower response times than matched 
controls on a number of well-known tests of information-processing speed including 
the Stroop test (e.g. Denney, Gallagher, & Lynch, 2011; Lynch, Dickerson, & 
Denney, 2010), the Paced Auditory Serial Addition Test (PASAT; e.g. Drake et al., 
2010; Fisk & Archibald, 2001; Forn, Belenguer, Parcet-Ibars, & Ávila, 2007), the 
Symbol Digit Modalities Test (SDMT; e.g. Drake et al., 2010) and reaction time (RT) 
tasks (e.g. Bodling, Denney, & Lynch, 2012; Reicker, Tombaugh, Walker, & 
Freedman, 2007). Furthermore, the difference in performance between participants 
with MS and healthy controls on information-processing speed tasks has been shown 
to increase with increasing cognitive load of a task (e.g. Denney et al., 2011; 
Paramenter, Shucard, & Shucard, 2007a; Reicker et al., 2007), further emphasising 
information-processing deficits in MS. Finally, significantly reduced information-
processing speed on such a wide variety of tasks as listed above, which also involve a 
number of other cognitive functions (e.g. working memory, attention, inhibition, 
planning), further advocates for a generalised deficit in information-processing speed 
in MS (Denney et al., 2011). More recent studies continue to provide further evidence 
for this. For instance, processing speed rather than working memory accounted for the 
majority of the explained variance in performance on a Keeping Track Task for 
participants with MS (Genova, Legenfelder, Chiaravalloti, Moore, & DeLuca, 2012). 
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In a longitudinal study, Bergendal and colleagues (2007) demonstrated that these 
information-processing deficits in MS appear to worsen substantially over time 
(Bergendal, Fredrickson, & Almkvist, 2007). Interestingly, they also showed that 
information-processing deficits were the strongest predictor of further cognitive 
decline in MS. Indeed, the ‘Relative Consequence Model’ (DeLuca, Chelune, Tulsky, 
Lengenfelder, & Chiaravalloti, 2004) asserts that reduced information-processing 
speed is the primary cognitive deficit in MS and underlies other MS-related cognitive 
dysfunction. This model arose from studies which show that information-processing 
deficits were significantly more common than working memory (WM) deficits in a 
large MS sample (e.g. DeLuca et al., 2004). Moreover, on a modified version of the 
PASAT, participants with MS performed similarly to a control group on WM but 
required significantly greater processing time, suggesting that information-processing 
speed is the primary deficit. When task demand increased, requiring greater WM 
capacity, participants with MS who possessed greater processing speed deficits made 
more errors. This supports the viewpoint that information-processing speed interacts 
with WM to cause a secondary difficulty during more complex tasks (Lengenfelder et 
al., 2006). In relation to new learning, information-processing speed has been shown 
to be a much stronger predictor of new learning than is WM (Chiaravalloti, 
Stojanovic-Radic, & DeLuca, 2013), again espousing the Relative Consequence 
Model.  
In summary then, in order for presentation format to influence risk awareness in 
MS, one must suppose that this format should facilitate increased information-
processing speed which would then have positive implications for new learning, later 
recall and understanding of this information. 
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1.4.4. Language Comprehension 
While acquisition of new information is reduced in MS, likely owing at least in part to 
reduced information-processing speed, language comprehension appears to be largely 
intact.  
Many studies have employed the Verbal Comprehension Index (VCI) of the 
Wechsler Adult Intelligence Scale, Third Edition (WAIS-III; Wechsler, 1997) to 
assess language abilities in MS groups. They have found that MS groups typically 
perform at a level similar to healthy controls on Vocabulary, Information and 
Similarities subtests, indicating that verbal comprehension and expression, abstract 
verbal reasoning, and general knowledge are usually preserved (e.g. Clemmons et al., 
2004; Drew, et al., 2008; Prakash, Snook, Lewis, Motl, & Kramer, 2008).   
In one such study, participants’ performance on the WAIS-III was compared 
with a measure of their pre-morbid intelligence (Wechsler Test of Adult Reading; 
WTAR) which provided a predicted score for the performance IQ and verbal IQ 
measures of the WAIS-III. Many patients with MS scored significantly lower that 
their predicted score on the performance IQ index but relatively few scored 
significantly lower than expected for verbal IQ (Drew et al., 2008). Performance IQ 
may be impacted in patients with MS due to visual or motor disturbance associated 
with the disease.  This finding of intact verbal IQ replicates the findings of a previous 
study which also employed the Verbal Comprehension Index (VCI) subtests of the 
WAIS-III. Again, they found verbal abilities in people with MS to be largely 
preserved with patients performing in the average to high-average standardised range 
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(Clemmons et al., 2004). Overall it was concluded that there is little evidence of a 
verbal deficit in MS. 
Ryan and colleagues (2012) recently conducted the first assessment of 
neuropsychological performance of participants with MS on the WAIS-IV (Wechsler, 
2008), an updated version of the WAIS-III. Again, using this battery, verbal abilities 
were found to be largely preserved and scores on the VCI were significantly greater 
than on the Processing Speed Index (PSI) for the MS group (Ryan, Gontkovsky, 
Kreiner, & Tree, 2012). This suggests that MS impacts less on an individual’s verbal 
comprehension relative to processing speed. However, it should be noted that this 
study included only those with RRMS. In a sample of patients with RRMS, PPMS 
and SPMS, it was found that where overall cognitive performance was high, cognitive 
decline was largely restricted to the domains of perceptual and processing speed. 
However, where these overall cognitive performance levels were low, all cognitive 
domains were typically affected, whether perceptual, processing speed, working 
memory or verbal comprehension (Drew et al., 2008). This suggests that verbal skills 
may be an additional area of decline in more progressive forms of MS as were 
included in the current study.  
Based on the current evidence, one should expect that verbal abilities will not 
generally impact on participants’ ability to comprehend risk information and, in line 
with evidence discussed earlier, comprehension is more likely to be impacted by poor 
numeracy.  
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1.4.5. Executive Function 
Executive function refers to a set of complex, higher-order cognitive processes 
including inhibition, planning, initiation, working memory (WM) and reasoning 
(Lezak, 2004). Executive function deficits have been documented in people with MS 
but have been shown to be less common than other cognitive impairments, most 
notably information-processing speed and memory deficits (Guimares & Sa, 2012).  
There is not yet a definitive account of the aspects of executive dysfunction 
characteristic to MS, with much variability between individuals (Drew et al., 2008). 
One study found that participants with MS performed significantly worse than 
controls on the Wisconsin Card Sorting Test (WCST) and Delis-Kaplan Executive 
Function System (DKEFS) test, suggesting that MS impacts on one’s ability to plan 
strategically, shift attention, inhibit automatic responses and problem-solve 
(Parmenter et al., 2007b). Using the DKEFS test battery, Drew et al. (2008) also 
found some evidence of reduced inhibition and ability to shift attention, working 
memory and verbal fluency.  
There is also some evidence for reduced performance by people with MS on 
everyday functional tasks which involve executive function. Reduced performance on 
simple cooking and bill payment tasks was correlated with reduced performance on 
the Tower of London task, a test that assesses planning and inhibition, in a group of 
participants with MS (Voebel et al., 2011). People with MS also performed 
significantly worse than healthy controls on a functional task involving planning and 
organisation in which they were asked to purchase a return-trip airline ticket using the 
internet (Goverover, O’Brien, Moore, & DeLuca, 2010).  
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However, it is acknowledged that an element of executive dysfunction in MS 
is attributable to slowed information-processing speed, for example timed tests of 
shifting and inhibition (Drew et al., 2008; Genova, DeLuca, Chiaravalloti, & Wiley, 
2013), planning (Denney et al., 2011) or working memory (Legenfelder et al., 2006).  
1.4.6. Factors Impacting on Cognitive Function in MS 
A number of common symptoms of MS may also impact on cognitive function, most 
notably fatigue, depression and chronic pain, although the current evidence for this is 
mixed.    
1.4.6.1. Fatigue 
Fatigue is often considered to be the most prevalent symptom of MS, and has been 
estimated to affect up to 90% of patients with MS (Bol et al., 2009), impacting 
significantly on level of disability and quality of life (Amato et al., 2001). Fatigue has 
been shown to impact on cognition both in healthy control (DeLuca, 2005) and MS 
participants, although the extent to which it contributes to cognitive impairment in 
MS is still debated. In MS populations fatigue has been associated with reduced 
performance on tasks of memory, executive function (e.g. planning) (Krupp & Elkins, 
2000) and information-processing speed (Diamond, Johnson, Kaufman, & Graves, 
2008). However, several studies suggest there is no evidence-based relationship 
between self-reported fatigue and cognitive performance in MS (e.g. Bailey et al., 
2007; Parmenter, Denney, & Lynch, 2003), and further research exploring the 
association between objective fatigue measures and cognitive performance would be 
informative.  
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1.4.6.2. Mood 
The lifetime prevalence rate of depression among the MS population, estimated at 
about 50% (Arnett & Strober, 2011; Goldman Consensus Group, 2005; Marrie, 
Cutter, Tyry, Campagnolo, & Vollmer, 2009), is higher than for the general 
population and this is generally thought to be an underestimation. Using the Beck 
Depression Inventory (BDI), many studies have found that a significantly greater 
number of patients with MS reach the cut-off criteria for depression relative to healthy 
controls (e.g. Mattioli, Bellomi, Stampatori, Parrinello, & Capra, 2011; Sundgren, 
Maurex, Wahlin, Piehl, & Brismar, 2013). Similar findings have resulted from studies 
involving other measures of mood such as the Centre for Epidemiologic Studies 
Depression Scale (CESD; Marrie et al., 2009) and the Hospital Anxiety and 
Depression Scale (HADS; Honarmand & Feinstein, 2009). This higher prevalence 
among the MS populations has been attributed to numerous factors including disease-
related changes in the brain, fatigue, pain, level of physical disability and reduced 
quality of life (Arnett, Barwick, & Beeney, 2008).  
In patients with MS who also suffer from depression, depression has been 
correlated with reduced information-processing speed, new learning and memory 
(Demaree, Gaudino, & DeLuca, 2003; Diamond et al., 2008) as well as executive 
function deficits (Arnett, Higginson, & Randolph, 2001) relative to non-depressed 
patients with MS. Thus, depression may impact patients’ understanding and recall of 
complex treatment-related risk information. However, as with fatigue, other studies 
have not found significant correlations between cognitive function and depression in 
MS (e.g. Karadayi, Arisoy, Altunrende, Boztas, & Sercan, 2014; Mattioli et al., 2011).  
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1.4.6.3. Pain 
Pain is another common symptom experienced by patients with MS although the 
extent to which it is viewed as a severe, disabling symptom depends on factors such 
as disease stage and severity as well as the location of the brain lesions (Foley et al., 
2013). Pain has been shown to reduce performance on cognitive tasks in many 
individuals including on tests of attention, executive function, memory and general 
cognitive function (Moriarty, McGuire, & Finn, 2011).  
1.4.7. Section Summary 
There is evidence of cognitive impairment in MS, estimated to occur in 40-70% of 
cases. A specific profile of cognitive deficits in MS is emerging. Information-
processing speed is the most common deficit along with impairments in new learning 
and memory. Executive function and attention are also affected, while language 
comprehension is typically spared. Recent evidence suggests that information-
processing speed is the primary cognitive deficit in MS and may account for 
difficulties in other cognitive domains such as memory, new learning and executive 
function. In addition to findings of low numeracy in people with MS and the general 
population, as well as reduced risk awareness in MS, MS-related cognitive 
impairments may further impact on patients’ ability to understand and recall 
treatment-related risk information. Furthermore, common MS symptoms of fatigue, 
depression and pain may also adversely affect cognitive function in MS, although 
research does not yet provide substantive support for this. Together, these findings 
again suggest that future research into modes of information presentation which 
reduce the impact of information-processing speed deficits and poor initial learning 
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may be beneficial in facilitating greater risk awareness in MS. However, researchers 
would firstly benefit from a greater understanding of the cognitive correlates of risk 
awareness in MS.  
1.5. Impact of MS-Related Cognitive Impairment on Risk Awareness 
In the context of the current study, risk awareness is operationalised as the 
capacity for new learning, understanding, and later recall of presented treatment 
information. This is similar to the construct of ‘capacity’ as used in everyday clinical 
practice (Grisso & Appelbaum, 1995). Capacity to make informed decisions about 
one’s care purportedly requires four main cognitive abilities: (i) understanding of 
relevant information, (ii) reasoning with treatment-related risks and benefits, (iii) 
appreciation of the significance of this information and (iv) expression of choice 
(Grisso, Appelbaum, & Hill-Fotouhi, 1997). Neuropsychological deficits may 
compromise some or all of these abilities (Basso et al., 2010). Risk awareness is 
typically evaluated by examining one’s ability to make informed decisions.  
While MS-relevant studies are scarce, much research has documented 
correlations between specific cognitive functions (e.g. working memory, new 
learning, executive function, attention) and treatment-related decision-making in 
other cognitively-impaired populations, particularly dementia and Parkinson’s 
disease. Overall, problems in understanding appear most common across disorders 
(Basso et al., 2010) and are impacted primarily by memory and executive function 
deficits. Like other neurological disorders such as dementia and Parkinson’s, MS also 
involves memory and executive function difficulties. Thus, it is not unreasonable to 
expect that patients with MS would also struggle to understand, reason with and 
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appreciate risk information. It is also logical to surmise that reduced information-
processing speed, the most common MS-related cognitive deficit, may limit the 
amount of information initially registered, again limiting understanding.  
Only recently have studies begun to directly examine this relationship 
between cognitive deficits and informed decision-making in MS. Patients with MS 
who also had neuropsychological deficits performed significantly worse than a group 
of MS patients without neuropsychological deficits and a healthy control group on an 
Understanding Treatment Disclosures Scale (UTD). Moreover, poor understanding of 
treatment information correlated with reduced capacity for new learning as well as 
executive dysfunction (Basso et al., 2010).  
 McKnight (2007) developed the Test of Reasoning using Statistical 
Information (TRUSI) - a measure of statistical reasoning which includes an 
assessment of reasoning ability in relation to MS-related risk. Participants with MS 
demonstrated significantly weaker performance on this test relative to control 
participants. This finding was not replicated by Hans (2009). However, both studies 
revealed substantial correlations between statistical reasoning and cognitive functions 
of WM, sustained attention, processing speed and other reasoning domains. This 
suggests that patients with MS who have cognitive impairment in these domains may 
also have difficulties in reasoning about proposed treatments.  
A more recent study employed the Game of Dice Task (GDT) to explore 
correlations between working memory, executive function and decision-making in 
MS. This is a decision-making task in which participants are presented with 
probabilistic risk information on potential gains and losses. Working memory deficits 
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and reduced information-processing speed correlated with more risky decisions but 
there was no correlation between executive function and decision-making in the 
context of risk-based decisions. Where information-processing speed and working 
memory deficits were more pronounced, those patients tended to make decisions 
involving higher levels of risk (Farez, Crivelli, Leiguarda, & Correale, 2014). These 
findings suggest that impairments in working memory or information-processing 
speed may impact on decision-making in the context of risk information.  Notably, 
this study lacked a treatment-related risk context. Perceived importance of the risk-
based decision may impact on an individual’s effort or performance in terms of 
understanding, appreciating, reasoning and making decisions when presented with 
risk information.   
Of course, other MS-related cognitive functions, such as complex attention or 
information-processing speed, and their relation to treatment-related decision-making 
capacity have not yet been explored fully. Once investigated, researchers will know 
more about how best to present treatment-related risk information in MS settings and 
which cognitive deficits to target. This is important given the emphasis on shared-
decision making in clinical settings. Nonetheless, some studies have already begun to 
explore how different methods of presenting information to people with MS might 
improve risk understanding and recall by attempting to target these cognitive deficits. 
1.5.1. Section Summary 
Cognitive deficits may impact on an individual’s risk awareness including their 
capacity to (i) understand, (ii) reason with, and (iii) appreciate treatment-related risk 
information and to (iv) express a choice regarding their medical care. Across a range 
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of disorders, reduced understanding of risk appears to be most commonly 
compromised. Cognitive deficits in working memory and executive function appear 
to correlate most often with this reduced understanding of risk.  
Studies have only recently begun to explore the cognitive correlates of 
reduced risk awareness in MS. The findings to date suggest that people with MS may 
also demonstrate reduced understanding of risk which also appears to correlate with 
MS-related working memory and executive function deficits. Deficits in working 
memory, executive function, information-processing speed or attention in MS may 
also correlate with reduced ability to reason with risk information. Future research 
and replication studies are necessary to fully elucidate the cognitive correlates of 
reduced risk awareness in MS which in turn could inform clinical practice. In 
particular it could help to highlight alternative modes of presentation of information 
in clinical settings.  
1.6. Presentation of Treatment-Related Information in MS 
1.6.1. Repetition 
A series of studies by DeLuca and colleagues found that additional learning trials 
enabled participants with MS to perform as well as controls on verbal recall and 
recognition tasks (DeLuca et al., 1998; 1994). This suggests that repetition of 
treatment information may increase learning, understanding and recall of risk 
information in MS. However, this group also argues that simple repetition alone is not 
always sufficient and that individuals with MS may require more intensive strategies 
to improve new learning and memory (Chiaravalloti, Demaree, Gaudino, & DeLuca, 
2003).  
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1.6.2. Self-generation 
Self-generated learning refers to a strategy whereby individuals generate their own 
ideas, images, or words to aid recall of presented information (Slamecka & Graf, 
1978). Self-generated information requires more attention and effort than didactic 
information, is more deeply encoded and thus better remembered (Goverover, Basso, 
Wood, Chiaravalloti, & DeLuca, 2011). One study demonstrated significant 
improvements in recall of sentence endings in MS following a sentence-completion 
task relative to a didactic task (i.e. whole sentence heard) (Goverover & DeLuca, 
2002). While, these participants with MS did not have memory impairments, it was 
later found that MS patients with memory impairment also benefit from self-
generation (Basso, Ghormley, Lowery, Combs, & Bornstein, 2008). However, a more 
recent study has noted that the benefit of self-generation for learning and memory in 
patients with MS is dependent on intact executive functions (Goverover, 
Chiaravalloti, & DeLuca, 2013). Despite poor ecological validity, these studies 
suggest that participants with MS may also show benefits of self-generation in 
understanding and recall of treatment-related risk information in clinical settings.  
1.6.3. Pacing 
‘Pacing’ refers to the presentation of information at a slower rate than is normal. A 
recent study revealed a benefit of pacing in MS. MS and healthy control participants 
were presented with two aural extracts detailing fictitious health information, one at a 
slow rate and the other at a fast rate. As expected, the MS group recalled significantly 
less information than the control group. Interestingly, slowed presentation led to 
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significantly improved recall of health information in both groups. Information-
processing speed partly accounted for this effect (Lloyd, 2012).  
Another study explored whether slowed presentation of the Rivermead 
Behavioural Memory Test led to improved recall memory in MS. They found that 
participants with MS could recall significantly more elements of the presented stories 
in the slow presentation condition relative to the fast presentation condition for both 
immediate and delayed recall, with this effect being more pronounced for delayed 
recall. Furthermore, this was the case for participants with MS with and without 
verbal memory problems (Arnett, 2004). Based on these findings, Arnett (2004) also 
hypothesised that processing-speed may explain the benefits of slowed presentation 
immediate and delayed recall memory in MS.  
1.6.4. Spacing 
Another possible method of communicating treatment information in MS is based on 
the spacing effect, a phenomenon whereby learning trials presented over time and 
interspersed with breaks lead to greater retention rates than with massed presentation 
(i.e. consecutive trials) (Ebbinghaus, 1964).  This effect has been well-established in 
the general population for example in advertising and consumer memory 
(Janiszewski, Noel, & Sawyer, 2003) and student learning (Carpenter, Cepeda, 
Rohrer, Kang, & Pashler, 2012). It has also been demonstrated in clinical populations, 
for example, traumatic brain injury (TBI) and amnesia.   
 Patients with amnesia were presented with word-lists that were either repeated 
altogether (massed) or with spaces in-between (spaced). Patients demonstrated 
enhanced recall and recognition of this word-list in the spaced relative to the massed 
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condition (Cermak, Verfaellie, Lanzoni, Mather, & Chase, 1996). It was hypothesised 
that this benefit of presenting trials over time, rather than in succession, is partly due 
to the greater information-processing time afforded by the delay between trials.   
Using a TBI sample, participants heard a large word list either once (massed 
condition), twice consecutively (massed with repetition condition) or twice in smaller 
word blocks (spaced condition). Participants recalled significantly more words in the 
spaced condition relative to the massed conditions indicating that spaced presentation 
may improve learning in individuals with TBI (Hillary et al., 2003). A later, more 
ecologically valid TBI study revealed a significantly greater benefit of spaced 
presentation for learning of functional tasks, relative to massed presentation. Thus, 
distributing the presentation of trials over time facilitated more learning (Goverover, 
Arango-Lasprilla, Hillary, Chiaravalotti, & DeLuca, 2009a).  
Only two studies, to this author’s knowledge, have explored the potential 
benefits of the spacing effect in MS, although neither do so in the context of risk 
information. The first engaged MS and healthy control participants in verbal 
(paragraph learning) and visual (route learning) learning tasks. In the spaced 
condition, the task was presented three times with a 5-minute break during the 
intervals. In the massed condition, the task was presented consecutively three times. 
All participants performed significantly better on verbal recall and recognition tasks 
in the spaced condition relative to the massed condition, with no difference in the 
level of ‘spacing’ benefit between the groups (Goverover, Hillary, Chiaravalloti, 
Arango-Lasprilla, & DeLuca, 2009b). This suggests that presenting information in 
chunks over time facilitates better verbal learning and memory in MS. The authors 
note that the spacing effect is typically greater for more meaningful information and 
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for information that is semantically complex rather than structurally complex, 
something which has also been mooted by others (e.g. Janiszewski et al., 2003).  
This group later hypothesised that self-generation and spaced learning together 
would lead to significantly enhanced learning and memory when compared with 
spaced learning alone. Participants performed three functional tasks (learning names, 
appointment times and object locations) in three conditions (massed, spaced, spaced 
with self-generation).  Recall was best in both MS and healthy control participants for 
the ‘self-generation with spaced learning’ condition across all three tasks, thus 
supporting their hypothesis. However, recall in the ‘spaced learning’ condition was 
also significantly better relative to the ‘massed’ condition, again demonstrating the 
usefulness of this strategy in improving learning and memory in MS (Goverover et 
al., 2011).  
One limitation of these studies is the difficulty in separating the effects of 
repetition and spacing, especially as repetition alone can improve learning (DeLuca et 
al., 1998; DeLuca, Leavitt, Chiaravalloti, & Wylie, 2013). Moreover these spacing 
studies focus on new learning and memory for simple everyday tasks rather than for 
complex risk information. Yet it has been shown that learning and memory deficits 
impact on MS-related risk awareness (e.g. Basso et al, 2010). Thus, it was felt that it 
would be worthwhile exploring the efficacy of spacing in facilitating greater risk 
awareness in MS in clinical settings as well as exploring the benefit of spaced 
presentation separate from the benefit of repetition.  
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1.6.5. Section Summary 
Limited research has been carried out to determine the ways in which presentation of 
information can be adjusted to facilitate improved learning and memory of new 
information in MS. While repetition of information demonstrates limited benefits, 
self-generation, pacing and spacing of information show promise in aiding learning 
and recall in MS. Pacing and spacing are thought to facilitate improved learning and 
recall by allowing extra time to process information, thus reducing the effects of 
information-processing speed deficits common in MS. However, these studies lack 
ecological validity. None explore the benefits of such strategies in a clinical setting, to 
aid understanding and recall of risk-information regarding potential treatment options.  
1.7. Rationale behind Efficacy of Spaced Presentation in Improving Learning 
and Memory in MS 
Given the ample evidence which points towards reduced information-processing 
speed as the primary deficit in MS, one may suppose that the spacing effect affords 
greater time to process new information. Certainly, this is the view which has been 
advocated by the few studies which have explored the benefits of the spacing effect 
for learning and memory in MS (Goverover et al., 2009b; Goverover et al., 2011) as 
well as in other neurological conditions (e.g. Cermak et al., 1996; Goverover et al., 
2009a).  
Theories of memory and encoding also provide an insight into the possible 
workings of this spacing effect.  One theory moots that a natural ‘encoding deficit’ 
becomes evident during massed presentation because the initial stimulus remains in 
WM while the second stimulus is presented. Conversely, spaced items benefit from 
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more time alone in WM and receive greater attention than do consecutively presented 
items, thus strengthening the memory trace (Braun & Rubin, 1998).  The ‘deficient 
processing hypothesis’ postulates that consecutive repetition causes habituation to that 
stimulus, leading to less processing and therefore reduced benefit of repetition 
(Hintzman, 1974). Since MS-related memory difficulties likely occur at encoding, 
these natural encoding phenomena may be more pronounced in MS, leading to a more 
prominent difficulty. This provides further rationale for additional exploration of the 
benefits of spaced presentation in MS.  
1.8 Outline of Research 
1.8.1. Objectives of the Proposed Study 
The present study aimed to establish whether the spacing effect could be used 
to facilitate greater risk awareness in people with MS within a health context. 
Specifically, it investigated whether spaced presentation of risk information could 
improve understanding and recall of treatment-related risk information in people with 
MS. It extended literature from cognitive rehabilitation in MS by exploring the 
potential benefit of spaced presentation using aural information detailing realistic risk-
benefit treatment information. In doing so, this study provided a more ecologically 
valid examination of the spacing effect in MS than has been carried out to date which 
may hold practical value in clinical settings. This study also examined the cognitive 
correlates of understanding and recall of treatment-related risk information. Finally, 
this study attempted to distinguish the effects of repetition and spacing by presenting 
information which was broken into chunks and heard just once, rather than repeating 
the same trial interspersed with breaks as in previous studies.  
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1.8.2. Rationale for the Proposed Study 
With the development of newer, more efficacious second-line MS medications which 
carry potentially life-threatening side effects, patients with MS must comprehend 
complex risk-benefit information regarding potential MS treatments. Furthermore, the 
promotion of a shared decision-making (SDM) model within health settings means 
patients must also use this complex information to make decisions regarding their 
medical treatment. Yet, numerous studies have documented reduced risk awareness in 
MS which may be associated with the well-documented cognitive impairments of 
reduced information-processing speed, memory and new learning in MS.  
While the provision of EBPI can improve risk knowledge in MS, inadequate 
risk awareness persists in a high proportion of patients. This suggests that that an 
increase in the quantity of information (i.e. EBPI alone) is unlikely to facilitate greater 
risk awareness in the majority of this population. Limited research has explored ways 
of facilitating greater learning and recall in MS by altering the mode of information 
presentation. However no study has explored the benefit of such methods in 
facilitating greater risk awareness in MS. Several recent studies have provided 
tentative evidence for the benefits of different presentation formats in facilitating 
greater recall of information in MS. Repetition, pacing, self-generation and spacing of 
information have all been shown to improve recall in MS, seemingly because this 
reduces the impact of information processing speed deficits.  
The current study draws on prior research by Goverover and colleagues 
(2009a; 2009b; 2011) who report a benefit of the spacing effect in facilitating greater 
verbal recall memory in MS and TBI. Hillary and colleagues (2003) also reported a 
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benefit of the spacing effect in facilitating verbal memory recall in patients with TBI 
who, like patients with MS, have been shown to suffer from encoding memory 
deficits. The current study builds on such research by exploring the benefits of spaced 
presentation in facilitating greater risk awareness in MS, specifically greater 
understanding and recall of treatment-related risk information. The use of aurally-
presented fictitious information which describes realistic risk-benefit ratios of various 
treatment options offers a more ecologically valid study of the spacing effect. This 
will help to establish the potential clinical effectiveness of spaced presentation and its 
ability to aid the advancement of true SDM.  
Finally, the current study is the first, to this author’s knowledge, which has 
attempted to distinguish the effects of repetition and spacing by presenting 
information which was presented just once in either a massed or spaced format. It is 
also the first to include a massed-with-delay condition in order to ascertain whether an 
otherwise significant benefit of spaced presentation could be confounded by time 
delay during the ‘spaces’ and the effect of this delay on recall.  
1.8.3. Research Questions  
1. Does spaced presentation of treatment-related risk information lead to 
improved understanding and recall of risk information in all participants when 
compared to massed presentation? 
2. Are people with MS differentially affected by spaced presentation of 
treatment-related information relative to healthy controls in terms of recall and 
understanding of risk information?  
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3. What are the specific cognitive functions associated with understanding and 
recall of treatment-related risk information?  
1.8.4. Hypotheses  
1. It was hypothesised that the MS group would understand and recall 
significantly less treatment-related risk information relative to the healthy 
control group in all presentation conditions.  
2. It was hypothesised that the spaced presentation of treatment-related risk 
information would significantly improve recall and understanding of 
treatment-related risk information in both MS and healthy control participants 
relative to massed presentation of information.   
3. It was hypothesised that there would be a greater benefit of spaced 
presentation of risk information in the MS group relative to the control group.  
4. The specific cognitive correlates of understanding and recall of treatment-
related risk information were explored. It was hypothesised that reduced speed 
of information-processing would be associated with reduced recall and 
understanding of treatment-related risk information in both the MS and 
healthy control group.  
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2. Method 
2.1. Research Approval 
The project received ethical approval from the NHS National Research Ethics Service 
following Proportionate Review (see Appendix A). The Research and Development 
department of University College London Hospitals NHS Foundation Trust gave 
permission for the recruitment of the MS group from the National Hospital for 
Neurology and Neurosurgery (NHNN) (see Appendix B). Finally, ethical approval 
was also obtained from the Research Ethics Committee, Royal Holloway, University 
of London.  
2.2. Design 
The project employed a cross-sectional mixed experimental design to test the effects 
of presentation format on participants’ recall and understanding of risk information. A 
neuropsychological test battery was also administered. A 3 X 2 mixed model was 
used to explore differences in recall and understanding of risk information across 
different modes of information presentation (within-subject variable) between MS and 
healthy control participants (between-subject variable). The within-subject variable 
(presentation format) had three levels (massed, massed-with-delay, spaced). The 
between-subject variable (group) had two levels (MS; healthy control). The primary 
dependent variables were immediate recall score and understanding of risk 
information score. Groups were matched on age, gender and pre-morbid intellectual 
functioning.  
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2.3. Participants 
A total of 60 participants were recruited for the study; 30 MS participants and 30 
healthy control participants. Suitability for participation was assessed using the 
following inclusion and exclusion criteria.  
Inclusion criteria: 
 English as a first language  
 Aged between 25-60 years 
 For MS participants only: A definite clinical diagnosis of MS (relapsing-
remitting, primary progressive or secondary progressive) by a Consultant 
Neurologist in accordance with the McDonald criteria (McDonald et al., 2001) 
Exclusion criteria: 
 History of a neurological or other medical condition, other than MS for the 
MS group, that may impact cognition 
 A previous or current significant psychiatric diagnosis 
 Current or previous history of drug or alcohol misuse 
 A significant visual or hearing impairment that would interfere with the 
person’s ability to engage with cognitive testing 
 Lack of mental capacity to provide informed consent 
 For MS participants only: Currently experiencing a relapse of MS, defined as 
a recent exacerbation of symptoms or presence of new symptoms up to 28 
days prior to the study 
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 For MS participants only: significant change to medication regime up to 28 
days prior to the study 
2.4. Recruitment 
2.4.1. MS Participants 
The MS group was recruited from a database held at the London-based National 
Hospital for Neurology and Neurosurgery (NHNN). This database contained a list of 
patients with MS who had previously expressed an interest in being contacted 
regarding upcoming research studies. Potential participants were identified by a 
member of the patients’ direct healthcare team (Clinical Psychologist, Clinical Nurse 
Specialist and Consultant MS Nurse). An invitation letter (see Appendix C), 
participant information sheet (see Appendix D) and reply form were then sent to these 
patients via post. Participants contacted the MS researcher directly to express interest 
in the study by returning the reply form. The MS researcher then contacted each 
participant by telephone to discuss the study in more detail and answer any questions. 
All participants were assured that their participation was entirely voluntary and that a 
decision to decline to take part would not have any impact on their ongoing provision 
of medical care. All MS participants completed the study in their own homes.  
2.4.2. Healthy Control Participants 
In order to ensure that the MS and healthy control groups were matched on gender,  
age and pre-morbid intellectual function, recruitment of healthy control participants 
began only once an indication of age, pre-morbid intelligence level and gender began 
to emerge in the MS sample. 
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Healthy control participants were recruited through several avenues: An 
opportunistic sampling approach was employed in recruiting within friends and 
family networks (London-based) who were sent an invitation letter and information 
sheet via email or post (see Appendix E and Appendix F). Additionally, letters of 
request were sent to a named representative within personnel departments of local 
companies (i.e. London-based) (see Appendix G), along with an information sheet. 
All participants were given information sheets (see Appendix F) and those interested 
in the study contacted the researcher directly. A subsequent telephone conversation 
was arranged to further discuss the study and answer any questions. Healthy control 
participants were given the choice to complete the study at their home (friends or 
family only), place of work, or at a central London office belonging to Royal 
Holloway, University of London.  
2.4.3. All participants 
All participants were given at least two weeks prior to commencing the study to 
decide whether or not to partake. After this time, the researcher contacted them to 
arrange a study visit. Written informed consent was obtained from each participant 
before commencing any study tasks (see Appendix H for MS consent form and 
Appendix I for Healthy Control consent form).  
2.5. Safety Protocol 
A protocol which followed the Guidance from the National Health Service Lone 
Worker Policy (NHS Security Management, 2005) was established in order to ensure 
the researcher’s safety when undertaking study sessions, particularly in participants’ 
homes. All MS participants were known to their clinical care team and had undergone 
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previous home visits as part of their care. All healthy control participants were seen 
either at a central London location belonging to Royal Holloway, University of 
London, or at their place of work. Only those healthy control participants personally 
known to the researcher were seen at home.  
2.6. Power Analysis 
The sample size was calculated from a power analysis based on the expected findings 
from the primary outcome (i.e. whether a spaced presentation format improves recall 
and understanding of risk information). A 3 X 2 mixed analysis of variance 
(ANOVA) was the intended analysis for the main dependent variable (immediate 
recall) with ‘presentation format’ (spaced, massed, or massed-with-delay) as the 
within-subject variable and ‘group’ (MS or healthy control) as the between-subject 
factor.  
Using participants with traumatic brain injury, Hillary and colleagues (2003) 
compared the benefits of spaced versus standard presentation on a word-list learning 
and recall task. They found a significant benefit of spaced presentation with an effect 
size of partial 𝜂2 = .37. This is considered a medium effect size according to Cohen’s 
classifications (Cohen, 1992).  
G*Power (Faul, Erdfelder, Lang, & Buchner, 2007) was used to compute the 
power analysis. Considering the planned analysis (ANOVA), the anticipated medium 
effect size, the alpha level set at 0.5 and power set at 0.7, a sample of 60 participants 
was recommended. Therefore, a minimum of 30 MS and 30 healthy control 
participants was deemed sufficient for the current study.  
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2.7. Assessment Procedure 
Participants were informed that study visits would last approximately two hours. Each 
visit began with the researcher providing an explanation of the study and participants 
were invited to ask questions. Written informed consent was received before the 
commencement of any study tasks and participants were reminded that they may 
withdraw at any time.   
All participants were offered the opportunity to receive feedback on the results 
of the study. Those interested in feedback granted permission for their contact details 
to be temporarily retained and they were provided with an estimated date of feedback.  
Relevant demographic and clinical information was obtained for each 
participant; including age, date of birth, level of education, occupation, history of any 
neurological condition or significant psychiatric illness, and sensory impairments 
including hearing and vision. This information was obtained from the medical notes 
and patient self-report. MS participants also detailed their MS diagnosis (RRMS, 
PPMS, or SPMS), date of last relapse, whether they had fully recovered since their 
last relapse and any significant recent medication changes (< 28 days).  
2.8. Materials and Order of Test Administration 
The order of measures and test administration is outlined in Table 1. Participants first 
completed baseline measures of mood (Hospital Anxiety and Depression Scale, 
HADS; Zigmond & Snaith, 1983) and fatigue (Fatigue Severity Scale, FSS; Krupp, 
LaRocca, Muir-Nash, & Steinberg, 1989) and a baseline measure of comprehension 
(MTT). These indicated the level of anxiety, depression and fatigue symptoms 
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experienced by participants in everyday life. Participants then completed the 
experimental measure which was interspersed with several neuropsychological tests. 
On completion of the experimental measure, further neuropsychological tests were 
administered as well as a measure of statistical reasoning (TRUSI-B).  
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Table 1  
Order of Measures and Test Administration  
Study procedure Test order 
Baseline measures & measure of 
comprehension 
1. FSS 
2. HADS 
3. Modified Token Test (MTT) 
Experimental tasks (with some 
neuropsychological testing) 
 
Order of presentation format was 
counterbalanced across participants. One 
example of the order of presentation format 
is: 
1. Standard presentation of Vignette A 
2. Spaced presentation of Vignette B 
3. Standard presentation-with-delay of 
Vignette C 
Wechsler Test of Adult Reading (WTAR), 
Symbol Digit Modalities Test (SDMT), & 
Arithmetic subtest (WAIS-III) administered 
during delays. 
See Table 2 for detailed description of each 
experimental condition 
Neuropsychological testing (continued) 
 
1. California Verbal Learning Task 
(CVLT-II) first five recall trials 
2. The Verbal and Spatial Reasoning 
Test - Verbal Analogies subtest 
3. The Verbal and Spatial Reasoning 
Test - Verbal Series subtests  
4. Test of Reasoning Using Statistical 
Information Version B (TRUSI-B) 
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2.8.1. Experimental Measure:  
The experimental measure consisted of three short aural extracts, or vignettes, which 
were heard by all participants. These vignettes were played to participants in audio 
tape format to allow for consistency across all participants. Each vignette provided 
information about one of three different fictitious diseases (Durkins Disease, 
Shannon’s Disease, Raylick’s Disease) and two fictitious drug treatments for each 
(Ganlin and Tylon, Limac and Braddex, Trixon and Fylene) (see Appendix J). Each 
was designed to replicate the type of information provided to patients during clinical 
consultations. As such, these vignettes detailed the symptoms, prognosis, treatments, 
and treatment side-effects and benefits for each fictitious disease. Information leaflets 
written by the pharmaceutical companies detailing side-effects of some common MS 
and non-MS medications were referred to when choosing the wording of symptoms 
and the format of numerical and statistical risks for the current vignettes. Again, this 
was to ensure that the style of information provided was similar to that which lay 
people are likely to encounter when making medical decisions. These vignettes were 
then reviewed by a neuropsychologist with much past experience in MS clinic settings 
and feedback was also sought from 5 MS participants during the pilot study. While 
these participants felt that the information contained in each vignette was rather 
complex, they all reported it to be of similar complexity to the type of treatment-
related information they heard on receiving an MS diagnosis, albeit somewhat briefer.  
Each vignette was presented in a different format which is detailed in Table 2 
below. One vignette was presented in its entirety (massed presentation). Another was 
presented in three shorter segments of equal length with a 5-minute break between 
each segment (spaced presentation). The final vignette was presented in its entirety 
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followed by a 10-minute delay before recall (massed presentation with delay). This 
final presentation format was included because the primary outcome measure of the 
study is immediate recall. However, the time between participants receiving one-third 
of the information in the spaced condition and their recall of this information is 
approximately ten minutes. Therefore, the inclusion of a ‘massed with 10-minute 
delay’ condition helps to ascertain whether an otherwise significant benefit of spaced 
presentation could be confounded by time delay for recall of the blocked presentation.  
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Table 2 
Composition of Experimental Conditions (Massed, Spaced and Massed-with-delay 
Presentation Formats) 
Experimental condition Order of tests 
Massed presentation 1. Vignette A presented in full 
2. Immediate recall of vignette A 
3. Measure of understanding of information 
for vignette A  
Spaced presentation 1. Vignette B (Part 1) presented  
2. Wechsler Test of Adult Reading 
(WTAR) (during 5 minute interval) 
3. Vignette B (Part 2) presented  
4. Symbol Digit Modalities Test (SDMT) 
(during 5 minute interval) 
5. Vignette B (Part 3) presented 
6. Immediate recall of vignette B 
7. Measure of understanding of information 
for vignette B 
Massed presentation with delay 1. Vignette C presented in full 
2. Arithmetic subtest from Wechsler Adult 
Intelligence Scale Third Edition (WAIS-
III) (during 10-minute interval) 
3. Recall of vignette C 
4. Measure of understanding of information 
for vignette C  
Immediate recall and understanding of risk information were assessed 
following each vignette. The vignettes and their corresponding scoring criteria were 
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developed specifically for the current study. As such there is no established validity or 
reliability for these measures. However, the development of each vignette and the 
scoring method applied for immediate recall was based on the style and scoring 
method used by several well-established neuropsychological tests of verbal memory, 
for example the BIRT Memory Information Processing Battery (BMIPB; Coughlan, 
Oddy, & Crawford, 2007). Participants received two points for correctly recalled 
elements of information and one point for each partially correct element. There were 
35 elements of information within each vignette, with a maximum possible score of 
70 points (see Appendix K for sample record form and Appendix L for scoring 
examples). This score was then translated into a ‘percentage correct’ score indicating 
the amount of the vignette accurately recalled by each participant.  
Understanding of the risk information was measured after each vignette using 
a set of eight questions designed to capture participants’ understanding of numerical 
and verbal risk information (see Appendix M). Again, participants received two 
points for correctly recalled items and one point for each partially correct item (see 
Appendix N for scoring examples). A maximum total score of 16 was possible and 
total scores were converted into a ‘percentage correct’ score prior to data analysis.  
Each vignette was approximately two minutes in duration. A timeline 
highlighting the equivalence of timings for each presentation format and interim 
neuropsychological tests is provided in Table 3 below.   
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Table 3 
Design Schedule Depicting the Timings for Each of the Three Presentation Formats – 
Massed, Massed-with-delay, and Spaced.  
Minutes Vignette A  
Massed 
presentation 
Vignette B  
Spaced 
presentation 
Vignette C 
Massed-with-delay 
presentation 
1-2  X X 
3-4   X 
5-6    
7-8  X  
9-10    
11-12 X   
13-14 X X  
15-16 Recall Recall Recall 
Note. X indicates start time of each presentation condition or neuropsychological test.   
Elements of the neuropsychological test battery were administered in the 5-
minute (i.e. during the ‘spaced’ presentation condition) and 10-minute (i.e. during the 
‘massed-with-delay’ presentation condition) delay periods. An effort was made to 
ensure that these tasks were relatively low-level so as not to interfere with recall and 
understanding of the presented risk information. The tests administered during these 
breaks were kept constant for all participants so as not to add a further confounding 
variable.  
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To control for potential order effects, the order of presentation of format was 
counterbalanced across participants using a Latin Square. This ensured that similar 
numbers of participants heard the three fictitious vignettes (Durkins disease, 
Shannon’s disease and Raylick’s disease) in each sequence of the three presentation 
formats (massed, massed-with-delay, spaced). Using a Latin Square, three different 
combinations of order of vignette presentation format were possible (see Table 4 and 
Table 5).  
Table 4  
Latin Square Presentation Formats  
A B C 
B C A 
C A B 
Note. Where A = massed, B = spaced, C = massed with delay  
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Table 5 
Latin Square Resulted in the Following Three Possible Sequences of Presentation 
Format for Each of the Three Disease Vignettes 
Sequence 1 A1 B2 C3 
Sequence 2 B1 C2 A3 
Sequence 3 C1 A2 B3 
Note: Where A = massed, B = spaced, C = massed with delay; 1 = Durkin’s disease 
vignette, 2 = Shannon’s disease vignette, 3 = Raylick’s disease vignette 
For example, Sequence 1 was selected as the initial block in the MS group. 
This refers to the A1-B2-C3 sequence. Therefore the first MS participant heard the 
vignette for Durkin’s disease in the ‘massed’ condition, then Shannon’s disease in the 
‘spaced’ condition, followed by Raylicks disease in the ‘massed-with-delay’ 
condition. An equal number of participants (n=10) in both the MS and healthy control 
groups completed each of the three different sequences.  
2.8.2. Neuropsychological Test Battery and Measures 
The neuropsychological test battery was administered for several reasons: (1) 
to explore whether any cognitive functions were correlated with understanding and 
recall of risk information; (2) to ensure that the MS sample was representative of the 
wider MS population in terms of cognitive ability, to enable generalisability of the 
results.  
The neuropsychological test battery consisted of eight different measures 
assessing a range of cognitive functions. These measures are outlined in Table 6 
below (also see Appendices O-X).  
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Table 6 
Neuropsychological Test Battery and Corresponding Cognitive Domains Measured  
Test Cognitive domain measured 
Wechsler Test of Adult Reading (WTAR; 
Holdnack, 2001) 
Pre-morbid intellectual function 
California Verbal Learning Task (CVLT-
II) first five recall trials (Delis et al., 
2000) 
Immediate verbal recall & recognition 
memory 
Arithmetic subtest from Wechsler Adult 
Intelligence Scale Third Edition (WAIS-
III; Wechsler, 1997)    
Working memory & arithmetic ability 
The Modified Token Test (MTT; 
Coughlan & Warrington, 1978)  
Comprehension 
Symbol Digit Modalities Test, oral 
response form (SDMT; Smith, 1982) 
Information processing speed 
The Verbal and Spatial Reasoning Test - 
Verbal Analogies subtest (VESPAR; 
Langdon & Warrington, 1995) 
Verbal inductive reasoning 
The Verbal and Spatial Reasoning Test - 
Verbal Series subtests (VESPAR; 
Langdon & Warrington, 1995) 
Arithmetic  
Test of Reasoning Using Statistical 
Information Version B (TRUSI-B; 
McKnight, 2007; Hans, 2009) 
Statistical reasoning 
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Given that motor impairments and chronic fatigue are common difficulties 
associated with MS, test selection considered those measures which do not rely 
heavily on motor skills and which are of relatively short duration in order to minimise 
the impact of such difficulties on test performance. Each measure is detailed below.  
2.8.2.1. California Verbal Learning Test (CVLT-II):  
The California Verbal Learning Test-2
nd
 Edition (CVLT-II; Delis, Kramer, 
Kaplan, & Ober, 2000) consists of a 16-item word list which is read aloud to 
participants five times, at the rate of one word per second. Participants are asked to 
verbally recall as many words as possible following each trial. Both the CVLT-II and 
SDMT (outlined below) make up part of an MS cognitive screening battery known as 
the Brief International Cognitive Assessment for Multiple Sclerosis, which is 
recommended as a gold standard assessment of cognition in MS by an expert 
consensus group (BICAMS; Langdon, Amato, Boringa et al., 2012). The CVLT-II has 
been shown to have good test-retest reliability for healthy control (Delis et al., 2000; 
Woods, Delis, Scott, Kramer, & Holdnack, 2006) and MS participants (Benedict, 
2005; Delis et al., 2000). It also has high construct, concurrent and external validity in 
people with MS and the total recall score obtained from the five consecutive trials 
used in this study has been shown to reliably distinguish MS participants from healthy 
controls (Stegen et al., 2010). 
2.8.2.2. Symbol Digit Modalities Test (SDMT): 
The Symbol Digit Modalities Test (SDMT oral form; Smith, 1982) is a 
measure of information-processing speed. Participants are presented with a visual key 
consisting of nine single digits, each matched to a particular abstract symbol. Rows of 
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these abstract symbols are then presented and participants must verbally state which 
number corresponds with each symbol. The total score is the number of correct 
responses provided within a 90-second time limit. Importantly, this measure reduces 
the potential confounding effect of motor function with the oral response format. The 
SDMT has high test-retest reliability, good predictive and construct validity (Benedict 
et al., 2006) and can reliably indicate cognitive impairment and distinguish MS and 
healthy control participants (Benedict et al., 2006; Orchard, Giovannoni, & Langdon, 
2013).  
2.8.2.3. The Verbal and Spatial Reasoning Test (VESPAR): 
The Verbal and Spatial Reasoning Test (VESPAR; Langdon & Warrington, 
1995) was designed to minimise the effects of sensory, motor or cognitive 
impairments on performance on tests of reasoning ability in adults with a neurological 
condition (Langdon & Warrington, 2000) and has been used to assess verbal and 
spatial reasoning in MS populations. It comprises six subtests, two of which are 
included in the present study and consist of 25-items: the Verbal Analogies subtest 
which measures verbal inductive reasoning by analogy and the Verbal Series subtest 
which measures numerical inductive reasoning by series completion. In Verbal 
Analogies, each item consists of a word pair containing two related words, followed 
by a single word and four potential matches. Participants choose the word which best 
fits with the single word to form a second word pair with the same relation as the 
initial word pair. In Verbal Series, participants are given three numbers which form a 
particular numerical pattern and are asked to choose which of four other numbers best 
completes this pattern.  
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2.8.2.4. Arithmetic Subtest of Wechsler Adult Intelligence Scale-Third Edition  
(WAIS-III):  
The Arithmetic subtest from the Working Memory Index of the Wechsler Adult 
Intelligence Scale-Third Edition (WAIS-III; Wechsler, 1997), a measure of general 
cognitive functioning for adults aged 16 to 89 years, was employed in the present 
study in order to evaluate working memory and arithmetic ability. This subtest 
consists of 20 timed mental arithmetic problems of graded difficulty. These are read 
aloud to participants who must solve them without the assistance of paper, pen, 
calculator or other aid. The WAIS-III has established validity and reliability. Studies 
have demonstrated high internal consistency (α=.94-.98) and high inter-rater 
reliability (α=>.90) for most subtests. There is also evidence of high concurrent and 
construct validity across subtests (Wechsler, 1997). The WAIS-III is a valid measure 
of differentiating between individuals with and without a neurological condition, 
including MS (Smith, Cerhan, & Ivnik, 2003).  
2.8.2.5. Test of Reasoning Using Statistical Information (TRUSI): 
The Test of Reasoning Using Statistical Information (TRUSI; McKnight, 2007) 
requires participants to apply statistical reasoning across three different categories of 
questions; general everyday risks, health-related risks, and MS-specific health-related 
risks. Each of these three sections consists of eleven multiple choice questions. One 
point is allocated for each correct response, with a maximum total score of 33. The 
TRUSI is a reliable and valid measure of statistical reasoning ability in MS and again 
enables discrimination between MS and healthy control samples (Hans, 2009). It 
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possesses good concurrent validity with other measures of reasoning and arithmetic 
ability as well as good internal consistency for all three sections (between 0.74-0.8).  
2.8.2.6. Wechsler Test of Adult Reading (WTAR):  
The Wechsler Test of Adult Reading (WTAR; Holdnack, 2001) was included 
in the test battery as a measure of pre-morbid intellectual function. This was required 
to match MS and healthy control participants, ensuring that both groups did not differ 
significantly in their level of general intellectual functioning. The WTAR consists of 
50 irregular words which are read aloud by participants. One point is allocated for 
each correct pronunciation (maximum 50 points). Total scores are converted into a 
WAIS-III Full-Scale IQ score. As reading is largely preserved following brain injury, 
even in the case of decline in other cognitive abilities (Lesak, Howieson, & Loring, 
2004), WTAR scores provided a measure of MS participants’ expected level of 
functioning prior to any MS-related cognitive decline. Concurrent validity correlation 
coefficients for the WTAR are high (range from r=.75-.78) when compared with the 
Reading subtest of the Wide Range Achievement Test-Fourth Edition (WRAT-IV) 
(Mullen & Fouty, 2014). The WTAR is strongly correlated with WAIS-III measures 
of verbal IQ, full-scale IQ and verbal comprehension (Spreen & Strauss, 2006) and it 
has high test re-test reliability (r=.90-.94) (Holdnack, 2001).  
2.8.2.7. Modified Token Test (MTT):  
The Modified Token Test (MTT; Coughlan & Warrington, 1978) was adapted from 
DeRenzi’s and Vignolo’s (1962) longer Token Test. It was selected in this study to 
provide a brief measure of participants’ ability to comprehend and follow verbal 
commands. Participants heard 15 requests to execute a particular action using 
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randomly placed shapes (e.g. “Put the red circle on the green triangle”). One point 
was awarded for each correct answer (maximum score=15). Participants who scored 
below the cut-off score (<12) are typically classified as having reduced verbal 
comprehension and these cut-off scores can effectively distinguish between healthy 
control participants and those with brain lesions resulting in comprehension 
impairment (Coughlan & Warrington, 1978).  
2.8.2.8. Hospital Anxiety and Depression Scale (HADS): 
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) is a 
self-report measure of anxiety and depression symptoms which is widely used in 
clinical settings and was designed to avoid overlap with those symptoms which may 
also be linked to physical or somatic illness, for example fatigue, insomnia, or 
appetite changes. In this way, it has greater power to detect depression and anxiety 
symptoms in those with a chronic physical illness such as MS (Zigmond & Snaith, 
1983). It consists of 14 items (seven anxiety-related and seven depression-related 
items) which are scored on a 4-point scale from 0-3 (3 indicating greater symptom 
severity). Scores on both the anxiety and depression scale range from 0-21.  
The HADS is also a valid measure of symptom severity and has good 
reliability in detecting depression and anxiety in the general population, mental health 
or primary care settings (Bjelland, Dahl, Haug, & Neckelmann, 2002; Zigmond & 
Snaith, 1983) as well as in MS (Watson, Ford, Worthington, & Lincoln, 2014). A 
large-scale review established the HADS to have good internal consistency for both 
anxiety (mean α=.83) and depression (mean α=.82) as well as good concurrent 
validity, correlating well with other measures of anxiety and depression (r=.49-.83) 
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including the Beck Depression Inventory (BDI) and General Health Questionnaire 
(GHQ) (Bjelland et al., 2002). This review also supported Zigmond’s & Snaith’s 
(1983) recommended cut-off scores for clinically significant depression and anxiety 
symptoms (normal (0-7), mild (8-10), moderate (11-14) and severe (15-21)). 
2.8.2.9. Fatigue Severity Scale (FSS):  
The Fatigue Severity Scale (FSS; Krupp, LaRocca, Muir-Nash, & Steinberg, 1989) is 
a nine-item self-report measure of fatigue exploring the effects of fatigue on a range 
of functional activities (e.g. physical function, work and social life). Participants rate 
each item on a Likert scale from 1-7 (where 1 = strongly disagree, 7 = strongly agree), 
with a possible total score between 7-63. This total score can be averaged to get a 
mean score between 1-7 for each participant. It was originally developed to assist 
researchers in measuring fatigue within MS but has well-established validity and 
reliability in detecting the impact of fatigue on functional ability in other neurological 
and medical disorders (e.g. Grace, Mendelsohn, & Friedman, 2006; Rosa et al., 2014). 
It reliably distinguishes MS-related fatigue from fatigue experienced by healthy 
controls (Motl, McAuley, Wynn, & Vollmer, 2011). The FSS demonstrates high 
internal consistency (α=0.81 for MS population, α=0.88 for healthy population; Krupp 
et al., 1989), concurrent validity (e.g. correlates well with the VAS fatigue scale; Motl 
et al., 2011), and test-retest reliability (Krupp et al., 1989; Dittner, Wessley, & Brown, 
2004).  
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2.9. The Pilot Study 
A pilot study comprising five MS and five healthy control participants was conducted 
in order to enable development of the novel experimental procedure (i.e. aural extracts 
and measure of understanding of risk information) and the order of testing. No 
subsequent modifications were made to the experimental stimuli or testing order. 
Therefore, the data collected during the pilot study was included in the main analysis.  
2.10. Main Analysis 
Quantitative analysis was carried out using an advanced statistical software package, 
the IBM Statistical Package for the Social Sciences (IBM SPSS) version 21.0 for 
Windows (IBM Corp., 2012). Normality of distribution was assessed for all variables. 
Two variables were non-normally distributed. One of these variables (depression) was 
transformed so that it satisfied the conditions for parametric tests. The second variable 
(Modified Token Test raw scores) did not meet the assumption of normally 
distributed data even after trialling several different transformations. Therefore non-
parametric tests were used in analysing this data (see section 3.1. for further details).  
The following parametric tests were used in examining group comparisons, cognitive 
variables and the experimental condition.  
2.10.1. Group Comparisons 
Independent sample t-tests were used to explore whether the groups were matched on 
age and pre-morbid intelligence. A chi-square test determined whether the groups 
were matched for gender. If the groups had differed significantly on one of these 
demographic variables, this variable would have been used as a covariate in 
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subsequent analyses in order to control for any possible influence on the outcome. 
However, this was not necessary in the present study. Independent sample t-tests were 
also used to determine whether the groups differed significantly in terms of self-
reported depression, anxiety and fatigue.  
2.10.2. Cognitive Variables 
Independent sample t-tests were carried out to assess whether the two groups differed 
on any of the cognitive measures (i.e. Arithmetic subtest of WAIS-III, SDMT; CVLT-
II, Verbal Analogies (VESPAR), Verbal Series (VESPAR), TRUSI-B).  Bonferroni 
corrections were applied to account for the number of comparisons made. Significant 
group differences for any cognitive variables would undergo further exploratory 
analysis. Specifically, Pearson correlations would be performed to explore the 
associations between each of these cognitive variables and the dependent variables 
(i.e. recall and understanding of risk information). The non-parametric equivalent of 
an independent sample t-test, the Mann-Whitney U test, was used to explore group 
differences on the Modified Token Test (MTT).  
2.10.3. Experimental Condition 
The primary dependent variable was immediate recall scores as this was felt to reflect 
the amount of information which had been encoded by participants for each of the 
three presentation formats. This in turn has potential implications for an individual’s 
ability to make informed healthcare decisions. A 3 X 2 mixed ANOVA was 
performed on the primary dependent variable (immediate recall) with presentation 
format (‘massed’ versus ‘spaced’ versus ‘massed-with-delay’) as the within-subject 
factor and Group (MS versus healthy control) as the between-subject factor. This 
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established whether immediate recall of health information differed between the MS 
and healthy control group and across different presentation formats. Significant 
results for presentation format were explored further using paired-sample t-tests. 
The secondary dependent variable was the understanding of risk information 
scores. Another 3 X 2 mixed ANOVA was performed with presentation format 
(‘massed’ versus ‘spaced’ versus ‘massed-with-delay’) as the within-subject factor 
and Group (MS versus healthy control) as the between-subject factor to assess 
whether MS and healthy control participants differed in their level of understanding of 
health-related risk information and to investigate whether participants differed in their 
level of understanding of risk information across different presentation conditions.  
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3. Results 
3.1 Exploratory Data Analysis   
Quantitative analysis of the data was carried out using IBM SPSS version 21.0 for 
Windows (IBM Corp., 2012). Prior to analysis, the data was checked for missing 
values and overall accuracy of data entry. One MS participant failed to complete the 
TRUSI measure in its entirety resulting in eight missing values and was therefore 
excluded from analysis of this variable. There were no other instances of missing data 
for either group.   
Distribution of the data was also assessed to establish whether the data met the 
assumption of normally distributed data for parametric analysis. As suggested by 
Tabachnick and Fidell (2007), a z-score cut-off of between -2.58 and 2.58 for both 
Skewness and Kurtosis was used to determine normality of distribution for each 
variable.  
The Modified Token Test raw score was significantly negatively skewed in 
both the MS (z=-6.46) and healthy control (z=-6.58) groups. The depression raw score 
obtained using the HADS was significantly positively skewed (z=4.18) in the healthy 
control group only. Based on Tabachnick and Fidell’s (2007) recommendations for 
moderately positively skewed data, the depression raw scores were transformed using 
square root transformations via the SQRT(X) function (i.e. taking square root of all 
raw scores to bring larger scores closer to the centre; Field, 2005). This 
transformation produced normally distributed data for the Depression raw score 
across both groups (see Appendix W).  
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Using Tabachnick and Fidell’s (2007) recommendations for severely 
negatively skewed data, inverse (reciprocal) transformations were used to transform 
the substantially negatively skewed data for the Modified Token Test using the 1/(K-
X) function. However, the Modified Token Test raw score remained significantly 
negatively skewed across both groups. Therefore, the non-parametric equivalent of an 
independent sample t-test, the Mann-Whitney U test, was used to explore group 
differences on the Modified Token Test (MTT).  
3.2. Demographic and Clinical Variables 
Descriptive statistics were calculated for each of the demographic and clinical 
variables of interest for both the MS and healthy control groups. These included 
gender, age and pre-morbid intelligence function (see Table 7) and fatigue, anxiety 
and depression.  
3.2.1. Gender 
The ratio of male to female participants was 10:20 in the MS group and 14:16 in the 
healthy control group. A Chi-square analysis revealed no significant difference 
between the groups in terms of gender (𝑥2 (1) = 1.11, p =.29). Therefore, the two 
groups were matched on gender and this variable was not considered in any 
subsequent analysis.  
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Table 7 
Summary of the Descriptive Statistics for the Demographic Variables of Gender, Age 
and Pre-morbid Full-Scale IQ Scores across the MS and Healthy Control Groups 
Group Gender Age Pre-morbid FSIQ 
 Male:Female M (SD) Range M (SD) Range 
MS 10:20 49.7 (8.3) 30-60 107.2 (9.1) 89-121 
HC 14:16 45.4 (11.5) 25-60 108.8 (6.6) 92-119 
Note. M = mean, SD = standard deviation 
3.2.2. Age  
Participants’ ages ranged from 25 to 60 years (M = 47.5, SD = 10.2). In the MS 
group, participants were aged between 30 and 60 years (M = 49.7, SD = 8.3). In the 
healthy control group, participants were aged between 25 and 60 years (M = 45.4, SD 
= 11.5). An independent t-test was used to compare the participants’ ages between 
both groups. Separate variance estimates were used as homogeneity of variance 
assumptions were not met (F = 4.12, p = .047). There was no significant difference 
between the two groups in terms of age (t(52.67) = 1.67, p = .1).  The two groups 
were therefore matched for age. Consequently, age was not considered in any 
subsequent analyses.  
3.2.3 Estimated Pre-Morbid IQ 
The Wechsler Adult Reading Test (WTAR; Holdnack, 2001) was used to estimate 
participants’ pre-morbid Full-Scale intelligence level (FSIQ). Overall, participants’ 
FSIQ scores ranged from to (M = 108, SD = 7.9). MS participants’ scores ranged 
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from 89 to 121 (M = 107.2, SD = 9.1). In the healthy control group, scores ranged 
from 92 to 119 (M = 108.8, SD = 6.6). Separate variance estimates were used as 
homogeneity of variance assumptions were not met (F = 4.69, p = .034). There was no 
significant difference between the two groups in terms of pre-morbid FSIQ (t(52.82) 
= 1.67, p = .44) indicating that the two groups were matched for pre-morbid IQ 
scores. Consequently, pre-morbid IQ was not considered in any subsequent analyses.   
3.2.4. MS Subtypes 
The MS sample consisted of five patients with Relapsing Remitting MS (RRMS, 
16.7%), ten patients with Primary Progressive MS (PPMS, 33.3%) and fifteen with 
Secondary Progressive MS (SPMS, 50%).   
3.2.5. Fatigue  
Independent t-tests were also performed in order to explore potential group 
differences in self-reported levels of fatigue, anxiety and depression. The Fatigue 
Severity Scale (FSS) was employed to measure fatigue and the following categories 
were applied; no fatigue (FSS < 4), borderline fatigue (4 < FSS < 5) and fatigued 
(FSS > 5). The MS and healthy control groups differed significantly in terms of 
fatigue (t(58)=6.81,p<.001) with MS participants reporting significantly greater levels 
of fatigue (M=43.83, SD=10.25) relative to healthy controls (M=26.1, SD=9.92). The 
possible influence of this difference in levels of fatigue between the two groups is 
discussed in later sections.  
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3.2.6. Depression and Anxiety 
Depression and anxiety were measured using the self-report Hospital Anxiety and 
Depression Scale (HADS). The standard HADS cut-off scores for depression and 
anxiety include normal (0-7), mild (8-10), moderate (11-14) and severe (15-21) 
(Zigmond & Snaith, 1983; Bjelland et al., 2002).  
Based on these categorisations, 33.3% of participants with MS scored above 
the cut-off for clinically significant depression (mild (16.7%), moderate (16.7%), 
severe (0%)), while 66.7% of participants with MS scored in the ‘normal’ range. Just 
10% of the healthy control participants met the criteria for clinically significant 
depression (mild (6.7%), moderate (3.3%), severe (0%)) while 90% were in the 
‘normal’ range.  
Regarding anxiety, 26.7% of participants with MS met the cut-off for 
clinically significant levels of anxiety (mild (20%), moderate (3.3%) severe (3.3%)), 
while 73.3% had no significant anxiety symptoms. In the healthy control group, 
33.3% demonstrated clinically significant anxiety symptoms (mild (23.3%), moderate 
(6.7%), severe (3.3%)) while 66.7% were within the ‘normal’ range.  
Independent t-tests revealed a significant difference in levels of self-reported 
depression between the MS and healthy control groups (t(58)=5.09, p<.001), with MS 
participants (M=6.07, SD=3.25) reporting significantly higher levels of depression 
relative to healthy control participants (M=2.47, SD=2.7).  There was no significant 
difference in anxiety levels between the two groups (t(58)=.56, p=.58), with both the 
MS (M=5.33, SD=3.59) and healthy control (M=5.87, SD=3.81) groups reporting 
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similar levels of anxiety. The possible influence of this difference in levels of 
depression between the two groups is discussed in later sections.  
3.3. Cognitive Variables 
Independent samples t-tests were used to compare both the MS and healthy control 
group on all but one of the cognitive variables. Scores for both groups on the 
neuropsychological measures are shown in Table 8.  The two groups demonstrated 
comparable performance on the Verbal Analogies (VESPAR) subtest (t(58)=1.4, 
p=.166). The groups differed on the CVLT-II (t(58)=2.54, p=.014), the SDMT 
(t(58)=6.7, p<.001), the Arithmetic (t(58)=2.79, p=.007), the Verbal Series 
(VESPAR) (t(58)=2.3, p=.025) and the TRUSI (t(57)=3.00, p=.004). The healthy 
control group performed significantly better than the MS group on each of these five 
measures. Once Bonferroni corrections were made for the number of comparisons 
performed, only the difference on the SDMT, Arithmetic and TRUSI variables 
remained significant (p<.008 was taken as the appropriate level of significance). 
Using the Mann-Whitney U test, it was found that the two groups also performed 
comparably on the Modified Token Test (MTT) (U=432.00, p=.59).    
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Table 8  
Summary of the Means, Standard Deviations and Significance Levels for the 
Cognitive Variables across the MS and Healthy Control Groups  
 MS HC Significance 
level  
 M (SD) 
 
Range M (SD) Range (p-value) 
CVLT-II 55.33 
(11.4) 
28-74 62.4 
(10.12) 
39-74 0.014 
SDMT 40.73 
(9.88) 
17-59 57.83  
(9.9) 
39-81 <0.001* 
Arithmetic 9.63  
(2.81) 
3-17 11.57 
(2.56) 
8-17 0.007* 
Verbal 
Analogies 
(VESPAR) 
18.43 
(2.76) 
12-24 19.40 
(2.57) 
13-23 0.166 
Verbal 
Series 
(VESPAR) 
17.8  
(2.57) 
14-23 19.47 
(3.00) 
12-24 0.025 
TRUSI 20.59 
(6.28) 
8-32 24.87 
(4.57) 
12-32 0.004* 
Modified 
Token Test 
(non-
parametric) 
Mean rank 
= 29.9  
 
13-15 
Mean rank 
= 31.1 
 
14-15 
 
0.59 
Note. M = mean, SD = standard deviation, *p<.008 (following Bonferroni 
corrections)  
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3.3.1. Specific Cognitive Impairment 
Using a similar procedure to that of earlier studies (e.g. Camp et al., 1999; Camp et 
al., 2005), a cognitive impairment index was created for each participant using their 
scores on the CVLT-II, SDMT, Arithmetic (WAIS-III), Verbal Analogies (VESPAR) 
and Verbal Series (VESPAR) and TRUSI subtests. The mean and standard deviation 
of the standardisation sample for each measure was employed as a reference (Delis et 
al., 2000; Langdon & Warrington, 1995; McKnight, 2007; Smith, 1982; Wechsler, 
1997) and current MS and healthy control participants’ scores were compared with 
this data for each subtest.  
Participants were allocated a grade for each subtest based on the number of 
standard deviations they fell below the standardised mean. Participants were graded as 
follows: Grade 0 if they scored at or above the mean, Grade 1 if they scored within 
one standard deviation below the mean (<1SD), Grade 2 if they scored more than one 
but less than two standard deviations from the mean (1SD < x < 2SD), Grade 3 if they 
scored more than two but less than three standard deviations below the mean (2SD < 
x < 3SD), and so on until all participant scores were graded. The grades for each 
subtest were then summed to provide one overall score for each participant, indicating 
their level of cognitive impairment. A higher figure indicated greater cognitive 
impairment. The cognitive impairment index scores ranged from 0-11 (where 0 
indicated no impairment) with a mean score of 4.87 (SD = 2.89) in the MS group and 
2.63 (SD = 1.77) in the control group.  
Following the practice of several researchers (e.g. Achiron & Barak, 2003; 
Camp et al., 1999; Camp et al., 2005, Comi et al., 1995), clinical impairment on any 
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of the neuropsychological measures was defined as a score of greater than two 
standard deviations below the mean of the standardisation sample (Delis et al., 2000; 
Langdon & Warrington, 1995; McKnight, 2007; Smith, 1982; Wechsler, 1997). These 
researchers typically classified participants as having a more widespread cognitive 
impairment if they scored more than two standard deviations below the mean on three 
or more neuropsychological measures (see Table 9).  
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Table 9 
Frequency of Participants Classified as Clinically Impaired (i.e. score of >2 standard 
deviations below the mean) across all Neuropsychological Measures for the MS and 
Healthy Control (HC) Group 
Measure MS Group HC Group 
Modified Token Test 0 0 
SDMT 9 0 
CVLT-II 2 1 
Arithmetic (WAIS-III) 1 0 
TRUSI 2 0 
Verbal Analogies  
(VESPAR) 
0 0 
Verbal Series 
(VESPAR) 
0 0 
One participant in the MS group scored more than two standard deviations 
below the mean on three neuropsychological measures, indicating that one MS 
participant demonstrated more widespread cognitive impairment. No participants in 
the healthy control group scored more than two standard deviations below the mean 
on three or more measures.  
The Modified Token Test (Coughlan & Warrington, 1978) was used as a 
screening measure where participants were classified as having an impairment in 
comprehension if they scored below the clinical cut-off of 12. This is the level at 
which patients with neurological compromise were distinguished from the healthy 
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control group in the original sample. No participants scored below this cut-off and 
thus, all were deemed to have sufficient comprehension ability to complete the full 
neuropsychological test battery and experimental condition.   
3.4. Experimental Condition  
3.4.1. Vignette Condition and Presentation Order 
Order of presentation condition was counterbalanced across participants to ensure that 
an equal number of participants in each group (n=10) heard the three different 
presentation formats (massed, spaced, massed-with-delay) of the three aural risk 
information vignettes in each presentation order (i.e. (i) ‘massed’ first, ‘spaced’ 
second and ‘massed-with-delay’ third; (ii) ‘spaced’ first, ‘massed-with-delay’ second 
and ‘massed’ third; or (iii) ‘massed-with-delay’ first, ‘massed’ second and ‘spaced’ 
third) (see Table 5 and Abstract 14 for details of randomisation of order of 
presentation format).  
3.4.2. Dependent Variables 
The scores for immediate recall of risk information and understanding of risk 
information across Group (MS and healthy control) and Presentation Condition 
(massed, spaced, massed-with-delay) are summarised in Table 10 and Table 12 
below.   
3.4.3. Immediate Recall of Treatment-related Risk Information  
A 2 X 3 mixed analysis of variance (ANOVA) with Group (MS and healthy control) 
as the between-subjects factor and Presentation Condition (massed, spaced, massed-
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with-delay) as the within-subjects factor was performed on the immediate recall 
scores (i.e. percentage correct). There was a significant main effect of Group 
(F(1,58)=13.28, p=.001) indicating that the MS and healthy control groups differed 
significantly in their ability to immediately recall treatment-related risk information. 
Mean scores indicate that the healthy control group recalled significantly more risk 
information relative to MS participants (see Table 10 and Figure 1).  
Table 10  
Summary of the Descriptive Statistics for Immediate Recall of Risk Information 
Scores for MS and Healthy Control Participants across all Conditions 
Condition Group Mean Standard 
Deviation 
Range 
(%) 
Massed MS 22.76 14.91 1.4 - 67.1 
HC 34.1 13.18 12.9 – 57.1  
Spaced MS 28.09 12.74 10 – 55.7 
HC 37.48 16.49 8.6 – 65.7 
Massed with 
delay 
MS 14.33 10.37 1.4 – 40 
HC 23.86 10.37 8.6 – 45.7  
There was a highly significant main effect of Presentation Condition 
(F(2,116)=33.5, p<.001), indicating that presentation format, either massed, spaced or 
massed-with-delay, led to significant differences in the amount of risk information 
which participants were able to recall. Post-hoc t-tests were performed to further 
investigate this interaction. Paired sample t-tests revealed that participants recalled 
significantly more risk information in the spaced presentation condition relative to 
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both the massed presentation (t(59)=2.32, p=.034) and massed-with-delay 
presentation conditions (t(59)=8.37, p<.001) (see Table 11). Participants also recalled 
significantly more risk information in the massed presentation relative to the massed-
with-delay presentation condition (t(59)=5.97, p<.001). However, once Bonferroni 
corrections were considered (p=0.017), the difference in participants’ recall of risk 
information between the massed presentation and spaced presentation condition was 
no longer significant.  
Table 11 
Summary of Post-hoc Analysis Exploring Differences in Immediate Recall Scores 
between Massed, Spaced and Massed-with-Delay Presentation Conditions  
Comparison Mean SD Significance level 
(p-value) 
Massed 
V 
Spaced 
28.43 15.08 0.024 
32.79 15.36 
Spaced 
V 
Massed with delay 
32.79 15.36 <0.001* 
19.1 11.23 
Massed 
V 
Massed with delay 
28.43 15.08 <0.001* 
19.1 11.23 
Note. SD = standard deviation, *p<.017 (after Bonferroni corrections) 
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The interaction between Group and Presentation Condition was not significant 
(F(2,116)=.21, p=.82). While the MS group showed a benefit of spaced presentation 
for immediate recall of treatment-related risk information, they were not differentially 
helped by this spaced presentation condition relative to healthy controls, with both 
groups demonstrating a similar pattern of performance on immediate recall for each 
presentation condition (massed, spaced, massed-with-delay).  
 
Figure 1. Plot of Immediate Recall of Risk Information Scores for Group and 
Presentation Condition 
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3.4.4. Understanding of Treatment-related Risk Information  
Another 2 X 3 mixed analysis of variance (ANOVA) was performed on participants’ 
scores on a measure assessing understanding of treatment-related risk information. 
Again, Group (MS and healthy control) was the between-subjects factor and 
Presentation Condition (massed, spaced, massed-with-delay) was the within-subjects 
factor. This revealed a highly significant main effect of Group (F(1,58)=14.79, 
p<.001) indicating that the two groups differed significantly in their ability to make 
sense of treatment-related risk information. Mean scores indicate that the healthy 
control group demonstrated a significantly greater understanding of risk information 
relative to MS participants (see Table 12).   
Table 12 
Summary of the Descriptive Statistics for Understanding of Risk Information Scores 
for MS and Healthy Control Participants across all Conditions 
Condition Group Mean Standard 
Deviation 
Range 
(%) 
Massed MS 30.44 20.68 6.3 - 75 
HC 43.97 17.63 6.3 – 75  
Spaced MS 29.18 13.96 6.3 – 62.5 
HC 44.19 20.94 6.3 – 87.5 
Massed with 
delay 
MS 28.76 13.69 6.3 – 62.5 
HC 35.43 15.85 6.3 – 75  
There was no significant main effect of Presentation Condition 
(F(2,116)=1.95, p=.15), with participants demonstrating a similar level of 
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understanding of risk information across massed, spaced and massed-with-delay 
information-presentation formats. There was also no significant interaction between 
Group and Presentation Condition (F(2,116)=1.22, p=.3) suggesting that 
understanding of treatment-related risk information was not differentially affected by 
any of the three presentation conditions (massed, spaced, massed-with-delay) in the 
MS and healthy control groups (see Figure 2).  
 
Figure 2. Plot of Understanding of Risk Information Scores for Group and 
Presentation Condition 
3.4.5. Covariance 
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In order to control for the potential confounding effects of significant group 
differences, many researchers perform an Analysis of Covariance (ANCOVA). This 
can establish whether the groups differ on the dependent variable once the effect of 
other potentially confounding variables are statistically partialled out. However, this is 
not always appropriate. Despite statistically significant differences between the MS 
and healthy control groups in levels of self-reported fatigue and depression, an 
ANCOVA was not performed in the current study. This decision was based on 
recommendations by Miller and Chapman (2001) who warn against attempts to 
control for pre-existing, meaningful group differences. This is primarily because the 
variables of fatigue and depression both represent an inherent difference between the 
two groups rather than being merely noise or error variance. Thus, entering depression 
(HADS scores) or fatigue (FSS scores) as covariates would remove meaningful 
variance from the independent variable (Group) and, in turn, lead to difficulties in 
interpreting the effect of Group on the dependent variables (immediate recall and 
understanding of risk information).  
The MS and healthy control groups also differed significantly on a measure of 
information-processing speed (SDMT scores), working memory (Arithmetic subtest 
scores) and statistical reasoning (TRUSI scores). However, for similar reasons, it was 
again decided not to enter these variables as covariates in the analysis. The 
justification for covariate omission will be outlined and evaluated further in the 
discussion section of this paper. 
3.4.6. Cognitive Variables Associated with Immediate Recall and Understanding 
of Treatment-related Risk Information  
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In order to explore the associative relationship between each cognitive variable and 
the dependent variables of immediate recall and understanding of risk information, 
Pearson correlations were performed. Spearman’s rho correlations were performed to 
explore the relationship between Modified Token Test scores and understanding and 
recall of risk information in both groups. Each correlation is depicted in Table 13 and 
Table 14 below. Correlations were calculated for each group separately using the 
split-file function in SPSS. These correlations were calculated separately for the MS 
and healthy control groups given that healthy control participants scored significantly 
higher than MS participants on several of the neuropsychological tests (SDMT, 
Arithmetic, and TRUSI). This precaution therefore reduced the chance of obtaining 
artificially inflated correlation co-efficients which could have resulted in misleading 
significant correlations.  
3.4.6.1. Cognitive Variables Associated with Immediate Recall of Risk 
Information in the MS Group 
Initial Pearson correlations revealed a significant positive correlation between MS 
participants’ SDMT scores and immediate recall of risk information (r(28)=.51, 
p=.004). Therefore, higher scores on the SDMT were associated with higher 
immediate recall of risk information in the MS group (see Table 13). There was also a 
highly significant positive correlation between CVLT-II scores and immediate recall 
of risk information in the MS group (r(28)=.77, p<.001). This indicates that as verbal 
memory scores increase, immediate recall scores also increase.  
Table 13  
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Correlations between the Cognitive Variables and the Dependent Variables of 
Immediate Recall and Understanding of Risk Information in the MS Group 
Independent 
Variable 
Immediate Recall of Risk 
Information 
Understanding of Risk 
Information 
 Pearson 
Correlation 
Significance 
Level 
Pearson 
Correlation 
Significance 
Level 
SDMT .512** .004 .536** .002 
CVLT-II .768** <.001 .654** <.001 
Arithmetic .577** .001 .577** .001 
TRUSI .582** .001 .400* .032 
Verbal 
Analogies 
(VESPAR) 
.649** <.001 .481** .007 
Verbal Series 
(VESPAR) 
.582** .001 .374* .042 
MTT (non-
parametric) 
Spearman’s ρ 
.294 
 
.115 
Spearman’s ρ 
.237 
 
.207 
**Correlation significant at the 0.01 level (2-tailed)  
*Correlation significant at the 0.05 level (2-tailed) 
Another significant positive correlation was observed between MS 
participants’ scores on the Arithmetic subtest of the WAIS-III and immediate recall 
(r(28)=.58, p=.001) and between TRUSI scores and immediate recall (r(28)=.58, 
p=.001). Therefore, better performance on the arithmetic subtest and the TRUSI 
measure of statistical reasoning respectively were also associated with improved 
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immediate recall performance in the MS group. The significant positive correlation 
between MS performance on both verbal analogies (r(28)=.649, p<.001) and verbal 
series (r(28)=.582, p=.001) and immediate recall suggests that higher scores on both 
of these verbal inductive reasoning measures were also correlated with greater recall 
of risk information in the MS group. There was no significant correlation observed 
between scores on the Modified Token Test (MTT) and immediate recall of risk 
information suggesting that MTT scores were not strongly associated with recall of 
risk information (ρ(28)=.29, p=.12).  
3.4.6.2. Cognitive Variables Associated with Immediate Recall of Risk 
Information in the Control Group 
Initial Pearson correlations revealed a significant positive correlation between the 
scores of healthy control participants on the CVLT-II and immediate recall of risk 
information (r(28)=.52, p=.003). Therefore, higher scores on the CVLT-II were 
associated with better performance on a measure of immediate recall of risk 
information for healthy controls. Further significant positive correlations were 
observed in the control group between scores on the Arithmetic subtest of the WAIS-
III and immediate recall (r(28)=.43, p=.017), and between TRUSI scores and 
immediate recall (r(28)=.46, p=.01). Using a Spearman’s rho correlation analysis, a 
significant positive correlation was also observed between MTT scores and immediate 
recall (ρ(28)=.46, p=.01) (see Table 14). Therefore, better performance on the 
Arithmetic subtest, TRUSI measure of statistical reasoning and MTT respectively 
were also associated with improved immediate recall performance in the control 
group. A significant positive correlation was also revealed between scores on both 
verbal analogies (r(28)=.518, p=.003) and verbal series (r(28)=.502, p=.005) subtests 
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and immediate recall, indicating a relationship between higher verbal and numerical 
inductive reasoning scores and improved recall of risk information in the healthy 
control group.   
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Table 14  
Correlations between the Cognitive Variables and the Dependent Variables of 
Immediate Recall and Understanding of Risk Information in the Healthy Control 
Group 
Independent 
Variable 
Immediate recall of risk 
information 
Understanding of risk 
information 
 Pearson 
Correlation 
Significance 
Level 
Pearson 
Correlation 
Significance 
Level 
SDMT .343 .004 .257 .171 
CVLT-II .518** .064 .276 .14 
Arithmetic .432* .017 .316 .089 
TRUSI .460* .01 .176 .354 
Verbal 
Analogies 
(VESPAR) 
.476** .008 .465** .010 
Verbal Series 
(VESPAR) 
.502** .005 .319 .085 
MTT (non-
parametric) 
Spearman’s ρ 
.456* 
 
.011 
Spearman’s ρ  
.335 
 
.071 
**Correlation significant at the 0.01 level (2-tailed)  
*Correlation significant at the 0.05 level (2-tailed)  
Interestingly, there was no significant correlation observed between SDMT 
scores and immediate recall of risk information (r(28)=.34, p=.063), although this did 
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approach significance, suggesting that  speed of information-processing was not 
strongly associated with recall of risk information in the control group.   
3.4.6.3. Cognitive Variables Associated with Understanding of Risk Information 
in the MS Group 
Pearson correlations were again performed to explore the associations between each 
cognitive variable and the understanding of risk information (see Table 13 above). 
These revealed a significant positive correlation between MS participants’ SDMT 
scores and understanding of risk information (r(28)=.54, p=.003). Therefore, higher 
scores on the SDMT were associated with better performance on a measure of 
understanding of risk information in the MS group. There was also a highly 
significant positive correlation between CVLT-II scores and the understanding of risk 
information in the MS group (r(28)=.65, p<.001). This indicates that increased verbal 
memory scores were associated with increased understanding of risk information. 
Another significant positive correlation was observed between MS 
participants’ scores on the Arithmetic subtest of the WAIS-III and understanding of 
risk information (r(28)=.58, p=.001) and between TRUSI scores and understanding of 
risk information (r(28)=.4, p=.032). Therefore, better performance on the Arithmetic 
subtest and the TRUSI measure of statistical reasoning respectively were also 
associated with improved understanding of risk information in the MS group. A 
significant positive correlation between scores on both verbal analogies (r(28)=.481, 
p=.007) and verbal series (r(28)=.374, p=.042) subtests and understanding of risk 
information was also revealed, suggesting that higher scores on both of these verbal 
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inductive reasoning measures was also correlated with greater comprehension of risk 
information in the MS group. 
There was no significant correlation observed between scores on the Modified 
Token Test (MTT) and understanding of risk information suggesting that MTT scores 
were not strongly associated with understanding of risk information (ρ(28)=.24, 
p=.21).  
3.4.6.4. Cognitive Variables Associated with Understanding of Risk Information 
in the Control Group 
Only one significant correlation was observed between the scores of healthy control 
participants on any of the cognitive variables and the understanding of risk 
information (see Table 14 above), that of verbal analogy (VESPAR) scores 
(r(28)=.465, p=.01). The correlation between the other verbal inductive reasoning test 
(Verbal Series) approached significance (r(28)=.319, p=.085). A positive correlation 
between the understanding of risk information and both Arithmetic scores (r(28)=.32, 
p=.089) and MTT scores (ρ(28)=.31, p=.071) did also approach significance. Overall, 
this suggests that understanding of risk information in the healthy control group was 
positively associated with verbal reasoning ability, albeit not consistently, but was not 
significantly associated with performance on measures of information-processing 
speed (SDMT), immediate verbal recall (CVLT-II), verbal comprehension (MTT), 
working memory (Arithmetic subtest) or statistical reasoning ability (TRUSI).   
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3.4.6.5. Association between the Cognitive Impairment Index Scores and 
Immediate Recall and Understanding of Treatment-Related Risk Information 
Pearson correlations were also conducted to explore the relationship between the 
cognitive impairment index scores and the dependent variables of immediate recall 
and understanding of risk information. Again, this was calculated separately for each 
group (see Table 15).  
Table 15 
Pearson r Correlations for the Association between Cognitive Impairment Index 
Scores and the Dependent Variables of Immediate Recall and Understanding of Risk 
Information in the MS and Healthy Control (HC) Groups 
  Immediate Recall of Risk 
Information 
Understanding of Risk 
Information 
Cognitive 
Impairment 
Index 
Scores 
 Pearson 
Correlation 
Significance 
Level 
Pearson 
Correlation 
Significance 
Level 
MS -.706** <.001 -.665** <.001 
HC -.593** .001 -.482** .007 
**Correlation significant at the 0.01 level (2-tailed) 
These analyses revealed a highly significant negative correlation between 
cognitive impairment index scores and immediate recall of risk information 
(r(28)=.706, p<.001) and understanding of risk information (r(28)=.665, p<.001) in 
the MS group. The same highly significant negative correlation was also observed 
between cognitive impairment index scores and immediate recall (r(28)=.593, p=.001) 
and understanding (r(28)=.482, p=.007) of risk information in the healthy control 
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group. Therefore, cognitive impairment scores were associated with both immediate 
recall and understanding of treatment-related information in both groups, with higher 
cognitive impairment scores being linked to reduced recall and understanding.  
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4. Discussion 
It has recently been suggested that the spaced presentation of information can improve 
recall in the MS population during simple laboratory-based tasks (Goverover et al., 
2009b; 2011). The current study aimed to explore whether spaced presentation of 
information could improve both recall and understanding of information in people 
with MS in a more clinically-relevant context, using treatment-related risk 
information. This study addressed the following questions: Does spaced presentation 
of treatment-related risk information facilitate improved recall and understanding of 
risk information? Are people with MS differentially affected by spaced presentation 
of treatment-related risk information relative to healthy controls? The specific 
cognitive functions associated with recall and understanding of treatment-related risk 
information were also explored.  
4.1. Review of the Findings  
4.1.1. Hypothesis 1 
The MS group will understand and recall significantly less treatment-related 
risk information relative to a healthy control group.  
This hypothesis was supported. Participants with MS performed significantly worse 
than healthy controls on measures of both immediate recall and understanding of 
treatment-related risk information. As the groups were matched for age, gender and 
pre-morbid IQ, these differences in performance cannot be attributed to age-related 
cognitive changes, gender-related cognitive differences, or pre-existing differences in 
level of general intellectual function respectively.  
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The groups did differ significantly in self-reported levels of fatigue and 
depression, with the MS group experiencing higher levels for both variables. Research 
into the effects of fatigue and depression on cognitive performance in MS have 
provided mixed results, with some studies demonstrating significant associations 
between reduced cognitive performance and depression (Arnett, Higginson, & 
Randolph, 2001; Demaree, Gaudino, & DeLuca, 2003; Diamond et al., 2008) or 
chronic fatigue (Diamond et al., 2008; Krupp & Elkins, 2000; ) in MS samples. 
However, other studies report no significant association between cognitive function 
and fatigue (Bailey et al., 2007; Parmenter et al., 2003) or depression in MS (Karadayi 
et al., 2014). In any case, it was not possible to explore the influence of fatigue or 
depression on cognitive function within the present study as it would have reduced 
power had either fatigue or depression been entered as a covariate in the analyses. 
Both fatigue and depression are known to be more prevalent in people with MS 
relative to healthy controls (e.g. Bol et al., 2009; Goldman Consensus Group, 2005; 
Sundgren et al., 2013) and this difference reflects a real clinical circumstance and 
common co-morbidity. Therefore, co-varying these two variables would have 
removed meaningful variance from the independent variable of Group and led to 
potentially spurious findings (Miller & Chapman, 2001).  
There were also significant differences between the MS and healthy control 
groups in their performance on a number of neuropsychological measures including a 
test of information-processing speed, working memory and statistical reasoning. The 
MS group demonstrated reduced performance on each of these tasks. However, 
previous research has rather consistently documented MS-related impairments in 
information-processing speed (Bodling, Denney & Lynch, 2012; Denney, Gallagher 
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& Lynch, 2011; Drake et al., 2010), working memory (Legenfelder, Chiaravalloti, 
Ricker & DeLuca, 2003) and, to a lesser extent, statistical reasoning (McKnight, 
2007). Again then, given that the significant difference in performance on these tasks 
likely reflects an inherent, meaningful difference between the two groups, it was 
decided not to include these cognitive variables as covariates in the analysis. Instead, 
the cognitive correlates of immediate recall and understanding of risk information 
were later explored. (This is discussed in section 4.1.4).  
4.1.2. Hypothesis 2 
The spaced presentation of treatment-related risk information will significantly 
improve recall and understanding of risk information in both MS and healthy 
control participants relative to massed presentation of information.   
This hypothesis was partially supported. Participants recalled a significantly greater 
amount of treatment-related risk information when the presentation of this 
information was interspersed with breaks (spaced presentation) relative to continuous 
presentation (massed presentation). Once Bonferroni adjustments were applied for the 
number of comparisons made, this finding approached significance and a larger 
sample size may have provided more power to maintain a significant effect. 
Nonetheless a strong trend for a benefit of spaced presentation on recall was observed.  
Participants also recalled significantly more risk information in the massed 
condition relative to the massed-with-delay condition, and in the spaced presentation 
relative to the massed-with-delay condition and these findings remained significant 
once Bonferroni corrections had been made. This finding of improved recall in the 
massed relative to the massed-with-delay condition is not surprising given that 
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participants either recalled the information immediately or had to wait for 10-minutes 
before recall and it is widely documented that recall declines even after several 
minutes delay (Cowan & AuBuchon, 2008; Oberauer & Lewandowsky, 2009).  
The finding of significantly greater recall of risk information in the spaced 
relative to the massed-with-delay condition is, however, a novel one and partially 
supports the hypothesis that there would be a benefit of spaced presentation of risk 
information. The ‘massed with 10-minute-delay’ condition was included to prevent an 
otherwise significant benefit of spaced presentation for recall being confounded by 
the time delay (2 X 5 minutes) between participants hearing the first and final sections 
of the drug extract in this spaced presentation condition. The finding of significantly 
greater recall of risk information in the spaced presentation relative to the massed-
with-delay condition, where both involve a similar time-delay, thus suggests that 
these breaks/spaces in information presentation afford some benefit over continuous 
presentation of information.  
 Overall then, the present study provides some support for the advantages of 
information-presentation interspersed with breaks in enhancing immediate recall of 
risk information. This study did not find evidence for a similar benefit of spaced 
presentation in facilitating improved understanding of risk information. Participants’ 
level of comprehension of treatment-related risk information did not differ greatly 
whether the information was presented in a continuous or spaced format.   
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4.1.3. Hypothesis 3 
There will be a greater benefit of spaced presentation of risk information in the 
MS group relative to a healthy control group. 
This hypothesis was not supported. As expected, both groups demonstrated a benefit 
of spaced presentation for immediate recall of risk information. However, it was 
hypothesised that the MS group would demonstrate a significantly greater benefit 
from a spaced information presentation style due to their well-documented 
impairments in speed of information-processing (e.g. Bodling et al., 2012; 
Chiaravalloti et al., 2013; Denney et al., 2011) and the potential for spacing to 
ameliorate this by providing more processing time. Instead, both groups demonstrated 
a similar pattern of performance for immediate recall across the different presentation 
conditions (massed, spaced, massed-with-delay).  
As mentioned above, there was no evidence to suggest that the spacing of 
information improves understanding of treatment-related risk information when 
compared with continuous presentation. Furthermore, both groups demonstrated a 
similar pattern of performance on a measure of understanding of risk information for 
each presentation condition (massed, spaced, massed-with-delay). This suggests that 
whether risk information is presented continuously or in a spaced format does not 
affect participants overall comprehension of risk information, regardless of whether 
they have MS or not.  
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4.1.4. Hypothesis 4 
Reduced speed of information processing will be associated with reduced recall 
and understanding of treatment-related risk information.  
This hypothesis was partially supported. Performance on the SDMT, a test of 
information-processing speed, was associated with both immediate recall and 
understanding of treatment-related risk information in the MS group. As expected, 
this relationship was positive, with reduced information-processing speed being 
linked to poorer recall and understanding of risk information in this group. However, 
in the healthy control group, SDMT performance was the only cognitive variable not 
significantly related to immediate recall of risk information. Moreover, information-
processing speed was also not related to understanding of risk information in the 
control group.  This may be because the range of SDMT scores in the healthy control 
group was too restricted to detect a significant correlation, with little spread of scores 
around the mean on this variable.  
Other cognitive correlates of risk awareness were also explored. Interestingly, 
in the MS group, only comprehension of risk information (i.e. scores on MTT) did not 
correlate with either recall or understanding of this information in this experiment. In 
the healthy control group, performance on a measure of comprehension (MTT) did 
correlate with recall of risk information. However, like the MS group, it was not 
associated with understanding of risk information. This is a relatively simple measure 
of comprehension for which the majority of participants were at ceiling level. Again 
then, lack of variability in MTT scores in either group likely reduced the likelihood of 
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observing a significant correlation between comprehension and risk awareness. This 
is discussed further in section 4.2.4.  
 Finally, in the healthy control group, only one of two verbal reasoning tasks 
correlated with understanding of risk information, although three other variables did 
approach significance (working memory, a numerical reasoning task, and 
comprehension). Notably however, the MS group performed significantly worse on 
five of the seven neuropsychological measures, although just three of these 
differences remained significant once adjustments were made for the number of group 
comparisons. This suggests that a relationship between risk awareness, in particular 
comprehension of risk information and these numerous cognitive functions, only 
becomes apparent in the context of cognitive deficits. A small spread of scores around 
the mean for these test scores in the control group is again likely to at least partly 
explain the present findings. (This is discussed further in section 4.2.4.)  
4.2. Interpretation   
4.2.1. The MS group demonstrated significantly lower treatment-related risk 
awareness (recall and understanding of risk information) when compared with a 
healthy control group.  
The finding of reduced recall of risk information in MS relative to a healthy control 
sample replicates results from many earlier studies (for review see section 1.4.2) 
which find that MS participants require a greater number of learning trials in order to 
perform at a similar level to healthy control participants on a number of verbal recall 
tasks (e.g. DeLuca et al., 1998; Demaree et al., 2000; Gaudino et al., 2001; Lafosse et 
al., 2013). This verbal recall deficit is thought to be due to reduced information-
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processing speed in MS which impacts on acquisition of verbal information by 
limiting the amount of information which can be encoded and processed for storage in 
long-term memory (Chiaravalloti et al., 2013).  
Reduced risk awareness in MS has also been documented by several previous 
studies. In relation to treatment-related risk, individuals with MS have previously 
been shown to underestimate the risk of experiencing severe treatment-related side 
effects such as cardiotoxicity or leukaemia (e.g. Hoffman et al., 2012) while 
overestimating treatment benefits (e.g. Hessen et al., 2010a). Certainly, reduced risk 
awareness in the general population is well-documented and thought to be due in 
large part to poor numeracy rates (Elwyn et al., 2012; Reyna et al., 2009) occurring 
across all educational backgrounds (Lipkus et al., 2001). These involve both 
underestimation (e.g. Knauper et al., 2005) and, less often, overestimations (e.g. 
Fuller et al., 2004) of the risk of experiencing negative side-effects resulting from a 
particular medication or lifestyle pattern. However, MS-specific studies suggest that 
reduced risk awareness in this group is more complex than this one factor of low 
numeracy levels. It is not unreasonable to assume that well-documented cognitive 
deficits in MS may further impede adequate risk awareness in MS, over and above 
that of low numeracy. Unfortunately, studies specifically addressing this are lacking.  
Only one study, to this author’s knowledge, directly explores the impact of 
MS-related cognitive difficulties on the understanding of treatment-related risk 
information. This study revealed that MS participants with cognitive deficits 
demonstrated poorer understanding of treatment information when compared with 
both a control group and an MS group without cognitive deficits. Furthermore, this 
reduced understanding of treatment-related information was associated with MS-
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related impairments in new learning and executive function (Basso et al., 2010). The 
present study provides some further evidence of reduced understanding of risk 
information in MS. Studies in a number of other patient groups have found that 
reduced ability to understand information about diagnoses and the risks and benefits 
of treatment options is most commonly associated with greater cognitive impairment 
(Dunn et al., 2006; Palmer & Salva, 2007) and so one might expect that MS-related 
cognitive impairments are no different in terms of their impact on comprehension of 
risk information.  
The present study provides some further tentative support for the assumption 
that MS-related cognitive deficits are associated with reduced risk awareness in MS 
by demonstrating that individuals with MS perform significantly worse than healthy 
controls on measures assessing recall and understanding of risk information. Since a 
degree of low numeracy would be expected in both the healthy control and MS group 
based on its relative frequency in the general population, this finding provides a sense 
of the impact of MS-related difficulties on risk awareness largely separate from 
numeracy ability. Moreover, it was clear from results on the TRUSI that the MS 
group had significantly poorer statistical reasoning ability relative to controls. It was 
not possible for this study to directly say whether this was a result of MS-related 
impairments but given that both groups were matched on pre-morbid IQ, it is possible 
that this was the case. Therefore, the present study somewhat informally suggests that 
MS-related cognitive deficits may contribute to the reduced risk awareness observed 
in the MS group. 
4.2.2. The spaced presentation of treatment-related risk information improved 
recall of risk information in both the MS and healthy control group relative to 
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massed presentation but did not improve understanding of risk information in 
either group.  
This study replicates the findings from the two studies which have previously shown 
that spaced presentation of information improves recall in MS (Goverover et al., 
2009b; Goverover et al., 2011). These studies found that spacing out learning trials on 
paragraph learning or functional tasks (learning names, appointment times or object 
locations) led to significantly greater recall of this information when compared with 
performance following continuous presentation of the same material. They thus 
concluded that presenting information in chunks over time facilitates better verbal 
learning and memory in MS. These studies were however limited in that they 
possessed little ecological validity. Paragraph learning tasks, for example, typically 
comprise simple stories that have no personal meaning for the individual. The same 
can be said for name-learning trials. This makes these findings difficult to generalise 
to more meaningful and complex everyday situations facing individuals with MS.   
The present study was able to overcome this limitation by using realistic risk-
benefit treatment information, similar to that often presented to patients with MS in 
clinical settings. In doing so, this more ecologically valid study demonstrated that the 
benefits of presenting information in a spaced format, interspersed with breaks, hold 
true in MS even in the case of memory for complex, meaningful and highly relevant 
information. Thus, learning and recall of risk information in MS is facilitated by the 
distribution of learning trials over time and these effects may be generalised to MS 
clinical settings to aid the recall of risk-benefit information for different medication 
options.  
118 
 
 
Moreover, the present study was the first to separate out the effects of spaced 
presentation on recall from that of repetition in MS. Goverover and colleagues’ 
(2009b; 2011) had not done so. In the spaced condition, their task was presented in 
full and repeated after 5-minute intervals. In the massed condition, their task was 
presented consecutively three times. Yet, other studies have documented a benefit of 
repetition alone for recall in MS (e.g. DeLuca et al., 1998; DeLuca et al., 2013). In the 
present study, extracts in the spaced condition were presented in three separate 
segments with each heard just once. The findings show that spaced presentation can 
improve recall of risk information in MS, independent from any benefit of repetition, 
thus strengthening the support for a benefit of spaced presentation on recall in MS.  
In contrast to verbal recall memory in MS, no studies, to this author’s 
knowledge, had previously explored the benefit of spaced presentation for 
understanding of information in MS. Due to the more ecologically valid nature of the 
present study, using aurally-presented complex and meaningful medication-related 
information rather than simple paragraph or name learning tasks, it was more feasible 
to also test understanding of risk information in MS. However, the present study did 
not find any evidence to support the hypothesis that presenting information over time 
and interspersed with breaks would facilitate greater understanding of risk 
information in either the MS or healthy control group. Thus, it can be concluded that 
spaced presentation of treatment-related risk information can improve participants’ 
ability to recall this complex information but does not improve their ability to 
comprehend this information. 
There are many possible reasons as to why the spacing effect seems not to 
improve understanding of treatment-related risk information in either group. Firstly, 
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the information presented is highly complex, containing multiple forms of statistical 
and numerical information (e.g. percentages, frequencies, risk-benefit ratios) that are 
difficult for people to comprehend (Peters, 2012; Reyna et al., 2009). Providing 
greater time to process this complex information may be sufficient to improve recall 
but is unlikely to help individuals overcome a more fundamental difficulty in 
statistical reasoning.  
Secondly, comprehension of risk information is likely to involve the 
interaction of a number of cognitive abilities, and in this way, is a more complex and 
higher-order cognitive function when compared to verbal recall. Understanding risk 
information likely relies to some degree on memory, verbal reasoning and arithmetic 
ability in order to calculate one’s personal risk, statistical reasoning in order to infer 
meaning from these calculations, and executive functions such as identifying, 
planning and organising key pieces of information (Peters et al., 2007). As such, 
improving recall of risk information by using spaced presentation may only be 
addressing one of several key components necessary for successful comprehension of 
risk information. Further alterations in the way information is presented are therefore 
required to improve understanding of risk information in MS and other groups.  
One strategy may be to alter the syntax, or structure, of information extracts. 
One study asked patients facing abdominal surgery to describe their illness and 
treatment in their own words. They found that using patient-worded information led 
to greater comprehension of illness and treatment information when compared with 
doctor-developed information and this patient-worded information was better 
understood across a range of educational levels (Kusec et al., 2006). This study 
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recommends greater service user involvement in the development of treatment-related 
information and this may also be of benefit in MS clinic settings.  
Altering the type of statistical information provided may also help. 
Consistency in the types of numerical formats used is important when presenting 
statistical information about risks, for example, comparing percentages with 
percentages rather than percentages with frequencies (Lipkus, 2007). Many 
researchers (e.g. Lipkus, 2007; Garcia-Retamero, Okan, & Cokely, 2012) also 
advocate the use of visual aids (e.g. graphs, bar charts) in conjunction with numerical 
risk information when depicting levels of risk, something which was not afforded in 
the present study. Finally, studies of different patient populations recommend that 
clinicians employ an interactive communication strategy in order to improve both 
participants’ recall and comprehension of health-related information (e.g. Kripalani & 
Weiss, 2006; Schillinger et al., 2003). This strategy involves clinicians assessing 
patients’ recall and understanding of new information presented in clinic, also known 
as the ‘teach-back’ method.  
4.2.3. Both the MS and Healthy Control groups demonstrated an equal benefit of 
spaced presentation on immediate recall of risk information. 
It was hypothesised that the MS group would demonstrate a greater benefit of spaced 
presentation for recall of risk information because of the expected deficit in speed of 
information-processing within this group. Owing to this deficit, it was felt that 
participants with MS may have more to gain from regular breaks during the 
presentation of information. Although the MS group was found to have significantly 
reduced information-processing speed relative to the control group, this did not 
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translate into a greater improvement in recall of risk information following spaced 
presentation when compared to control participants.  
While the hypothesis was not supported, this finding is in line with previous 
studies which also report equal benefit of spaced presentation for recall on a 
paragraph learning task (Goverover et al., 2009b) and name-learning task (Goverover 
et al., 2011)  in MS and healthy control groups. In these studies, the MS group also 
performed significantly worse than the control group on a measure of information-
processing speed. However, the current study is similar to these earlier studies in that 
not all participants with MS demonstrated reduced performance on the SDMT. Hence, 
as was similarly suggested by Goverover and colleagues (2011), a future study using a 
group of participants with MS, all of whom demonstrate reduced information-
processing speed, may reveal a greater benefit of spaced presentation on recall of risk 
information in people with MS relative to healthy controls.  
 It may also be that there is an optimum break time that ensures greatest 
compensation for information-processing speed impairments, above or below which 
the benefit of spaced presentation for recall in people with MS may decline. 
Moreover, the optimum timing of spaces may vary depending on the amount and 
complexity of risk information provided. It has been shown that as cognitive load 
increases, the difference in performance on information-processing speed tests 
between MS and control groups also increases (e.g. Denney et al., 2011; Paramenter 
et al., 2007; Reicker et al., 2007). The current study provides complex treatment-
related risk information which is much more cognitively demanding in nature than 
that conveyed in the simple paragraph or name learning tasks of previous studies. 
Thus, one could expect greater compensation to occur if an optimum break time was 
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employed in the spaced condition. This may then have resulted in significantly greater 
benefit of spacing in MS relative to control groups. Further studies could explore 
different time lengths of the breaks or ‘spaces’ provided in spaced presentation 
conditions, during which time an additional benefit for the MS group may be found.  
4.2.4. Reduced speed of information-processing was associated with reduced 
recall and understanding of treatment-related risk information in the MS group 
only, while comprehension did not correlate with either recall or understanding 
of risk information.  
Reduced speed of information-processing was associated with reduced risk awareness 
in the MS group. This is the first study to document this relationship in MS. While 
many studies demonstrate reduced recall in MS and attribute this largely to a deficit in 
information acquisition associated with reduced processing time (e.g. Arnett, 2004; 
Chiaravalloti et al., 2013; DeLuca et al., 1994; Lafosse et al., 2013), only a limited 
number have directly measured the association between information-processing speed 
and recall of information. These few studies reveal positive correlations between 
verbal recall and information-processing speed in MS (e.g. DeLuca et al., 1994; 
Diamond et al., 2008) and one recent study reported information-processing speed to 
be the strongest predictor of new learning ability in MS (Chiaravalloti et al., 2013).  
Notably, these previous studies found an association between information-
processing speed and recall in MS in the context of simple laboratory-based tasks 
(e.g. word-list learning, paragraph or story learning) which possess little relevance or 
meaning and limited generalisability to everyday or clinical encounters. Furthermore, 
none, to this author’s knowledge, have directly explored the association between 
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information-processing speed and the understanding of information in an MS 
population. The present study therefore goes a step further by providing evidence of 
the benefits of spaced presentation for recall even in the context of more complex, 
ecologically valid and clinically-relevant information, namely treatment-related risk 
information. It also directly explores the association between information-processing 
speed and the understanding of information in MS.  
Only one previous study had alluded to a relationship between understanding 
of risk information and information-processing speed in MS. A significant inverse 
association between information-processing speed deficits in MS and capacity to 
make risk-based decisions was reported (Farez et al., 2014). Participants with MS 
who scored lower on a test of information-processing speed (SDMT) were more likely 
to make high-risk decisions. However, understanding is just one of four key 
components (understanding, reasoning, appreciation, expression; Grisso et al., 1997) 
thought to relate to decision-making capacity, and so this earlier study did not directly 
highlight the link between understanding of risk information and  processing speed.  
In contrast to the MS group in the present study, speed of information-
processing did not correlate with risk awareness in the healthy control group. Healthy 
control participants performed significantly better than participants with MS on the 
SDMT and, unlike participants with MS, all scored within the normal range on this 
measure. Unsurprisingly then, there was much less variability in this group relative to 
the MS group, with very little spread of scores around the mean. Given that control 
group participants were not impaired on this variable, it is perhaps not surprising that 
their recall and understanding of treatment-related risk information was not associated 
with information-processing speed.  
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Comprehension, as measured by performance on the Modified Token Test 
(MTT), was the only cognitive function not associated with either recall or 
understanding of treatment-related risk information in the MS group. It was also only 
correlated with recall of risk information in the control group. This is a rather simple 
test in which all participants, whether in the MS or control group, performed within 
the normal range. In fact, most participants were at ceiling level, scoring 15/15. The 
purpose of this test in the present study was more as a screening measure than an 
optimum measure of comprehension ability. As such, it ensured that participants’ 
level of comprehension was sufficient to proceed with the full experimental test but it 
did not capture potentially significant group differences or within-group variability in 
comprehension levels. Therefore, it is not surprising that comprehension did not 
typically correlate with risk awareness in this study.  Furthermore, verbal 
comprehension has been shown to be intact in people with MS (Clemmons et al., 
2004; Drew, et al., 2008; Prakash, et al., 2008; Ryan et al., 2012) and so it was not 
expected that there would be a significant correlation between comprehension and 
recall or understanding of risk information in this group.  
However, the cognitive impairment index scores correlated strongly with both 
the understanding and recall of risk information in both the MS and healthy control 
groups. Thus, overall cognitive performance was associated with understanding and 
recall of risk information, where greater cognitive function was linked to better risk 
awareness in both groups.   
4.3. Limitations of the Study  
4.3.1. Neuropsychological Tests Completed During Presentation Breaks 
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Participants completed neuropsychological tests during the breaks of the spaced 
presentation condition and during the 10-minute break of the massed-with-delay 
condition. This was primarily due to the lengthy nature of the full test battery and was 
aimed at limiting the time burden and fatigue experienced by participants. Yet a vast 
number of studies provide evidence for memory decay over time (e.g. Cowan & 
AuBuchon, 2008; Portrat, Barrouillet & Camos, 2008), which many attribute to 
interference and distraction which prevents rehearsal of the new information (e.g. 
Fernandes & Moscovitch, 2000; Oberauer & Lewandowsky, 2009). Consequently, the 
administration of these neuropsychological tests may have increased task difficulty 
making it more difficult to later recall and comprehend the treatment-related risk 
information in the spaced and massed-with-delay conditions. Hence, this may have 
reduced the likelihood of observing a significant benefit of spaced presentation 
relative to massed presentation in improving risk awareness. Nonetheless, a 
significant benefit of spaced presentation relative to massed presentation was still 
observed for recall, although this only approached significance once Bonferroni 
corrections were made. Perhaps a stronger benefit of spaced presentation for recall 
would have been observed had participants not completed neuropsychological tests in 
any of the presentation conditions.  
Moreover, the tests administered in the spaced presentation breaks (WTAR 
and SDMT) and 10-minute delay period (Arithmetic subtest) were consistent across 
all participants. Therefore, one could argue that the inclusion of neuropsychological 
measures in break periods was unlikely to have influenced findings of group 
differences in recall and understanding of risk information. Conversely, research has 
also shown that memory decay may be more pronounced in MS relative to healthy 
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control participants with greater susceptibility to interference and distraction in this 
group (e.g. Diamond, DeLuca, Kim, & Lee, 1996; Johnson, DeLuca, Diamond, & 
Natelson, 1998; Griffiths et al., 2005). Thus, the interference caused by the 
administration of neuropsychological tasks may be a potential confound, possibly 
inflating the observed group differences in risk awareness.  
4.3.2. Ecological Validity of the Experimental Tasks 
The three fictitious treatment-related vignettes, as well as the measure of 
understanding of risk information for each vignette, were developed specifically for 
this study. As such, there is no established validity or reliability for the vignettes or 
the measures of recall and understanding used. In terms of vignette development, 
review of the vignettes by a number of MS consultants and MS nurses who work 
within MS clinics and who regularly provide treatment-related information to MS 
patients may have provided valuable feedback prior to the beginning of this study in 
terms of ecological validity and use of appropriate language and statistics. While 
outside the scope of the present study, it would also be possible to correlate the 
fictitious vignettes with information provided in a clinical context. However, the 
scoring method applied for immediate recall in the present study was based on the 
scoring method used by several well-established neuropsychological tests of verbal 
memory, for example the BMIPB (Coughlan et al., 2007). Moreover, the measure 
used to assess understanding of risk information was designed to capture participants’ 
understanding of numerical and verbal risk information and was scored in a way 
similar to some well-established measures of comprehension (e.g. Comprehension 
subtest of the WAIS-III where participants also receive 0-2 points depending on 
whether their response is correct, partially correct or incorrect; Wechsler, 1997a). 
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Furthermore, every effort was made to ensure that the type of information presented 
emulated that typically provided in MS clinics (e.g. style, wording, format of 
statistical information), although the similarity to real-world examples has not been 
formally tested. Nevertheless, it is typical for information provided in clinic to vary 
based on many factors such as clinician’s communication style (e.g. Robinson, 2002) 
or format of presentation (e.g. verbal, written, visual) and so some variability in 
presentation is natural. 
It could be argued that the use of non-MS relevant treatment-related risk 
information may have reduced the ecological validity and generalisability of the 
current findings. Based on previous research which documents increased recall for 
more meaningful stimuli (e.g. Barense, Henson, & Graham, 2011; Janiszewski et al., 
2003), it may be that greater meaning and relevance of MS treatment information may 
have led to a greater benefit of spaced presentation for recall in the MS group relative 
to healthy controls. However, the inclusion of MS-specific treatment-related risk 
information may also have introduced further potentially confounding factors which 
might impact on risk awareness, for example increased anxiety among patients with 
MS following the presentation of  prognosis and treatment information (Kessels, 
2003) or greater prior knowledge of the risk-benefit profiles in participants with MS 
relative to controls. Furthermore, MS-specific information would have been biased in 
favour of the MS group as it would have been more meaningful for people with MS 
and would therefore have unfairly disadvantaged the control group. Using realistic but 
neutral treatment-related risk information arguably provided a more accurate sense of 
the group differences in risk awareness and also the relative benefits of spaced 
presentation for each group, aspects which were of primary interest in this study.    
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It has also been discussed in earlier sections how the effects of depression and 
anxiety on cognitive performance remain unclear with both significant and non-
significant correlations reported between both anxiety and depression and cognitive 
function (e.g. Diamond et al., 2008; Karadayi et al., 2014). In the current study, it was 
not expected that the MS group would have had a significantly greater number of 
emotional barriers to processing, recalling and understanding the presented treatment-
related risk information when compared with healthy control participants. Firstly, 
while the MS group self-reported higher levels of depression, both groups reported 
similar levels of anxiety. Secondly, non-MS related information was employed and 
the three fictitious vignettes instead comprised realistic, non-MS specific treatment 
information. As mentioned above, this was chosen in part to reduce the potential 
confound of greater emotional barriers in the MS group when processing information 
relevant to their condition. Finally, observations and conversations with participants 
revealed that test anxiety featured in both groups for a small number of participants 
and numerous members of both groups had endured significant health difficulties in 
the past (e.g. cancer) which could potentially increase anxiety in either group on 
hearing health-related information. Overall then, it was not felt that emotional barriers 
to the processing of risk information would have confounded findings of group 
differences in aspects of risk awareness within the current study. 
 Anecdotally, some participants reported that they typically write down 
information in clinic or bring a spouse or relative along to help them recall and weigh 
up treatment-related and prognostic information. For many participants with MS then, 
the current experimental task possessed some notable differences to their typical 
clinic visit. However, the use of a verbal recall measure and the lack of external 
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memory aids in the current study were arguably a better method of exploring group 
differences in risk awareness and to get a baseline measure of the potential benefit of 
spaced presentation for risk awareness. Furthermore, some participants with MS were 
no longer able to write well and several relied on carers rather than relatives or 
friends.  Of course, spaced presentation is just one of several ways of improving risk 
awareness in MS and, where possible, writing down clinic information or bringing 
along an accompanying relative or friend, are also likely to benefit risk awareness in 
many cases.  
Again, while not being within the scope of this study, a more detailed 
assessment of risk understanding in MS could have provided further much-needed 
insight into comprehension level in this patient group. Specifically, it would be 
interesting to know whether participants with MS tended to overestimate or 
underestimate risks. Of the few studies which document reduced risk awareness in 
MS, most reveal a tendency for patients to overestimate treatment benefits (Heesen et 
al., 2010a) and underestimate severe treatment side effects (Hoffman et al., 2012). 
Moreover, a multiple choice question format (perhaps offered if participants initially 
failed to provide the correct response) may have helped assess whether patients with 
MS could respond correctly with support. This in turn might indicate whether they 
can demonstrate improved understanding once memory has been prompted using the 
options provided. In this way, it might also disentangle recall from the other elements 
involved in understanding risk information, for example planning and organising 
elements of the presented information.  
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4.3.3. Choice of Neuropsychological and Clinical Measures 
No significant correlation was found between comprehension and either 
understanding or recall of risk information in the MS group. Comprehension also did 
not correlate with understanding of risk information in the healthy control group. 
However, comprehension was measured using the Modified Token Test (MTT) 
which, as discussed above, has a low ceiling and was included more as a screening 
measure to ensure a basic level of comprehension in the sample. Perhaps another 
more complex measure of comprehension could have been employed, for example the 
Comprehension or Information subtests of the Wechsler Adult Intelligence Scale 
(WAIS-III; Wechsler, 1997a; or WAIS-IV; Wechsler, 2008). This may have resulted 
in more variability within and between the groups and provided a more accurate 
account of the relationship between comprehension and risk awareness.  
The neuropsychological test battery assessed several cognitive domains 
thought to be most relevant to recall and understanding of treatment-related risk 
information, the variables central to the present study.  A more extensive 
neuropsychological battery was not deemed possible given the time-constraints for 
completion of the study and the need to both reduce the impact of fatigue on MS 
participants and to encourage study participation by both MS and healthy controls, 
many of whom obliged to participate despite working full-time. Therefore, several 
important cognitive functions were not assessed. Most notably, executive function 
was not assessed. Measures from the DKEFS battery (Delis et al., 2001) such as the 
Tower of London or the Colour-Word Interference subtests could have assessed 
abilities such as planning, problem-solving and inhibition. Individual tests such as the 
Stroop Colour-Word Test (Stroop, 1935), Wisconsin Card Sorting Test (WCST; Berg, 
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1948) or The Brixton Spatial Anticipation Test (Burgess & Shallice, 1997) would also 
have provided information on inhibition, problem-solving and planning abilities 
respectively. These abilities may be correlated with understanding of complex risk 
information in that a deficit in one or several domains of executive function may 
reduce one’s ability to adequately identify, organise and sort key pieces of risk 
information or to inhibit less relevant information. Indeed, studies of risk awareness 
and decision-making in other neurological conditions, such as Parkinson’s Disease 
and dementia, have documented a correlation between understanding of risk 
information and performance on tests of executive function. Furthermore, one test of 
understanding of risk information in MS found a significant positive correlation 
between executive function and understanding of risk information, whereby reduced 
performance on the WCST was associated with reduced understanding of risk (Basso 
et al., 2010).  
The inclusion of measures of complex attention may also have provided 
further insight into possible correlates of understanding of risk information, 
particularly in the MS group. Furthermore, tests of narrative memory rather than the 
word-list learning verbal memory task (CVLT-II) may have added merit to the study. 
The first five recall trials of the CVLT-II have well-established validity and reliability 
in screening for verbal learning difficulties in MS (Langdon et al., 2012) and are 
commonly used to assess verbal recall in clinical and research settings. However, 
narrative based measures such as the Story recall subtest of the BIRT Memory and 
Information Processing Battery (BMIPB; Coughlan et al., 2007) or Logical Memory 
subtest of the Wechsler Memory Scale (WMS-III UK; Wechsler, 1997b; WMS-IV 
UK; Wechsler 2009) are more similar in nature to the experimental task, affording 
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more ecological validity, and may have thus been correlated with the experimental 
task.  
In regards to the clinical measures, it may also have been worthwhile to 
include a measure of adaptive functioning. While severity of fatigue was assessed 
using a self-report questionnaire, a self-report measure of physical disability may also 
have provided some information on the severity of physical symptoms within the MS 
group and the impact of this on ability to perform everyday tasks. The Expanded 
Disability Status Scale (EDSS; Kurtzke, 1983) is commonly used to measure physical 
disability and adaptive functioning in MS and would have enabled the researcher to 
explore the correlation between severity of physical disability and performance on the 
dependent variables of recall and understanding of treatment-related risk information. 
This may have been particularly informative given that the level of physical disability 
in the MS group varied from those with no real observable difficulties in mobilising to 
those who were dependent on carers for all tasks of daily living including personal 
care and meal preparation. Several studies exploring the relationship between physical 
disability status and cognitive impairment in MS have found a positive association 
between physical disability and performance on a number of neuropsychological tests 
including verbal memory and information processing speed (e.g. Alajbegovic et al., 
2009; Lynch, Parmenter, & Denney, 2005; Patti et al., 2009). However, other studies 
report no significant correlation (e.g. Gaudino et al., 2001).  
4.3.4. Statistical Power 
The recruitment target of 60 participants was reached. This was the minimum sample 
size recommended in the prospective power analysis based on an expected medium 
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effect size of presentation condition. The actual effect size of presentation condition 
on recall of risk information was within the medium range (𝜂2 = .37). While the 
minimum recommended sample size was obtained, a larger sample size would have 
added more power to detect significant results.  
The power calculation was based on a study that could be considered to be 
below the optimum similarity to the current study. It differed in terms of the clinical 
group of interest (TBI patients), levels of the presentation condition (two levels; 
spaced and massed), number of dependent variables (immediate recall only) and 
experimental paradigm (word-list learning task). Only two studies have explored the 
effect of spaced presentation on recall in MS (Goverover et al., 2009b; 2011). Neither 
of these studies were felt to be suitable for the power analysis as the effect size was 
small (𝜂2 = .10, Goverover et al., 2009b; 𝜂2 = .13, Goverover et al., 2011), the effect 
size was not reported for all recall measures (only object location; Goverover et al., 
2011), and one study examined the benefit of two strategies (spaced presentation and 
self-generation) on recall of risk information, with an emphasis on self-generation. 
Although using the same clinical group, both studies would also have differed from 
the current study in terms of the levels of presentation condition, experimental 
paradigm and number of dependent variables.  
A number of analyses were conducted to test the four hypotheses. This may 
have limited the power of the study to some extent, increasing the likelihood of 
finding a significant result (Type 1 error). 
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4.3.5. Assessment Conditions   
The majority of participants with MS were tested in their homes due to mobility 
difficulties in attending hospital. The home environment differed from a typical 
testing environment in terms of environmental distractions, the level of which varied 
across participants. This is noteworthy given that the experimental task consisted of 
aural extracts played on a speaker. Healthy control participants were primarily tested 
in their place of work. This meant that environmental distractions outside of the 
researchers control were also a factor in this group. Furthermore, there were more 
likely to be time pressures due to a participant needing to be back to work at a given 
time. Time of testing also varied with participants completing the test battery in the 
morning, afternoon or evening. Consequently, daily fluctuations in fatigue levels may 
also have impacted on participants’ performance on measures of risk awareness. 
4.3.6. Representativeness of Samples Recruited  
Overall, the MS participants recruited were largely well-representative of the general 
MS population. The sample had a 2:1 female to male ratio (20 females, 10 males) 
which is slightly lower than the 2.35-3.4:1 female to male ratio universally reported in 
this population (Ahlgren, Oden, & Lycke, 2011; Mackenzie, Morant, Bloomfield, 
MacDonald, & O’Riordan, 2013; Wallin et al., 2012). The study was not powered to 
distinguish between performance for different MS subtypes (RRMS, PPMS, SPMS).  
The mean age of the MS (49.7 years) and healthy control (45.4 years) samples 
were biased towards a slightly older age group. It is well-documented that some 
cognitive functions decline in middle age, including memory and new learning 
(Nilsson, 2003). It may be that the sample performed worse on measures of recall and 
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understanding of treatment-related risk information, although this is unlikely to have 
confounded group differences in risk awareness as the groups were matched for age. 
Nonetheless, the findings of reduced risk awareness in the MS group are likely to be 
less generalisable to younger MS participants. A greater benefit of spaced 
presentation for learning and memory has also been documented in younger relative 
to older adults, although both groups do benefit (Simone, Bell, & Cepeda, 2012). It is 
likely that an even greater benefit of spaced presentation for recall of treatment-
related risk information in MS may be found in a younger MS sample. It would also 
be interesting to explore whether a significant benefit of spaced presentation for 
understanding of risk information would be found in a sample of younger MS 
participants.  
The cognitive deficits observed in the study were largely what would be 
expected in an MS sample. The MS group performed significantly worse than healthy 
controls on a measure of information-processing speed and working memory which is 
in line with the evidence base detailing domain-specific MS-related cognitive 
impairments (Bodling et al., 2012; Denney et al., 2011; Legenfelder et al., 2003). 
Reduced statistical reasoning in MS has also been observed (McKnight, 2007), 
although this has not been widely explored. It is perhaps surprising that the MS group 
did not perform significantly worse than healthy controls on the CVLT-II, a measure 
of immediate recall. Previous studies report verbal recall memory and learning to be 
another common MS-related cognitive deficit (Demaree et al., 2000; Gaudino et al., 
2001; Lafosse et al., 2013). However, as hypothesised, immediate recall of treatment-
related risk information was significantly reduced in the MS relative to the control 
group. Moreover, the group difference in CVLT-II performance was significant until 
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Bonferroni corrections were applied. A larger sample size may have increased the 
power to detect a significant group difference on the CVLT-II.  
4.3.7. Potentially Confounding Factor of MS Medication on Cognitive 
Performance 
Approximately 23% of the MS group were taking prescribed DMTs. This may have 
been a confounding factor in that there is some recent evidence to suggest that DMTs 
can stabilise or improve cognitive function in MS (e.g. Iaffaldano et al., 2012; Kunkel 
et al., 2015). However, a significant group difference was still observed whereby the 
MS group performed significantly worse than healthy control participants on 
measures of recall and understanding of treatment-related risk information. 
Furthermore, a significant benefit of spaced presentation over massed presentation 
was still observed in the MS group for recall of risk information. Perhaps a greater 
benefit of spaced presentation may have been evident in a medication-naïve MS group 
where there may be greater compensation in light of potentially more impaired 
information-processing speed. Future research could explore the benefit of a spacing 
method of presentation of risk information when comparing two groups of MS 
participants, where one is prescribed DMTs and the other is a medication-naïve group.   
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4.4. Clinical Implications of the Study 
4.4.1. Benefits of spaced presentation of treatment-related risk information in 
MS clinic settings 
Individuals with different MS subtypes (RRMS, PPMS, SPMS) demonstrate reduced 
recall and understanding of treatment-related risk information relative to matched 
healthy controls, as well as poorer performance on measures of information-
processing speed, working memory and statistical reasoning. Clinicians could use a 
spaced presentation method of communicating treatment-related risks and benefits to 
patients with MS during consultations. By interspersing this treatment information 
with breaks, clinicians could help to improve patients’ recall of risk-benefit profiles of 
potential MS medications. It is likely that the benefit of spaced presentation for 
remembering the risks and benefits of different medication options would generalise 
to this clinical context where information is heard in person.  
The financial cost of implementing such a strategy is minimal. However, 
presenting information over time and interspersed with breaks will naturally increase 
the amount of clinic time allocated to each MS patient in a context where clinicians’ 
time resources are already stretched. It would be feasible for other clinical staff (for 
example MS nurses) to provide longer consultations in which they discuss the relative 
risks and benefits of various MS medication options with patients, using a spaced 
format, prior to them making a decision about their treatment.  It would also be 
possible to alter the format of clinical contacts in which DMTs are discussed with 
patients in order to allow for timing of spaced presentation of DMT-related 
information. For example, some DMT-related information could be discussed, 
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followed by a physical exam, then further provision of DMT-related information, 
followed by a social and emotional review, and so on. This would provide a patient-
centred approach in which the clinical contact time does not change but the format of 
information delivery and activities engaged in is altered to meet the needs of the 
patient. NICE guidelines (2003) recommend a more staged process of information 
provision in MS (e.g. through a number of different clinician-patient contacts). Yet, 
DMT information in MS clinics is currently often provided in a one-off manner rather 
than as a staged process likely due in large part to lack of time. Perhaps a staged 
process which requires a change in format of clinical contact rather than an increase in 
clinician time, such as that just discussed above, would be more successfully 
implemented. If effective, such a spaced presentation method may also help to 
standardise the way in which information is provided to newly diagnosed patients 
with MS by encouraging the uptake of a spaced or staged presentation of information 
in a greater number of MS clinics. However, the oral spaced presentation of 
information is of course just one element. Written information should also be 
provided (NICE, 2003) and this may further enhance recall of risk information in MS.   
It has been shown that evidence-based patient information (EBPI) can lead to 
some improvement in risk awareness in patients with MS. Recall of treatment-related 
EBPI is key to the success of shared decision-making and so spaced presentation of 
medication risk-benefit profiles may help to make SDM a reality for patients with MS 
within UK health settings. Previous research has trialled the use of CDs as one means 
of communicating risk-benefit treatment-related information in MS (Solari et al., 
2010). Presenting treatment information on a CD in a spaced format may improve the 
benefit of EBPI for enhancing risk awareness in MS. Not only would this reduce time 
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pressures for clinicians, it would also enable participants to rehearse this information 
at a later time when anxiety and other factors which potentially impact on risk 
awareness have diminished.  
In a similar vein, the benefit of aural spaced presentation for recall of risk-
benefit treatment information is likely to transfer to other modes of communicating 
spoken information such as DVDs or internet video clips. Many people with MS rely 
on internet-based forums to provide them with EBPI on prognosis, benefits and side-
effects of treatments, advances in drug treatments, and lifestyle-relevant information 
(Colombo et al., 2014; Synnot et al., 2014). Links to video clips or podcasts on such 
websites and forums could offer another mode of presenting EBPI interspersed with 
breaks to patients with MS. In these clips, MS health professionals could present 
treatment options but could also provide educational and practical information on 
other topics deemed as important by patients in the aforementioned studies, such as 
lifestyle-relevant information. The use of spaced presentation of information may also 
generalise to everyday spoken conversation.  
Finally, health professionals could also employ a spaced presentation strategy 
when assessing decision-making capacity in patients with MS. While spaced 
presentation does not directly improve understanding of risk information, it improves 
recall of complex risk information. Recall is an important component in being able to 
adequately understand, appreciate, and reason with risk information before expressing 
a well-informed choice.    
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4.4.2. Cognitive rehabilitation in Multiple Sclerosis   
The present study adds further support to studies which suggest that altering the 
method of information presentation to allow more time to process information can 
improve cognitive function in MS. Adding in regular breaks when conveying 
information likely improves recall as it allows more time for the information to be 
encoded and processed for later retrieval from memory.  
It has previously been shown that spaced presentation of information can be 
used to improve recall of simple information in MS such as word-lists, appointments, 
names, or object locations (Goverover et al., 2009b; 2011). Yet spaced presentation 
can also aid the recall of quite complex information. Moreover, this information does 
not necessarily need to be repeated in order to improve memory for information. This 
makes spaced presentation a potentially more realistic cognitive rehabilitation strategy 
to be incorporated into everyday life. It may also reduce frustration or embarrassment 
among patients with MS when compared with needing to ask for information to be 
repeated several times. 
Indeed, repetition alone has not been found to reliably improve recall of risk 
information (Chiaravalloti et al., 2003), likely because it is not necessarily allowing 
extra time to process information. Chiaravalloti and colleagues (2003) showed that 
greater cognitive impairment in information-processing ability was associated with 
reduced benefit of repetition on new learning in MS. The present study suggests that 
new learning and immediate recall in MS can instead be optimised by presenting 
information in a way that increases the time available to attend to, process, and 
encode information, resulting in improvements in everyday functional tasks.   
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Cognitive impairments in information-processing speed, working memory, 
verbal recall, and verbal and statistical reasoning were associated with reduced recall 
of treatment-related risk information. Therefore, use of spaced presentation of 
information to improve recall in patients with MS may also have indirect benefits for 
these other cognitive functions. However, these remain to be explored.  
4.5. Directions for Future Research  
Future studies would benefit from exploring the optimal time duration of the breaks or 
‘spaces’ in the spaced information-presentation condition in order to optimally 
enhance recall in people with MS. This optimal break time may vary as a function of 
cognitive load of a task. Furthermore, the benefits observed may vary based on the 
frequency of cognitive-deficits in the MS group. Therefore, studies exploring 
differences in benefit of spaced presentation on risk awareness between two MS 
groups, one with and one without information-processing speed deficits, would be 
insightful and may reveal a greater benefit of spaced presentation for recall in the MS 
group with information-processing speed impairments.  
Future studies which recruit larger sample sizes may add further support to 
this benefit of spaced presentation for recall in people with MS by demonstrating a 
stronger effect on recall relative to massed presentation. These larger studies may also 
allow for the exploration of differential benefits of spaced presentation across 
different MS subtypes. While cognitive deficits exist across all MS subtypes, MS-
related cognitive difficulties are known to worsen as the disease progresses (Benedict 
et al., 2006; Chiaravalloti & DeLuca, 2008). It would be interesting to see whether a 
greater or lesser benefit of spaced presentation for recall of risk information is evident 
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in later disease stages. It would also be worthwhile exploring whether spaced 
presentation may aid understanding of risk information in those with shorter disease 
duration. Perhaps cognitive deficits other than information-processing speed, for 
example executive dysfunction, which may impact on level of comprehension may 
not yet be evident in this group. Larger sample sizes would provide more power to 
detect a significant result in such studies.  
It is important that future research continues to consider other ways of 
presenting information to participants with MS that might reduce the impact of 
slowed information-processing speed on recall of risk-information, for example, by 
using a teach-back method (Kripalani & Weiss, 2006) or self-generation (Goverover 
et al., 2011). It will be imperative for future research to also consider other more 
successful ways of improving understanding of risk information in MS. This may 
involve first identifying the cognitive abilities underlying comprehension of complex 
risk information. In addition, concurrent studies may develop ways of reducing the 
complexity of the information presented to patients in MS clinical contexts, for 
example by using visual aids alongside statistical information (Garcia-Retamero et al., 
2012) or patient-worded information (Kusec et al., 2006). By reducing both the 
impact of MS-related cognitive impairments on comprehension ability as well as 
reducing the complexity of the information itself, participants with MS are more 
likely to be able to make well-informed decisions about their medical treatment in line 
with a true shared-decision making approach.   
One other way to reduce the complexity of the treatment-related risk 
information presented to people with MS may be to standardise MS medication 
information. A consensus on how risk information should be presented would make it 
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easier for patients to compare across MS medications. Future studies which explore 
the most effective ways of presenting information about medication risks to people 
with MS would benefit from keeping this overarching goal in mind. Relatedly, such 
studies may support an argument for drug companies to simplify their style of 
presenting information about treatment risks. One method might be to grade the 
complexity of the information to be understood, for example DMTs could come with 
a colour coded label (e.g. red for high complexity, amber for medium complexity, and 
green for low complexity) indicating the complexity of the information to be 
processed. This would signal to patients and clinicians alike that more time may need 
to be allocated to the explanation and processing of red-coded DMT information.  
4.6. Conclusion 
The present study explored the advantages of using a spaced information-
presentation style, whereby information is interspersed with breaks, to enhance risk 
awareness for treatment-related risk information in MS. Participants with MS 
performed significantly worse than healthy controls on measures of immediate recall 
and understanding of treatment-related risk information. Yet both groups 
demonstrated an equal benefit for recall from spaced presentation of information 
relative to continuous presentation. Reduced information-processing speed was 
associated with reduced recall in the MS group. Overall then, the present study 
provides some initial support for the advantages of using a spaced information-
presentation style in order to enhance immediate recall of risk information in MS and 
this may be linked to MS-related deficits in information-processing speed.   
144 
 
 
Conversely, spaced presentation did not aid the comprehension of medication 
risk information in either the MS or healthy control groups. The breaks in information 
presentation may ameliorate effects of reduced information-processing speed on 
recall. Yet, the complexity of comprehending medication risk information may be too 
great a challenge for a spacing intervention to overcome in the context of MS-related 
cognitive impairment.  
A spaced presentation strategy of presenting information about medication 
risks could be incorporated into MS clinical settings and may increase the potential 
benefits of evidence-based patient information (EBPI) in improving risk awareness in 
MS. Future studies would benefit from examining the optimal break time provided 
during spaced presentation, recruiting a larger sample size, exploring other strategies 
of presenting information in MS, as well as ways of reducing the complexity of the 
information presented.  Such studies may strengthen support for the use of the spacing 
effect in improving recall for complex risk information and may elucidate ways of 
improving comprehension of risk information in MS. Ultimately then, participants 
with MS may be more empowered to make well-informed decisions about their 
medical treatment in line with a true shared-decision making approach.   
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Appendix C: Letter of invitation to partake in research study for MS group 
 
          National Hospital for Neurology & Neurosurgery  
MS Clinic 
Queen Square 
London 
WC1N 3BG 
Website: www.uclh.nhs.uk 
 
 
 
 
 
 
 
Dear __________, 
I would like to invite you to take part in our study investigating how well drug 
information is processed by people with MS and how this relates to mood and other 
cognitive abilities (e.g. understanding, memory, decision-making). This is an 
important area of research as people with MS must often choose between a number of 
potential drug treatments which vary in terms of their effectiveness and side effects. 
This study aims to inform clinicians how best to present drug treatment information in 
order to improve people’s understanding of the different treatment options, as well as 
increasing confidence in their treatment decisions.   
 
The research project is jointly co-ordinated by Dr. Samantha Altendorff (Highly 
Specialist Clinical Psychologist, National Hospital for Neurology and Neurosurgery) 
and Prof. Dawn Langdon (Clinical Psychologist, Royal Holloway University of 
London). We are asking people with a diagnosis of MS under the care of the National 
Hospital for Neurology and Neurosurgery, if they would be willing to participate. You 
previously indicated that you are willing to be contacted about research.  
 
I enclose a copy of the information sheet that provides more detailed information. 
 
Please complete the reply sheet attached to this letter and return it in the pre-paid 
envelope. If you are interested in participating in the research, I will contact you by 
telephone to provide further information and answer any questions you may have.  
 
Department of Psychology  
Doctorate in Clinical Psychology 
Royal Holloway,  
University of London,  
Egham, 
Surrey, 
TW20 0EX 
Email: nxjt006@live.rhul.ac.uk 
Tel: 01784 414 388 
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Thank you for considering participating in the research. 
I hope to hear from you soon. 
 
Kind Regards, 
 
 
Michele Burns 
Trainee Clinical Psychologist 
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Appendix D: Participant information sheet: MS group
 
           National Hospital for Neurology & Neurosurgery  
MS Clinic 
Queen Square 
London 
WC1N 3BG 
Website: www.uclh.nhs.uk 
 
 
 
 
 
 
 
 
Title of study: Risk awareness and treatment information in Multiple Sclerosis 
(MS)  
Ethics number: 14/EM/0153 
 
Research Participation Information Sheet: 
 
My name is Michele Burns and I am a Trainee Clinical Psychologist. I am inviting 
you to take part in my research study. Before you agree to take part, it is important 
that you understand a bit about my reasons for undertaking this research and what it 
will involve. Please take some time to read the following information. Feel free to ask 
me for further information or to clarify anything that is unclear. Please take your time 
to decide whether you would like to take part. Before you decide, you may also wish 
to discuss this information with others, for example family or your GP. 
 
What is the purpose of this study? 
My study is exploring how well drug information is processed in patients with MS 
and without MS and how this relates to mood and other cognitive abilities.  We have 
prepared some tapes with fictional drug information. These tapes will be played to 
you and you will also complete a number of other short tasks.  
 
  
Department of Psychology  
Doctorate in Clinical Psychology 
Royal Holloway,  
University of London,  
Egham, 
Surrey, 
TW20 0EX 
Email: nxjt006@live.rhul.ac.uk 
Tel: 01784 414 388 
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Where will this study take place? 
You may choose whether you wish to undertake this study at the NHNN, at a 
University of London office in Central London, or at your own home. You may 
choose whichever is the most convenient location for you. Unfortunately no travel 
expenses will be available.  
 
Why have you been asked to take part? 
Most patients with MS who attend the MS clinic at the National Hospital of 
Neurology and Neurosurgery (NHNN) are being invited to participate.  
 
Do you have to take part in this study? 
There is no obligation for you to take part in this study. If you do decide to take part, I 
will ask you to sign a consent form. By signing this form you would be providing me 
with permission to record your contact details and to access some medical information 
which is of relevance to the study. Once you have provided consent, you are still free 
to withdraw from the study at any time without needing to provide an explanation or 
without any consequence to your ongoing medical care.  
 
If you agree to participate, what will the study involve? 
If you decide to take part in this study, I will ask you to attend a one-off appointment 
with me at a location convenient to you. This appointment will last a maximum of two 
hours. I will ask you to first complete a number of short questionnaires which will 
involve questions about your mood and level of fatigue. Then some tapes will be 
played on which you will hear some fictional drug information. I will also ask you to 
do concentration and problem solving tasks. If you feel tired, you can take breaks at 
any time during this appointment. If at any point you decide that you no longer want 
to be part of this research, you may withdraw from the study immediately without 
providing a reason and without any consequence to your ongoing medical care. One 
of the questionnaires may show that you could be depressed. In this case, you will be 
informed of the result and advised to see your GP. 
 
What are the benefits to taking part? 
There will be no direct benefit to you for participating in this research. However, by 
increasing the knowledge available on risk awareness in MS, there may be indirect 
benefits for future MS-related clinical practice. Additionally, my study will help you 
to gain more knowledge about the ways in which individuals are affected by MS. You 
will have the opportunity to ask questions and you will be provided with a copy of the 
final report once it has been published in a peer-reviewed journal. You will not be 
identified in any report or publication.  
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What are the disadvantages and risks to taking part?   
Some people can find the completion of problem-solving tasks or discussions of mood 
or their medical conditions tiring. Please let me know if you feel tired or distressed at 
any point during the session. You will be free to take a break or to stop testing 
completely. There will also be time to talk about any concerns that you might have. 
Your ongoing medical care will not be affected in any way by whether you decide to 
take part in this study.   
 
What will happen to the information I provide and who will have access to this? 
All data will be collected and stored in accordance with the Data Protection Act 1998. 
Any of your personal details (e.g. name, contact details) will be kept strictly 
confidential and will be accessible only to myself and my supervisor Dr. Samantha 
Altendorff, Clinical Neuropsychologist at the NHNN. All the other information you 
provide will be stored anonymously and will not be linked to your personal 
information in any way.  
 
This project has been approved by the NHS Research Ethics Service (NRES) and 
by the Research and Ethics Committee at Royal Holloway, University of London.  
 
If you would like to ask any further questions about this research, please email 
me on nxjt006@live.rhul.ac.uk. You may also leave a message on 01784 414 388. 
Please make sure that you state clearly that your message relates to the MS 
research project with Michele Burns and leave your contact number. I will get 
back to you as soon as possible.  
 
If you have a concern about the way in which this study is being conducted and 
wish to make a complaint, you may do so by contacting the study supervisor, 
Professor Dawn Langdon, at the following email address: 
D.Langdon@rhul.ac.uk    
 
Thank you for taking the time to read this information sheet. 
 
Michele Burns 
Trainee Clinical Psychologist and Chief Investigator 
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Appendix E: Letter of invitation to partake in research study for Healthy Control 
group 
          National Hospital for Neurology & Neurosurgery  
MS Clinic 
Queen Square 
London 
WC1N 3BG 
Website: www.uclh.nhs.uk 
 
 
 
 
 
 
 
Dear __________, 
I would like to invite you to take part in our study investigating how well drug 
information is processed by people with and without Multiple Sclerosis (MS) and how 
this relates to mood and other cognitive abilities (e.g. understanding, memory, 
decision-making). This is an important area of research as people with MS must often 
choose between a number of potential drug treatments which vary in terms of their 
effectiveness and side effects. This study aims to inform clinicians how best to present 
drug treatment information in order to improve people’s understanding of the 
different treatment options, as well as increasing confidence in their treatment 
decisions.   
 
The research project is jointly co-ordinated by Dr. Samantha Altendorff (Highly 
Specialist Clinical Psychologist, National Hospital for Neurology and Neurosurgery) 
and Prof. Dawn Langdon (Clinical Psychologist, Royal Holloway University of 
London). We are asking people with and without a diagnosis of MS if they would be 
willing to participate. This comparison can help us to establish whether there are any 
important differences between healthy people and people with MS in terms of their 
risk awareness about treatment information. 
 
I enclose a copy of the information sheet that provides more detailed information. 
 
Department of Psychology  
Doctorate in Clinical Psychology 
Royal Holloway,  
University of London,  
Egham, 
Surrey, 
TW20 0EX 
Email: nxjt006@live.rhul.ac.uk 
Tel: 01784 414 388 
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Please complete the reply sheet attached to this letter and return it in the pre-paid 
envelope. If you are interested in participating in the research, I will contact you by 
telephone to provide further information and answer any questions you may have.  
 
Thank you for considering participating in the research. 
I hope to hear from you soon. 
 
Kind Regards, 
 
 
Michele Burns 
Trainee Clinical Psychologist 
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Appendix F: Participant information sheet: Healthy Control group 
           National Hospital for Neurology & Neurosurgery  
MS Clinic 
Queen Square 
London 
WC1N 3BG 
Website: www.uclh.nhs.uk 
 
 
 
 
 
 
 
Title of study: Risk awareness and treatment information in Multiple Sclerosis 
(MS) 
Ethics number: 14/EM/0153 
 
Research Participation Information Sheet: 
 
My name is Michele Burns and I am a Trainee Clinical Psychologist. I am inviting 
you to take part in my research study. Before you agree to take part, it is important 
that you understand a bit about my reasons for undertaking this research and what it 
will involve. Please take some time to read the following information. Feel free to ask 
me for further information or to clarify anything that is unclear. Please take your time 
to decide whether you would like to take part. Before you decide, you may also wish 
to discuss this information with others, for example family or your GP. 
 
What is the purpose of this study? 
My study is exploring how well drug information is processed in patients with MS 
and without MS and how this relates to mood and other cognitive abilities. This study 
hopes to develop ways of helping people with MS to better understand drug 
information. We have prepared some tapes with fictional drug information. These 
tapes will be played to you and you will also complete a number of other short tasks.  
 
  
Department of Psychology  
Doctorate in Clinical Psychology 
Royal Holloway,  
University of London,  
Egham, 
Surrey, 
TW20 0EX 
Email: nxjt006@live.rhul.ac.uk 
Tel: 01784 414 388 
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What is Multiple Sclerosis (MS)? 
Multiple sclerosis is a chronic neurological condition which affects the brain and 
spinal cord. The outside of nerve cells have become damaged and this causes a 
disruption in the way nerve cells communicate and transmit signals to each other. The 
exact cause of MS is unknown but it is likely to involve a combination of genetic and 
environmental factors. It is typically diagnosed in young adulthood. It is a progressive 
disease and so it gets worse over time. Common symptoms include fatigue, difficulty 
in walking and balancing, visual problems and spasms. MS is different for each 
individual. The severity of their symptoms will depend on the level of damage to the 
brain and spinal cord. There are different stages of MS. In earlier stages, many people 
will have periods where their symptoms subside (remission) as well as periods of 
varying severity in which their symptoms return (relapse). In later stages, symptoms 
become more permanent. There is no known cure for this condition but a number of 
different treatments are available including medications, diet changes, and 
physiotherapy.  
 
Where will this study take place? 
You may choose whether you wish to undertake this study at a University of London 
office in Central London, your place of work, or at another location which is 
convenient for you. Unfortunately no travel expenses will be available.  
 
Why have you been asked to take part? 
In order to best understand risk awareness about treatment information in MS, it is 
helpful to compare them to similar people from the general population who do not 
have MS. This comparison can help us to establish whether there are any important 
differences between healthy people and people with MS in terms of their risk 
awareness. This may also inform us about helpful ways in which we might alter the 
way we provide clinical services to people with MS.  
 
Do you have to take part in this study? 
There is no obligation for you to take part in this study. If you do decide to take part, I 
will ask you to sign a consent form. By signing this form you would be providing me 
with permission to record your contact details and some other personal information 
you might provide which is of relevance to the study. Once you have provided 
consent, you are still free to withdraw from the study at any time without needing to 
provide an explanation. 
 
If you agree to participate, what will the study involve? 
If you decide to take part in this study, I will ask you to attend a one-off appointment 
with me at a location convenient to you. This appointment will last for a maximum of 
2 hours. I will ask you to first complete a number of short questionnaires which will 
involve questions about your mood and level of fatigue. I will then ask you to listen to 
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the fictional drug information and also to complete some concentration and problem-
solving tasks. If you feel tired, you can take breaks at any time during this 
appointment. If at any point you decide that you no longer want to be part of this 
research, you may withdraw from the study immediately without providing a reason. 
 
What are the benefits to taking part? 
There will be no direct benefit to you for participating in this research. However, by 
increasing the knowledge available on risk awareness in MS, there may be indirect 
benefits for future MS-related clinical practice. Additionally, my study will help you 
to gain more knowledge about the ways in which individuals are affected by MS. You 
will have the opportunity to ask questions and you will be provided with a copy of the 
final report once it has been published in a peer-reviewed journal. You will not be 
identified in any report or publication.  
 
What are the disadvantages and risks to taking part?   
Some people can find the completion of problem-solving tasks tiring. However, it is 
very unusual for healthy people to feel uncomfortable. Please let me know if you feel 
tired or distressed at any point during the session. You will be free to take a break or 
to stop testing completely. There will also be time to talk about any concerns that you 
might have.  
 
What will happen to the information I provide and who will have access to this? 
All data will be collected and stored in accordance with the Data Protection Act 1998. 
Any of your personal details (e.g. name, contact details) will be kept strictly 
confidential and will be accessible only to myself and my supervisor Dr. Samantha 
Alterndorff, Clinical Neuropsychologist at the NHNN. All the other information you 
provide will be stored anonymously and will not be linked to your personal 
information in any way.  
 
 
This project has been approved by the NHS Research Ethics Service (NRES) and 
by the Research and Ethics Committee at Royal Holloway, University of London.  
 
If you would like to ask any further questions about this research, please email 
me on nxjt006@live.rhul.ac.uk. You may also leave a message on 01784 414 388. 
Please make sure that you state clearly that your message relates to the MS 
research project with Michele Burns and leave your contact number. I will get 
back to you as soon as possible.  
 
If you have a concern about the way in which this study is being conducted and 
wish to make a complaint, you may do so by contacting the study supervisor, 
Professor Dawn Langdon at the following email address: D.Langdon@rhul.ac.uk    
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Thank you for taking the time to read this information sheet.  
 
 
Michele Burns 
Trainee Clinical Psychologist and Chief Investigator 
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Appendix G: Letter of request for assistance with recruitment sent to work places and 
organisations local to the researcher 
 
         National Hospital for Neurology & Neurosurgery  
MS Clinic 
Queen Square 
London 
WC1N 3BG 
Website: www.uclh.nhs.uk 
 
 
 
 
Dear ____________, 
I am writing to enquire whether you would consider allowing members of your 
organisation to volunteer to participate in my research study on Multiple Sclerosis 
(MS). The research would provide us with a greater understanding of the process of 
risk awareness in individuals with MS. It would help us to develop ways of improving 
risk awareness in individuals with MS which would in turn help them to make more 
balanced decisions about their medical treatment. It would also tell us how their 
understanding of risk relates to their mood and cognitive abilities.  
In order to calibrate how well people with MS assess risk, it is necessary to 
investigate how well the average person performs on the same tasks. This is why I am 
asking for members of your organisation to participate. The study is registered as a 
DClinPsy (Doctorate in Clinical Psychology) with the University of London and it is 
supervised by Professor Dawn Langdon, Professor of Neuropsychology at Royal 
Holloway, University of London, and by Dr. Samantha Altendorff, Clinical 
Neuropsychologist at the National Hospital for Neurology and Neurosurgery 
(NHNN).  
Department of Psychology  
Doctorate in Clinical Psychology 
Royal Holloway,  
University of London,  
Egham, 
Surrey, 
TW20 0EX 
Email: nxjt006@live.rhul.ac.uk 
Tel: 01784 414 388 
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Volunteers would attend an interview session involving a range of memory and 
concentration tasks. They would also be asked to complete a number of short 
questionnaires. This process would take a maximum of 2 hours to complete. The 
usual arrangement is for me to visit the host organisation for a day to conduct the 
interviews. The only personal information required from volunteers would be their 
age and occupation. Any data obtained from these interviews would be kept strictly 
confidential. 
I have enclosed a participant information sheet which you may distribute to the 
individual volunteers. This document describes in greater detail what participation in 
this research study would involve. I have also enclosed a template consent form, 
copies of which I would bring with me. I am generally available between now and 
<INSERT DATE> should your organisation wish to take part. If you have any further 
questions, or would like to make arrangements for me to visit, I can be contacted by 
email (nxjt006@live.rhul.ac.uk) or at the address given at the above address. I look 
forward to hearing from you. 
 
Yours sincerely, 
____________________________ 
Michele Burns 
Trainee Clinical Psychologist 
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Appendix H: Informed consent form for MS group 
 
           National Hospital for Neurology & Neurosurgery  
MS Clinic 
Queen Square 
London 
WC1N 3BG 
Website: www.uclh.nhs.uk 
 
 
 
 
 
 
 
Title of study: Risk awareness and treatment information in Multiple Sclerosis 
(MS)  
Researcher:  Michele Burns, Trainee Clinical Psychologist, Royal Holloway, 
University of London 
Ethics number: 14/EM/0153 
 
Informed Consent Form for Research Participation: 
 
Thank you for your interest in taking part in this research. Before you agree to take 
part, the person organising the research must explain the project to you. If you have 
any questions arising from the Information Sheet or explanation already given to you, 
please ask the researcher before you decide whether to join in. You will be given a 
copy of this Consent Form to keep and refer to at any time. 
 
              Please tick here 
 I agree that I have read the Information Sheet and understand  
what the study involves.  
 
 I understand that sections of my medical notes relevant to this  
study may be viewed by the above named researcher. I give  
Department of Psychology  
Doctorate in Clinical Psychology 
Royal Holloway,  
University of London,  
Egham, 
Surrey, 
TW20 0EX 
Email: nxjt006@live.rhul.ac.uk 
Tel: 01784 414 388 
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my permission for this individual to access my records for the  
purposes of this research study. 
 
 I understand that such information will be treated as strictly 
 confidential and handled in accordance with the provisions 
 of the Data Protection Act 1998. 
 
 I understand my participation is voluntary and that if I decide 
 at any time that I no longer wish to take part, I can notify the 
 researchers involved and withdraw immediately without any 
consequence to my ongoing medical care.  
 
 I understand that one of the questionnaires may show that 
 I could be depressed, and if this is the case, that I will be  
advised to go and see my GP.  
 
 I agree to take part in this study.  
 
 
 
 
_____________________ ______________ ________________________ 
Name of Participant   Date   Signature 
 
 
______________________ ______________ _________________________ 
Name of Researcher   Date   Signature 
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Appendix I: Informed consent form for Healthy Control group 
 
           National Hospital for Neurology & Neurosurgery  
MS Clinic 
Queen Square 
London 
WC1N 3BG 
Website: www.uclh.nhs.uk 
 
 
 
 
 
 
 
 
Title of study: Risk awareness and treatment information in Multiple Sclerosis 
(MS)  
Researcher:  Michele Burns, Trainee Clinical Psychologist, Royal Holloway, 
University of London 
Ethics number: 14/EM/0153 
 
Informed Consent Form for Research Participation: 
 
Thank you for your interest in taking part in this research. Before you agree to take 
part, the person organising the research must explain the project to you. If you have 
any questions arising from the Information Sheet or explanation already given to you, 
please ask the researcher before you decide whether to join in. You will be given a 
copy of this Consent Form to keep and refer to at any time. 
 
              Please tick here 
 I agree that I have read the information sheet and understand  
what the study involves.  
 
 I consent to the processing of my personal information for 
 the purposes of this research study. 
Department of Psychology  
Doctorate in Clinical Psychology 
Royal Holloway,  
University of London,  
Egham, 
Surrey, 
TW20 0EX 
Email: nxjt006@live.rhul.ac.uk 
Tel: 01784 414 388 
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 I understand that such information will be treated as strictly 
 confidential and handled in accordance with the provisions 
 of the Data Protection Act 1998. 
 
 I understand my participation is voluntary and that if I decide 
 at any time that I no longer wish to take part, I can notify the 
 researchers involved and withdraw immediately.  
 
 I agree to take part in this study.  
 
 
 
 
_____________________    _____________  ________________________ 
Name of Participant   Date   Signature 
 
 
____________________   ____________  ________________________ 
Name of Researcher   Date   Signature 
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Appendix J: Vignettes containing treatment-related risk information heard by all 
participants 
 
Ganlin and Tylon Vignette 
You have been diagnosed with Durkin’s disease. Durkin’s disease is a genetic disease. 
It is a chronic disease which means that there is no known cure. It is usually 
diagnosed in middle age when people seek their doctor’s advice about difficulties 
with their sight. Their vision becomes increasingly restricted to a central area. If the 
disease is not treated, 50% of Durkin’s patients would be unable to drive within five 
years of diagnosis. The first drug usually prescribed for Durkin’s is Ganlin, which is a 
daily tablet. 80% of patients on Ganlin are still able to drive 10 years after diagnosis. 
Side effects of Ganlin are headache (30%), constipation (40%) and dry skin (20%). 
Some patients have more severe forms of Durkin’s disease. Their eyesight continues 
to decline quickly even when they are taking Ganlin. These patients can be prescribed 
Tylon, a stronger drug. Patients given Tylon from diagnosis have a 95% chance of 
driving after 15 years. However, Tylon has more serious side effects. 1 in a hundred 
patients will suffer liver failure requiring hospitalisation in the first 10 years of use. 
One in a thousand will die as a result. Patients on Tylon are also three times more 
likely than the general population to develop dementia once they reach the age of 70. 
 
Limac and Braddex Vignette 
You have been diagnosed with Shannon’s disease. It is a chronic disease which means 
that there is no known cure. This disease alters the shape of blood cells. This makes it 
more difficult for blood cells to travel through the bloodstream. This disease causes 
poor circulation, slow healing of wounds and bruises, and heart problems. If left 
untreated, 50% of patients will need heart surgery within 10 years. The usual 
treatment for Shannon’s disease is Limac. This is a liquid medicine that needs to be 
taken twice a day. This medication promotes the growth of new healthy blood cells 
and substantially reduces the risk of further blood vessel damage. Patients on Limac 
have only a 1 in 100 chance of needing heart surgery after 10 years. But they often get 
poor circulation and excessive bruises, which can be disfiguring and rarely lead to 
amputations in 1 out of every 1000 patients. There is a stronger drug available for 
Shannon’s disease called Braddex. This involves weekly injections. It has more 
serious side effects than Limac. Patients on Braddex hardly ever experience poor 
circulation or excessive bruising. However 1 in 50 will need hospitalisation for a heart 
attack during their lifetime, and 1 in 200 will die of a heart attack. Heart attacks can 
occur at any time once they start the drug. 
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Trixon and Fylene Vignette 
You have been diagnosed with Raylick’s disease. It is a chronic disease which means 
that there is no known cure. This is a rare disease which causes muscle wasting. 
Patients usually seek their doctor’s advice for fatigue and difficulty walking. 
Sportsmen and other physically active people notice the disease earlier than the 
general population and are three times more likely to have Raylick’s disease. There is 
a genetic component and once one member of a family is diagnosed, close relatives 
have ten times the normal risk and need to be carefully monitored. The usual 
treatment is Trixon, a thrice daily tablet that must be taken after food. 70% of patients 
who take Trixon will still be walking independently after 10 years. Sportsmen and 
physically active people usually have to change their lifestyle. Side effects of Trixon 
are sensitivity to sunlight (20%), indigestion (30%) and headache (10%). There is a 
stronger drug, Fylene. 99% of surviving patients on Fylene will still be walking 
independently after 20 years. However, Fylene has more serious side effects. One in 
70 will suffer a limb fracture in the first five years and one in 200 will not recover 
useful limb function. In addition, one in 50 will have stomach problems requiring 
additional chronic medication. One in 500 on Fylene will die from stomach bleeds.  
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Appendix K: Scoring sheets for immediate recall of treatment-related risk information 
Participant number: _______________  
Presented:    1
st
          2
nd
    3
rd
   
Standard  Spaced   
Standard with delay 
 
Ganlin and Tylon Vignette – Immediate Recall  
You have been diagnosed with Durkin’s disease./ Durkin’s disease is a genetic 
disease./ It is a chronic disease which means that there is no known cure./ It is usually 
diagnosed in middle age/ when people seek their doctor’s advice about difficulties 
with their sight./ Their vision becomes increasingly restricted to a central area./ If the 
disease is not treated,/ 50% of Durkin’s patients/ would be unable to drive/ within five 
years of diagnosis./ The first drug usually prescribed for Durkin’s is Ganlin,/ which is 
a daily tablet./ 80% of patients on Ganlin/ are still able to drive/ 10 years after 
diagnosis./ Side effects of Ganlin are headache (30%),/ constipation (40%)/ and dry 
skin (20%)./ Some patients have more severe forms of Durkin’s disease./ Their 
eyesight continues to decline quickly even when they are taking Ganlin./ These 
patients can be prescribed Tylon,/ a stronger drug./ Patients given Tylon from 
diagnosis have a 95% chance/ of driving/ after 15 years./ However, Tylon has more 
serious side effects./ 1 in a hundred patients/ will suffer liver failure/ requiring 
hospitalisation/ in the first 10 years of use./ One in a thousand/ will die as a result./ 
Patients on Tylon are also three times more likely than the general population/ to 
develop dementia/ once they reach the age of 70. 
Total:   _____/70 
Administration time: ___________ 
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Participant number: _______________  
Presented:  1
st
        2
nd
          3
rd
   
Standard  Spaced   
Standard with delay 
 
Limac and Braddex Vignette – Immediate Recall 
You have been diagnosed with Shannon’s disease./ It is a chronic disease which 
means that there is no known cure./ This disease alters the shape of blood cells./ This 
makes it more difficult for blood cells to travel through the bloodstream./ This disease 
causes poor circulation,/ slow healing of wounds and bruises,/ and heart problems./ If 
left untreated,/ 50% of patients/ will need heart surgery/ within 10 years./ The usual 
treatment for Shannon’s disease is Limac./ This is a liquid medicine/ that needs to be 
taken twice a day./ This medication promotes the growth of new healthy blood cells/ 
and substantially reduces the risk of further blood vessel damage./ Patients on Limac 
have only a 1 in 100 chance/ of needing heart surgery/ after 10 years./ But they often 
get poor circulation (60%)/ and excessive bruises (40%),/ which can be disfiguring/ 
and rarely lead to amputations/ in 1 out of every 1000 patients./ There is a stronger 
drug available for Shannon’s disease/ called Braddex./ This involves weekly 
injections./ It has more serious side effects than Limac./ Patients on Braddex hardly 
ever experience poor circulation or excessive bruising./ However 1 in 50/ will need 
hospitalisation/ for a heart attack during their lifetime,/ and 1 in 200/ will die of a 
heart attack./ Heart attacks can occur at any time once they start the drug. 
Total:   _____/70 
Administration time: ___________ 
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Participant number: _______________  
Presented: 1
st
       2
nd
          3
rd
   
Standard  Spaced   
Standard with delay 
 
Trixon and Fylene Vignette – Immediate Recall 
You have been diagnosed with Raylick’s disease./ It is a chronic disease which means 
that there is no known cure./ This is a rare disease which causes muscle wasting./ 
Patients usually seek their doctor’s advice for fatigue/ and difficulty walking./ 
Sportsmen and other physically active people notice the disease earlier than the 
general population/ and are three times more likely to have Raylick’s disease./ There 
is a genetic component/ and once one member of a family is diagnosed, close relatives 
have ten times the normal risk and need to be carefully monitored./ The usual 
treatment is Trixon,/ a thrice daily tablet/ that must be taken after food./ 70% of 
patients who take Trixon/ will still be walking independently/ after 10 years./ 
Sportsmen and physically active people usually have to change their lifestyle./ Side 
effects of Trixon are sensitivity to sunlight (20%),/ indigestion (30%)/ and headache 
(10%)./ There is a stronger drug,/ Fylene./ 99% of surviving patients on Fylene/ will 
still be walking independently/ after 20 years./ However, Fylene has more serious side 
effects./ One in 70/ will suffer a limb fracture/ in the first five years/ and one in 200/ 
will not recover useful limb function./ In addition, one in 50/ will have stomach 
problems/ requiring additional chronic medication./ One in 500/ on Fylene will die 
from stomach bleeds.  
Total:   _____/70 
Administration time: ___________ 
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Appendix L: Immediate recall scoring criteria for all vignettes  
Ganlin and Tylon Vignette 
1. You have been diagnosed with Durkin’s disease 
2 points: “Durkin’s disease” 
1 point: N/A 
2. “Durkin’s disease is a genetic disease” 
2 points: “genetic disease”, “hereditary”  
1 point: N/A 
3. “It is a chronic disease which means that there is no known cure” 
2 points: “chronic disease” AND “no known cure”  
1 point: “chronic disease” OR “no known cure” OR indication that the illness 
cannot be cured 
4. “It is usually diagnosed in middle age” 
2 points: “diagnosed in middle age” 
1 point: N/A 
5. “when people seek their doctor’s advice about difficulties with their 
sight” 
2 points: “when people visit their doctor” AND “difficulties with their sight” or 
“vision difficulties” or “problems with eyesight” 
1 point: either “when” people visit their doctor” OR “difficulties with their sight” 
or vision difficulties” or “problems with eyesight” 
6. “Their vision becomes increasingly restricted to a central area” 
2 points: “vision narrows” or “vision becomes restricted to central area” 
1 point: “lose peripheral vision” 
7. “If the disease is not treated” 
2 points: “if untreated” “if not treated” 
1 point: N/A 
8. “50% of Durkin’s patients”  
2 points: “50%” or “half”  
1 point: N/A 
9. “would be unable to drive” 
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2 points: “no longer able to drive” 
1 point: N/A 
10. “within five years of a diagnosis” 
2 points: “in 5 years” 
1 point: N/A 
11. “The first drug usually prescribed for Durkin’s is Ganlin” 
2 points: “Ganlin” 
1 point: N/A 
12. “which is a daily tablet” 
2 points: “tablet taken daily”, “tablet taken once a day” 
1 point: “daily”, “once a day”, “tablet” 
13. “80% of patients on Ganlin” 
2 points: “80%” 
1 point: N/A 
14. “are still able to drive” 
2 points: “can still drive” 
1 point: N/A 
15. “10 years after diagnosis.” 
2 points: “in 10 years” 
1 point: N/A 
16. “Side effects of Ganlin are headache (30%)”  
2 points: “headache” AND “30%” 
1 point: “headache” OR “30%” 
17. “constipation (40%)”  
2 points: “constipation” AND “40%” 
1 point: “constipation” OR “40%” 
18. “and dry skin (20%)” 
 2 points: “dry skin” AND “20%”  
1 point: “dry skin” OR “20%”  
19. “Some patients have more severe forms of Durkin’s disease.”  
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2 points: “more severe forms”, “more serious type” 
1 point: N/A 
20. “Their eyesight continues to decline quickly even when they are taking 
Ganlin.”  
2 points: “eyesight continues to get worse when taking Ganlin” 
1 point: “eyesight continues to get worse” 
21. “These patients can be prescribed Tylon,”  
2 points: “Tylon” 
1 point: N/A 
22. “a stronger drug.”  
2 points: “stronger drug” 
1 point: “more effective drug”  
23. “Patients given Tylon from diagnosis have a 95% chance”  
2 points: “95% chance” 
1 point: N/A 
24. “of driving”  
2 points: “still being able to drive” 
1 point: N/A 
25. “after 15 years.”  
2 points: “in 15 years” 
1 point: N/A 
26. “However, Tylon has more serious side effects.”  
2 points: “worse side effects” 
1 point: N/A 
27. “1 in a hundred patients”  
2 points: “1 in 100”, “1%” 
1 point: N/A 
28. “will suffer liver failure”  
2 points: “liver failure”, “liver damage” 
1 point: N/A  
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29. “requiring hospitalisation”  
2 points: “need to go to hospital” 
1 point: N/A 
30. “in the first 10 years of use.”  
2 points: “in 10 years” 
1 point: N/A 
31. “One in a thousand”  
2 points: “one in a thousand”  
1 point: N/A 
32. “will die as a result.”  
2 points: “will die”, “will be fatal”  
1 point: N/A  
33. “Patients on Tylon are also three times more likely than the general 
population”  
2 points: “three times greater than general population” 
1 point: “three times”, “more likely than the general population” 
34. “to develop dementia”  
2 points: “dementia” 
1  point: N/A 
35. “once they reach the age of 70.” 
2 points: “at 70”  
1  point: N/A 
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Limac and Braddex Vignette  
1. “You have been diagnosed with Shannon’s disease.”  
2 points: “Shannon’s disease” 
1 point: N/A 
2. “It is a chronic disease which means that there is no known cure.” 
2 points: “chronic disease with no cure” 
1 point: “chronic disease”, “no cure”, “incurable”  
3. “This disease alters the shape of blood cells.”  
2 points: “changes shape of blood cells”  
  point: “affects blood cells”  
4. “This makes it more difficult for blood cells to travel through the 
bloodstream.”  
2 points: “more difficult for blood cells to travel around the body” 
1 point: “impacts on blood cells”, “stops blood cells travelling” 
5. “This disease causes poor circulation,”  
2 points: “poor circulation” 
1 point: N/A 
6. “slow healing of wounds and bruises,”  
2 points: “slow healing of wounds and bruises” 
1 point: “slow healing of wounds”, “slow healing of bruises”  
7. “and heart problems.”  
2 points: “heart difficulties”, “cardio problems” 
1 point: N/A 
8. “If left untreated,”  
2 points: “if not treated” 
1 point: N/A 
9. “50% of patients”  
2 points: “50%” 
1 point: N/A 
10. “will need heart surgery”  
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2 points: “have heart surgery” 
1 point: N/A 
11. “within 10 years.”  
2 points: “in 10 years” 
1 point: N/A 
12. “The usual treatment for Shannon’s disease is Limac.”  
2 points: “Limac” 
1 point: N/A 
13. “This is a liquid medicine”  
2 points: “liquid” AND “medicine” 
1 point: “a liquid”, “a medicine” 
14. “that needs to be taken twice a day.”  
2 points: “twice daily” 
1 point: N/A 
15. “This medication promotes the growth of new healthy blood cells”  
2 points: “helps new blood cells grow” 
1 point: “fixes the blood cells”, “helps blood cells” 
16. “and substantially reduces the risk of further blood vessel damage.”  
2 points: “reduces blood cell damage” 
1 point: N/A 
17. “Patients on Limac have only a 1 in 100 chance”  
2 points: “1 in 100”, “1%” 
1 point: N/A 
18. “of needing heart surgery”  
2 points: “need heart operation” 
1 point: “need surgery” 
19. “after 10 years.”  
2 points: “in 10 years” 
1 point: N/A 
20. “But they often get poor circulation (60%)”  
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2 points: “poor circulation” AND “60%” 
1 point: “poor circulation” OR “60%” 
21. “and excessive bruises (40%),”  
2 points: “excessive bruises” AND “40%” 
1 point: “excessive bruises” OR “40%” 
22. “which can be disfiguring”  
2 points: “disfiguring”, “unsightly” 
1 point: N/A 
23. “and rarely lead to amputations”  
2 points: “rarely lead to amputations” 
1 point: “rare side effect” OR “amputations” 
24. “in 1 out of every 1000 patients.”  
2 points: “1 out of 1000” 
1 point: N/A 
25. “There is a stronger drug available for Shannon’s disease”  
2 points: “stronger drug” 
1 point: “more effective drug”  
26.  “called Braddex.”  
2 points: “Braddex” 
1 point: N/A 
27. “This involves weekly injections.”  
2 points: “weekly” AND “injections” 
1 point: “weekly”, “once a week” OR “injections”, “needle” 
28. “It has more serious side effects than Limac.”  
2 points: “worse side effects”  
1 point: N/A 
29. “Patients on Braddex hardly ever experience poor circulation or excessive 
bruising.” 
2 points: “poor circulation or excessive bruising is rare” 
1 point: “no poor circulation” “no bruising” 
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30.  “However 1 in 50”  
2 points: “1 in 50”, “2%” 
1 point: N/A 
31. “will need hospitalisation”  
2 points: “need to go to hospital” 
1 point: N/A 
32. “for a heart attack during their lifetime,”  
2 points: “for a heart attack at some time in their life” 
1 point: “for a heart attack” OR “at some time in their life”  
33. “and 1 in 200”  
2 points: “1 in 200” 
1 point: N/A 
34. “will die of a heart attack.”  
2 points: “will die from heart attack” 
1 point: “will die 
35. “Heart attacks can occur at any time once they start the drug.”  
2 points: “at any time” 
1 point: N/A 
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Trixon and Fylene Vignette 
1. “You have been diagnosed with Raylick’s disease.” 
2 points: “Raylick’s disease” 
1 point: N/A 
2. “It is a chronic disease which means that there is no known cure.”  
2 points: “chronic disease with no cure” 
1 point: “chronic disease”, “no cure”, “incurable”  
3. “This is a rare disease which causes muscle wasting.”  
2 points: “rare muscle wasting disease” 
1 point: “rare disease” OR “muscle wasting disease” 
4. “Patients usually seek their doctor’s advice for fatigue”  
2 points: “go to doctor about fatigue”  
1 point: “go to doctor”, “fatigue”, “tiredness” 
5. “and difficulty walking.”  
2 points: “trouble walking” 
1 point: “mobility difficulties” 
6. “Sportsmen and other physically active people notice the disease earlier 
than the general population”  
2 points: “Sportsmen and active people spot it earlier than most people”  
1 point: “Sportsmen notice it earlier”, “Active people notice it earlier”, 
“Sportsmen and active people get it” 
7. “and are three times more likely to have Raylick’s disease.”  
2 points: “three times”, “30%” 
1 point: N/A 
8. “There is a genetic component”  
2 points: “it’s genetic”. “hereditary” 
1 point: N/A 
9. “and once one member of a family is diagnosed, close relatives have ten 
times the normal risk and need to be carefully monitored.”  
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2 points: “relatives are ten times more likely to get it and need to watch carefully” 
1 point: “relatives are ten times more likely to get it” OR “relatives must watch 
carefully”  
10. “The usual treatment is Trixon,”  
2 points: Trixon 
1 point: N/A 
11. “a thrice daily tablet”  
2 points: “tablet taken three times a day” 
1 point: “tablet” OR “three times a day” 
12. “that must be taken after food.”  
2 points: “take after food” 
1 point: N/A 
13. “70% of patients who take Trixon”  
2 points: “70%” 
1 point: N/A 
14. “will still be walking independently”  
2 points: “will still be walking” 
1 point: N/A 
15. “after 10 years.”  
2 points: “in 10 years” 
1 point: N/A 
16. “Sportsmen and physically active people usually have to change their 
lifestyle.”  
2 points: “ 
1 point: 
17. “Side effects of Trixon are sensitivity to sunlight (20%),”  
2 points: “sensitivity to sunlight” AND “20%” 
1 point: “sensitivity to sunlight” OR “20%” 
18. “indigestion (30%)”  
2 points: “indigestion” AND “30%” 
1 point: “indigestion” OR “30%”  
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19. “and headache (10%).”  
2 points: “headache” AND “10%” 
1 point: “headache” OR “10%” 
20. “There is a stronger drug,”  
2 points: “stronger drug” 
1 point: “more effective drug”  
21. “Fylene.” 
2 points: “Fylene” 
1 point: N/A 
22. “99% of surviving patients on Fylene”  
2 points: “99%” 
1 point: N/A 
23. “will still be walking independently” 
2 points: “will still be walking” 
1 point: N/A 
24. “after 20 years.”  
2 points: “in 20 years” 
1 point: N/A 
25. “However, Fylene has more serious side effects.”  
2 points: “worse side effects”  
1 point: N/A 
26. “One in 70”  
2 points: “1 in 70” 
1 point: N/A 
27. “will suffer a limb fracture”  
2 points: “limb fracture”, “break a limb” 
1 point: “break a bone” 
28. “in the first five years”  
2 points: “in 5 years” 
1 point: N/A 
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29. “and one in 200”  
2 points: “one in 200” 
1 point: N/A 
30. “will not recover useful limb function.”  
2 points: “will not regain use of the limb” 
1 point: “will not recover” 
31. “In addition, one in 50”  
2 points: “one in 50”, “2%” 
1 point: N/A 
32. “will have stomach problems”  
2 points: “stomach difficulties” 
1 point: N/A 
33. “requiring additional chronic medication.”  
2 points: “requiring more medication” 
1 point: N/A 
34. “One in 500”  
2 points: “One in 500” 
1 point: N/A 
35. “on Fylene will die from stomach bleeds.” 
2 points: “will die from stomach bleeds”, “will suffer fatal stomach bleeds” 
1 point: “will die”, “will have stomach bleeds” 
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Appendix M: Measures of understanding of treatment-related risk information 
 
Measure of understanding of risk information relevant to Ganlin and Tylon 
Vignette: 
Q. 1. What is the chance that you will suffer from headaches after taking Ganlin? 
Q. 2. How likely is it that you will experience symptoms such as dry skin after taking 
Ganlin?  
Q. 3. What are the first signs of Durkin’s Disease? 
Q. 4. Who is more likely to develop Durkin’s Disease?  
Q. 5. How effective is Ganlin in terms of the percentage of people able to drive 
following diagnosis? 
Q. 6. How long can you expect to drive if Durkin’s Disease is left untreated?  
Q.7. How common is liver failure in someone who is taking Tylon?  
Q.8. How much more likely is someone to develop dementia when prescribed Tylon? 
 
Measure of understanding of risk information relevant to Limac and Braddex 
Vignette: 
Q. 1. What is the chance that you will need to undergo limb amputation after taking 
Limac? 
Q. 2. How typical is it for someone with untreated Shannon’s disease to require heart 
surgery?  
Q. 3. How likely is it that you will suffer from poor circulation while taking Limac?  
Q. 4. How likely is it that you will suffer from excessive bruising while taking Limac? 
Q. 5. What are the first symptoms of Shannon’s Disease? 
Q. 6. How effective is Limac in terms of the number of people requiring heart surgery 
when prescribed this medication? 
Q.7. How common is hospitalisation for heart attacks in those who are prescribed 
Braddex? 
Q.8. What is the risk of death for individuals who are prescribed Braddex? 
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Measure of understanding of risk information relevant to Trixon and Fylene 
Vignette: 
Q. 1. What is the chance that you will suffer headaches after taking Trixon? 
Q. 2. What is the chance that you will suffer sensitivity to sunlight after taking 
Trixon? 
Q. 3. What are the initial symptoms you might experience with Raylick’s Disease? 
Q. 4. How effective is Trixon in terms of the number of people able to walk 
independently 10 years after diagnosis? 
Q. 5. What is the risk of death in those who are prescribed Fylene? 
Q. 6. There is an increased risk of developing Raylick’s Disease in relatives of those 
with a diagnosis; how big is this increased risk? 
Q. 7. How effective is Fylene in terms of the number of people who maintain the 
ability to walk independently 20 years after diagnosis?  
Q. 8. How common is limb fracture in those who are prescribed Fylene?  
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Appendix N: Measures of understanding of treatment-related risk information scoring 
criteria for all vignettes  
Ganlin and Tylon Vignette 
Q. 1. What is the chance that you will suffer from headaches after taking 
Ganlin? 
2 points: 30% OR 3 in 10 OR 30 in 100  
1 point: N/A 
Q. 2. How likely is it that you will experience symptoms such as dry skin after 
taking Ganlin?  
2 points: 20% OR 2 in 10 OR 20 in 100  
1 point: N/A 
Q. 3. What are the first signs of Durkin’s Disease? 
2 points: “Difficulties with sight/vision” OR “vision becomes restricted to a central 
area” OR “loss of peripheral vision”  
1 point: N/A  
Q. 4. Who is more likely to develop Durkin’s Disease?  
2 points: “people in middle-age”  
1 point: N/A 
Q. 5. How effective is Ganlin in terms of the percentage of people able to drive 
following diagnosis? 
2 points: 80% or 8 in 10 people or 80 in 100 people  
1 point: N/A 
Q. 6. How long can you expect to drive if Durkin’s Disease is left untreated?  
2 points: 5 years 
1 point: N/A 
Q.7. How common is liver failure in someone who is taking Tylon?  
2 points: 1 in 100 patients OR 1% 
1 point: N/A 
Q.8. How much more likely is someone to develop dementia when prescribed 
Tylon? 
2 points: 3 times  
1 point: N/A 
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Limac and Braddex Vignette  
Q. 1. What is the chance that you will need to undergo limb amputation after 
taking Limac? 
2 points: 1 in 1000 patients  
1 point: N/A 
Q. 2. How typical is it for someone with untreated Shannon’s disease to require 
heart surgery?  
2 points: 50% OR 5 in 10 OR 50 in 100 OR “half”  
1 point: N/A 
Q. 3. How likely is it that you will suffer from poor circulation while taking 
Limac?  
2 points: 60% OR 6 in 10 chance OR 60 in 100  
1 point: N/A 
Q. 4. How likely is it that you will suffer from excessive bruising while taking 
Limac? 
2 points: 40% OR 4 in 10 OR 40 in 100  
1 point: N/A 
Q. 5. What are the first symptoms of Shannon’s Disease? 
2 points: 2 of 3 of the following: “poor circulation”, “slow healing of wounds and/or 
bruises”, “heart problems” 
1 point: 1 of the following: “poor circulation”, “slow healing of wounds and/or 
bruises”, “heart problems” 
Q. 6. How effective is Limac in terms of the number of people requiring heart 
surgery when prescribed this medication? 
2 points: 1 in 100 chance OR 1% 
1 point: N/A  
Q.7. How common is hospitalisation for heart attacks in those who are 
prescribed Braddex? 
2 points: 1 in 50 OR 2%  
1 point: N/A 
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Q.8. What is the risk of death for individuals who are prescribed Braddex? 
2 points: 1 in 200 
1 point: N/A 
 
Trixon and Fylene Vignette 
Q. 1. What is the chance that you will suffer headaches after taking Trixon? 
2 points: 10% OR 1 in 10 OR 10 in 100 
1 point: N/A  
Q. 2. What is the chance that you will suffer sensitivity to sunlight after taking 
Trixon? 
2 points: 20% OR 2 in 10 OR 20 in 100  
1 point: N/A 
Q. 3. What are the initial symptoms you might experience with Raylick’s 
Disease? 
2 points: Must say “fatigue” AND “difficulty walking/reduced mobility” 
1 point: Either “fatigue” OR “difficulty walking/reduced mobility” 
Q. 4. How effective is Trixon in terms of the number of people able to walk 
independently 10 years after diagnosis? 
2 points: 70% OR 7 in 10 OR 70 in 100 
1 point: N/A 
Q. 5. What is the risk of death in those who are prescribed Fylene? 
2 points: 1 in 500  
1 point: N/A 
Q. 6. There is an increased risk of developing Raylick’s Disease in relatives of 
those with a diagnosis; how big is this increased risk? 
2 points: 10 times OR 10 fold 
1 point: N/A 
Q. 7. How effective is Fylene in terms of the number of people who maintain the 
ability to walk independently 20 years after diagnosis?  
2 points: 99% OR 99 in 100 
1 point: N/A  
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Q. 8. How common is limb fracture in those who are prescribed Fylene?  
2 points: 1 in 70 
1 point: N/A 
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Appendix O: California Verbal Learning Test (CVLT-II) score sheet 
 
This material is unavailable due to copyright restrictions.  
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Appendix P: Symbol Digit Modalities Test (SDMT) score sheet 
 
This material is unavailable due to copyright restrictions.  
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Appendix Q: Verbal and Spatial Reasoning Test (VESPAR) score sheet 
 
This material for both the Verbal Analogies and Verbal Series subtests is unavailable 
due to copyright restrictions.  
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Appendix R: Arithmetic subtest of the Wechsler Adult Intelligence Scale-Third 
Edition (WAIS-III) Scoring Sheet 
 
This material is unavailable due to copyright restrictions.  
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Appendix S: Test of Reasoning Using Statistical Information (TRUSI) 
TRUSI 
 
On the following pages is a series of questions involving numbers. Please 
read each question and answer by circling one of the options given below the 
question. 
 
 
These questions are not taken from the real world. They are designed 
purely for this questionnaire to work out how good people are at dealing 
with numbers. 
 
If you do not know what the answer is, please take your best guess. 
 
If you change your mind, clearly cross out your first answer and circle 
another option  
 
Example: 
 
 
 
There will be three sets of questions: 
 
1) Questions about everyday things. 
2) Questions about health risks. 
3) Questions about health risks to do with Multiple Sclerosis (MS). 
 
These questions are not designed to catch you out. However, they 
are not all easy and very few people will get them all right.  
 
Over the page are some practice questions: 
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Please circle only one of the available options 
 
 
One in every two UK citizens goes on holiday in Britain each year? 
  
What are the chances that any UK citizen you meet goes on holiday in 
Britain each year? 
   
A. 1% E. 20% 
B. 2% F. 50% 
C. 5% G. 80% 
D. 10% H. 100% 
 
 
 
Lupus is a potentially fatal medical condition. 20% of people with 
Lupus will need a prolonged hospital stay. 
  
So far this year, 100 people have been diagnosed with Lupus in the UK. 
How many of them will require a prolonged hospital stay? 
   
A. 1 E. 20 
B. 2 F. 50 
C. 5 G. 80 
D. 10 H. 100 
 
 
 
There are twice as many diagnoses of Secondary Progressive MS 
each year as there are diagnoses of Primary Progressive MS. 
  
If there were 45 diagnoses of Primary Progressive MS last year, how many 
diagnoses of Secondary Progressive MS were there? 
   
A. 2 E. 135 
B. 22 F. 180 
C. 45 G. 360 
D. 90 H. 450 
234 
 
 
These questions are about everyday things. 
 
Please circle only one of the available options 
 
 
There are ten used vehicles parked on the forecourt of an approved car 
dealership. Eight of them are 2006 registered, one is 2005 registered and 
one is 2003 registered.  
 
If one vehicle is sold that morning, what are the chances that it is 2006 
registered? 
   
A. 10% E. 60% 
B. 15% F. 80% 
C. 20% G. 95% 
D. 50% H. 100% 
 
Oldport council have surveyed their residents to find out whether their 
refuse bins are big enough. 25% of people said that their rubbish didn’t 
fit in their bins less than once a month. 39% said that their rubbish 
always fitted into their bin. 
 
Of 200 people living in Walmsley Road in Oldport how many said that their 
rubbish always fitted into their bins? 
   
A. 9 E. 78 
B. 25 F. 98 
C. 39 G. 112 
D. 50 H. 131 
 
  
In the UK, 34% of people say apples are their favourite fruit, 38% say 
that bananas are their favourite fruit and 28% say some other fruit is 
their favourite. 
 
What are the chances that someone buying their favourite fruit in a shop will 
not be buying apples? 
   
A. 4% E. 34% 
B. 6% F. 38% 
C. 10% G. 66% 
D. 28% H. 72% 
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Tiny animals called “grewcocks” can attach themselves to the wings of 
domestic swallows to keep warm. 2 out of 10 domestic swallows with 
“grewcocks” attached will not be able to fly because of this. 
 
If there are 15 swallows with “grewcocks” attached to their wings, how many 
will not be able to fly because of this? 
   
A. 2 E. 6 
B. 3 F. 8 
C. 4 G. 9 
D. 5 H. 15 
Many British people travel to New York for a holiday. 2 out of 3 of those 
people will be able to use their mobile phones to call home. 
 
In a hotel lobby in New York, how likely is it that a British tourist sitting next to 
you will be able to call home on their mobile phone? 
   
A. 22% E. 50% 
B. 33% F. 54% 
C. 40% G. 60% 
D. 45% H. 67% 
In a new type of sweet called Tongue-Flamers, 20% are red, 20% are 
green, 20% are blue and 40% are yellow. 
 
If you pick one without looking, what are the chances it is blue? 
   
A. 1 in 2 E. 1 in 40 
B. 1 in 4 F. 1 in 50 
C. 1 in 5 G. 1in 80 
D. 1 in 20 H. 1 in 100 
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According to Government Statistics, working-age mothers are less likely 
to be in employment than working-age women without children. In fact 
68% of working-age mothers are employed compared with 73% of 
working-age women without children. 
 
In a typical group of 200 working-age women, of whom 100 have children, 
how many will be employed? 
   
A. 5 E. 141 
B. 68 F. 150 
C. 73 G. 168 
D. 111 H. 173 
 
15% of Horse Chestnut trees are infected with a disease called Firkins 
Canker. Around 2 out of 10 infected trees will die within 10 years. 
 
What are the chances that any Horse Chestnut tree will die from Firkins 
Canker in the next 10 years? 
   
A. 3% E. 17% 
B. 5% F. 20% 
C. 8%  G. 25% 
D. 15% H. 30% 
 
50% of graduates leave University without a job. An ambitious graduate 
employment agency plans to reduce the amount of graduates leaving 
University without a job by 20% 
 
What proportion of graduates will leave University without a job if the agency 
is successful? 
   
A. 10% E. 50% 
B. 20% F. 55% 
C. 30%  G. 60% 
D. 40% H. 70% 
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8 times out of 10, the leading brand of biological washing powder will 
completely remove cooking-oil stains. If the oil stain is left overnight, 
however, the washing powder will only be 1/3 as effective. 
 
If you are about to wash 15 oil-stained chef outfits from last night’s Superchef 
2008 competition, how many will be completely clean after washing with the 
leading brand of powder? 
   
A. 2 E. 10 
B. 3 F. 11 
C. 4  G. 12 
D. 5 H. 15 
 
The UK Tourist Regulatory Committee reported that: 
  
On the upcoming August Bank Holiday, we predict there will be an 18% 
chance of experiencing minor delays in reaching holiday destinations. 
 
Which of the following is the best interpretation of this information? 
   
A.  If you go on holiday at this time, plan a little extra time for potential 
delays. 
B.  People’s travel times are likely to be 18% longer than timetabled. 
C.  Travel to 18% of holiday destinations will be delayed. 
D.  There’s not too much chance of delay if you plan carefully. 
E.  18 out of 100 holiday journeys will be slightly delayed in reaching 
their destinations. 
F.  Other (Please explain below) 
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These questions are about health risks. 
 
Please circle only one of the available options 
 
 
Of 1000 serious Road Traffic Accidents included in a study of accidents 
in the UK, 800 involved a motorbike, 100 involved a car, and 100 
involved a heavy goods vehicle. 
 
If this survey is a fair reflection the UK as a whole what are the chances that 
any serious Road Traffic Accident involved a heavy goods vehicle? 
   
A. 10% E. 60% 
B. 15% F. 80% 
C. 20% G. 95% 
D. 50% H. 100% 
 
Deep Vein Thrombosis (DVT) is a very serious medical condition which 
is common in people who travel long distances by plane. However, the 
risk can be reduced by taking aspirin before travelling. 17% of people 
said that they take aspirin before travelling by plane, while 79% of 
people said that they did not take aspirin before flying. 
 
If you ask 200 people in an airport about what they take before flying, how 
many will say that they do not take aspirin? 
   
A. 17 E. 96 
B. 34 F. 100 
C. 52 G. 117 
D. 79 H. 158 
  
Your GP tells you that there is something unusual about a recent blood 
test. The GP says that in around 65% of similar cases, a rest would cure 
the problem. However, in 26% there is something that will need very 
urgent treatment and in the remaining 9% further investigation will be 
necessary. 
 
What are the chances that you will need more than a rest? 
   
A. 9% E. 50% 
B. 26% F. 74% 
C. 35% G. 91% 
D. 39% H. 100% 
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MRSA and CDiff are two sorts of resistant “superbug” which can have 
severe effects on people who are ill in hospital, including death. 15 out 
of 25 people admitted to Hospital come into contact with one of these 
“superbugs”. 
 
If 60 people are admitted to an inpatient ward next month, how many of them 
will come into contact with MRSA or CDiff?. 
   
A. 10 E. 30 
B. 15 F. 36 
C. 18 G. 40 
D. 28 H. 60 
There is concern about industrial mercury in the environment. Extensive 
damage to those industries’ safety systems could result in widespread 
mercury contamination. 2 out of 5 people with mercury contamination 
will experience memory problems. 
 
If you find out too late that your water supply has been contaminated with 
mercury, what are the chances of experiencing memory problems as a result 
of the contamination? 
   
A. 3% E. 20% 
B. 5% F. 36% 
C. 8% G. 40% 
D. 10% H. 60% 
The Agency for Health Improvement (AHI) reported in 1999 that the most 
common causes of death in UK adults are: Cancer 15%, Myocardial 
Infarction (Heart Attack) 61%, Other Causes 14%. 
 
What are the chances that any adult will die of cancer? 
   
A. 1 in 100 E. 4 in 15 
B. 1 in 15  F. 4 in 10 
C. 3 in 20 G. 3 in 5 
D. 2 in 10 H. 9 in 10 
240 
 
 
The Greater London Incident Prevention Research Council (GL-IPRC) 
reported last year that households without approved electrical circuitry 
were more likely than those with such circuitry to report a fatal 
household accident. Whereas 4.9% of households without approved 
circuitry reported a fatal accident, only 3.1% of approved households 
made such a report. 
 
In 200 typical Greater London households, where half of them have approved 
circuitry, how many fatal accidents were reported last year? 
   
A. 1 E. 31 
B. 8 F. 49 
C. 15 G. 67 
D. 18 H. 80 
 
It is estimated that there is a 10% chance of the H5N1 “Bird Flu” virus 
mutating to infect humans who have contact with infected birds. The 
results are likely to be fatal in 6 out of 20 human cases. 
 
What are the chances that human contact with an infected bird will result in 
human death? 
   
A. 1.5% E. 15% 
B. 3% F. 20% 
C. 10% G. 25% 
D. 13% H. 30% 
 
Only 40% of people diagnosed with asbestosis will survive more than 
ten years from time of diagnosis. If they do not begin treatment within 
two months of diagnosis, this survival rate drops by 30%. 
 
If you have been diagnosed with asbestosis four months ago and have not 
begun treatment, what are your chances of surviving beyond the next ten 
years? 
   
A. 5% E. 28% 
B. 10% F. 30% 
C. 14% G. 40% 
D. 16% H. 68% 
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Over a 20 year period, Accident and Emergency services in rural Eastern 
England report that 1 in 4 working-age adults who are struck by 
lightning will die as a result. If the person under 40, however, the strike 
will only be 1/3 as lethal. 
 
If 12 people under 40 were struck by lightning between 1987 and 2006, how 
many died? 
   
A. 1 E. 8 
B. 3 F. 10 
C. 4 G. 11 
D. 7 H. 12 
 
In the news it says: In London, a recent survey has found that there is 
now a 17% chance of being a victim of street crime.  
 
Which of the following is the best interpretation of this information? 
   
A.  If you live in London, there’s a good chance you’ll be the victim of 
street crime. 
B.  Street crime occurs in 17% of the London area. 
C.  You will be mugged 17% of the time you’re out. 
D.  17 out of every 100 people in London will be the victim of street 
crime. 
E.  If you live in London, you’re pretty unlikely to be a victim street 
crime. 
F.  Other (Please explain below) 
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These questions are about health risks to do with MS. 
 
Please circle only one of the available options 
 
 
Five people with a diagnosis of Multiple Sclerosis are in the waiting area 
at a West London MS clinic. Three of them have a diagnosis of 
Relapsing-Remitting MS, one has benign MS and one has Secondary 
Progressive MS. 
 
What are the chances that first person called in has Secondary Progressive 
MS? 
    
A. 1% E. 20% 
B. 3% F. 40% 
C. 5% G. 50% 
D. 10% H. 80% 
 
In the United Kingdom, there have been some rare reports of unrelated 
health issues being wrongly diagnosed as Multiple Sclerosis. 80% of 
people who turned out to have been wrongly diagnosed had sought only 
one previous medical opinion. 15% of people who turned out to have 
been wrongly diagnosed had sought two previous medical opinions. 
 
In 200 people who have been wrongly diagnosed, how many had sought two 
previous medical opinions? 
   
A. 15 E. 95 
B. 30 F. 160 
C. 40 G. 170 
D. 80 H. 185 
 
In the UK, 64% of Relapsing-Remitting MS patients say their worst fear 
is becoming wheelchair-bound, 27% say that it is loss of mental abilities 
and 9% said they most feared becoming hopeless. 
 
What are the chances that someone with Relapsing-Remitting MS has a worst 
fear which is not about their physical mobility? 
   
A. 9% E. 55% 
B. 18% F. 64% 
C. 27% G. 73% 
D. 36% H. 91% 
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It is common for people with MS to experience debilitating fatigue. 6 in 
every 10 people with Secondary Progressive MS will be too fatigued to 
leave the house more than twice a week. 
 
If there are 25 people with Secondary Progressive MS, how many of them will 
be too fatigued to leave the house more than twice a week? 
   
A. 1 E. 10 
B. 4 F. 12 
C. 6 G. 15 
D. 8 H. 25 
A at any given time, some people with Relapsing-Remitting MS are 
experiencing a relapse. Intensive community support will be required by 
3 out of 5 people with Relapsing-Remitting MS during relapse.  
 
If you have Relapsing-Remitting MS and are currently experiencing a relapse, 
what are the chances that you will need intensive community support? 
   
A. 1% E. 50% 
B. 3% F. 60% 
C. 10% G. 70% 
D. 20% H. 90% 
In an East London community disability service, an Admin Assistant 
explored Physiotherapy waiting list times for people with MS. 20% of 
people with MS had to wait less than a month, 18% had to wait between 
one and three months, 25% had to wait between three and six months 
and 15% were never seen. 
 
If you have been referred for Physiotherapy to this service, what are the 
chances you will have to wait between three and six months? 
   
A. 1 in 2 E. 3 in 10 
B. 1 in 4 F. 3 in 18 
C. 1 in 5 G. 1 in 25 
D. 3 in 20 H. ¾  
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A regional survey of people with MS found that significantly more 
people over 35 had experienced a progressive worsening of their 
condition in the last five years than those under 35. In fact, 10% of under 
35’s said that they had experienced progressive worsening compared 
with 48% of people over 35. 
 
If 200 people were surveyed, of whom 100 were under 35 how many people 
had experienced a progressive worsening in the last five years? 
   
A. 10 E. 53 
B. 20 F. 58 
C. 29 G. 96 
D. 48 H. 100 
 
Tozaril, a new drug for the prevention of relapse in Relapsing-Remitting 
MS has been distributed to 25% of UK Pharmacies. Despite the high 
demand for Tozaril, only 4 out of 10 of these Pharmacies have decided 
to sell it during the first six months. 
 
If you have a prescription for the drug, what are the chances that any 
pharmacist you go to in the next six months will sell you the drug? 
   
A. 4% E. 25% 
B. 6% F. 35% 
C. 10% G. 40% 
D. 15% H. 50% 
 
A herbal remedy, Calmadol, is reported to reduce urinary infections in 
people with Relapsing-Remitting MS by 5%.  
 
If in the last year you have had urinary infections roughly 20% of the time, 
how much of next year would you expect to have a urinary infection if you 
start taking Calmadol? 
   
A. 1% E. 19% 
B. 5% F. 20% 
C. 6% G. 25% 
D. 15% H. 50% 
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9 times out of 10, a clinic that sees people with suspected neurological 
problems can correctly diagnose MS. However, if the clinic does not 
have use of a Stelleron MRI scanner, the diagnosis is only 2/3 as 
reliable. 
 
If your GP sends you to a clinic that does not have use of a Stelleron MRI 
scanner and the clinic says that you have MS, what are the chances the 
diagnosis is correct? 
   
A. 9% E. 40% 
B. 10% F. 60% 
C. 19% G. 67% 
D. 25% H. 90% 
 
On the side of a bottle of prescription medication for prevention of 
relapses, it says:  
 
If taken alongside antibiotics there is a 10% chance of developing a 
kidney problem. If you notice any pain passing water, consult your 
physician. 
 
Which of the following is the best interpretation of this warning? 
   
A.  Don’t use the medication if you’re on antibiotics, there’s a good 
chance of developing a kidney problem. 
B.  If you’re on antibiotics, take only 10% of the recommended dose. 
C.  If you develop a kidney problem, it will probably affect 10% of the 
kidney tissue. 
D.  About 10 out of 100 people on antibiotics who use this medication 
will develop a kidney problem. 
E.  If you are on antibiotics, there is hardly any chance of developing a 
kidney problem. 
F.  Other (Please explain below) 
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Thank you very much for completing this Questionnaire. 
 
As explained at the beginning, none of the facts in the questions were 
true. They are imaginary examples to help us understand how good 
people are at dealing with numbers relating to the world and to 
situations affecting their health. 
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Appendix T: Wechsler Test of Adult Reading (WTAR) Scoring Sheet 
 
This material is unavailable due to copyright restrictions.  
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Appendix U: Modified Token Test (MTT) 
 
Modified Token Test  
Using Weigl’s Blocks in Random Array 
 
1. Put the red circle on the green triangle. 
2. Put the blue square behind the yellow circle. 
3. Touch the blue circle with the red triangle. 
4. Pick up the blue circle OR the red triangle. 
5. Put the green square away from the yellow square. 
6. If there is a black circle, pick up the red triangle. (Note. There is no black circle). 
7. When I touch the green circle, you take the green square. (Note. Wait a few 
seconds before touching the green circle). 
8. Put the green square beside the red circle. 
9. Touch the squares, slowly and the circles, quickly. 
10. Put the red circle between the yellow triangle and the green triangle. 
11. Except for the green one, touch the circles. 
12. Instead of the blue square, take the yellow circle. 
13. Together with the yellow circle, take the blue circle. 
14. After picking up the green square, touch the red circle. 
15. Before touching the yellow circle, pick up the red square. 
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Scoring notes 
Item No. 2: 'Behind' may be interpreted either with respect to the patient or the 
examiner (if facing the patient). Thus it may be necessary to ascertain which 
interpretation the patient has adopted. Credit is also given if the blue square is put 
under the yellow circle. Item No. 9: Omission of one circle and/or one square is 
permitted.  
250 
 
 
Appendix V: Hospital Anxiety and Depression Scale (HADS) score sheet 
 
Hospital Anxiety and Depression Scale (HADS) 
 
This questionnaire is designed to help the researcher to know how you feel. Read each 
item below and place a tick in the box opposite the reply which comes closest to how 
you have been feeling in the past week. Tick only one box in each section.  
Don’t take too long over your replies; your immediate reaction to each item will 
probably be more accurate than a long, thought-out response.  
 
I feel tense or ‘wound up’    
Most of the time     
A lot of the time 
From time to time, occasionally 
Not at all 
 
I still enjoy the things I used to enjoy 
Definitely as much 
Not quite so much 
Only a little 
Hardly at all 
 
I get a sort of frightened feeling as if  
something awful is about to happen 
Very definitely and quite badly 
Yes, but not too badly 
A little, but it does not worry me 
Not at all 
 
I can laugh and see the funny side of things 
As much as I always could 
Not quite so much now 
Definitely not so much now 
Not at all 
 
Worrying thoughts go through my mind 
A great deal of the time 
A lot of the time 
Not too often 
Very little 
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I feel cheerful 
Never 
Not often 
Sometimes 
Most of the time 
 
I can sit at ease and feel relaxed 
Definitely  
Usually 
Not often 
Not at all 
 
I feel as if I am slowed down 
Nearly all the time 
Very often 
Sometimes 
Not at all 
 
I get a sort of frightened feeling like  
‘butterflies’ in the stomach 
Not at all 
Occasionally 
Quite often 
Very often 
 
I have lost interest in my appearance 
Definitely 
I don’t take as much care as I should 
I may not take quite as much care 
I take just as much care as ever 
 
I feel restless as if I have to be on the move 
Very much indeed 
Quite a lot 
Not very much 
Not at all 
 
I look forward with enjoyment to things 
As much as I ever did 
Rather less than I used to 
Definitely less than I used to 
Hardly at all 
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I get sudden feelings of panic 
Very often indeed 
Quite often 
Not very often 
Not at all 
 
I can enjoy a good book or radio  
or television programme 
Often 
Sometimes 
Not often 
Very seldom 
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Appendix W: Fatigue Severity Scale (FSS) scoring sheet 
 
Fatigue Severity Scale 
The FSS questionnaire contains nine statements that attempt to explore severity 
of fatigue symptoms. Read each statement and circle a number from 1 to 7, 
depending on how appropriate you feel the statement applied to you over the 
preceding week. A low value indicates that the statement is not very 
appropriate whereas a high value indicates agreement (1 disagree, 7 agree).  
 
 
During the past week, I have found that:    Score 
 
1. My motivation is lower when I am fatigued.
  
 
2. Exercise brings on my fatigue.   
 
3. I am easily fatigued.        
 
4. Fatigue interferes with my physical 
functioning.  
 
5. Fatigue causes frequent problems for me. 
 
6. My fatigue prevents sustained physical 
functioning. 
 
7. Fatigue interferes with carrying out certain 
duties and responsibilities. 
 
8. Fatigue is among my three most disabling 
symptoms. 
 
9. Fatigue interferes with my work, family, or  
social life. 
 
1 2 3 4 5 6 7 
1 2 3 4 5 6 7 
1 2 3 4 5 6 7 
1 2 3 4 5 6 7 
1 2 3 4 5 6 7 
1 2 3 4 5 6 7 
1 2 3 4 5 6 7 
1 2 3 4 5 6 7 
1 2 3 4 5 6 7 
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 Appendix X: Z Score for Skew and Kurtosis across Variables 
Note: Z-Scores of <2.58 (p>0.1) can be considered normal 
 
  
255 
 
 
Table 16 
Skew and Kurtosis Z-Scores across all Demographic, Cognitive and Clinical 
Variables 
 MS Group HC Group 
 Skew Kurtosis Skew Kurtosis 
Age -1.97 -0.14 -1.33 -1.06 
Pre-morbid 
IQ (WTAR) 
Raw Score  
-1.01 -0.99 -1.97 0.88 
Anxiety   1.74 0.54 2.19 1.23 
Depression 0.38 -1.06 4.18 1.84 
Fatigue -0.44 -0.65 2.45 1.45 
CVLT Total 
Raw Score 
-0.72 0.82 -2.02 -0.39 
SDMT Raw 
Score  
-0.11 -0.44 1.07 0.27 
Modified 
Token Test 
Raw Score 
-6.46 2.84 -6.58 2.75 
Arithmetic 
subtest raw 
score 
0.64 1.25 0.001 -0.59 
Verbal 
Analogies 
Raw Score 
-0.28 -0.43 -2.19 0.65 
Verbal Series 
Raw Score 
0.92 -1.07 -1.46 0.53 
TRUSI Raw 
Score 
-0.22 -0.82 1.04 0.85 
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Table 17 
Skew and Kurtosis Z-Scores for transformed Depression Variable 
 MS Group Healthy Control Group 
 Skew Kurtosis Skew Kurtosis 
SQRT(Depression 
Raw Score) 
-0.79 -0.97 0.83 0.46 
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Table 18  
Skew and Kurtosis across Dependent Variables in Experimental Condition 
 MS Group Healthy Control Group 
 Skew Kurtosis Skew Kurtosis 
Massed Recall 2.43 1.26 0.12 -1.10 
Spaced Recall 0.001 -0.98 0.29 -1.10 
Massed-with-
delay Recall 
2.2 0.53 0.88 0.21 
Massed 
Understanding 
2.0 0.24 -0.87 -0.89 
Spaced 
Understanding 
0.49 -0.63 0.89 -0.47 
Massed-with-
delay 
Understanding 
1.98 0.98 1.35 0.72 
 
 
 
 
